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‘Who are you?’ said the Caterpillar.  
This was not an encouraging opening for a 
conversation. Alice replied, rather shyly, 
‘I--I hardly know, sir, just at present-- at 
least I know who I WAS when I got up this 
morning, but I think I must have been 
changed several times since then’.  
Lewis Carroll- 
Alice’s adventures in 
Wonderland- 
 
 
 
 
A mia madre Angela e a mio padre Luigi. 
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1. INTRODUCTION 
 
1.1 Vaccines and the immune system  
 
Prevention of infectious diseases by vaccination is one of the greatest medical achievements 
for mankind. During the past century, the average human life span has increased by 
approximately 30 years, a significant portion of which has been attributed directly to 
vaccination (Cooper and O’Reilly, 2002).The ability to elicit broadly neutralizing antibody 
and long-lasting immune responses against pathogens is a crucial goal for prophylactic and 
therapeutic vaccines. Prophylactic vaccination consists in eliciting immune responses able to 
prevent infections, while therapeutic vaccination is aimed to overcome a pre-existing 
pathology. Protection can be achieved by delivering antibodies (passive immunisation) or by 
training the immune system to actively face the pathogen (active immunisation). Today, 
despite the awareness that many diseases caused by viruses and bacteria can be prevented by 
vaccination, infections are still a major cause of morbidity and mortality. The need to develop 
new or improved vaccines is pointed out by the increase in the frequency of antibiotic-
resistant bacteria and the risk of re-emergence of eradicated pathogens, due to the threat of 
bioterrorism.  
 
1.1.1 A short outline of pathogen-biased immune responses 
In the past 200 years vaccine manufacturing has undergone many changes to obtain safer and 
more effective formulations (Ulmer et al., 2006). A better understanding of the molecular 
basis of immune responses has started a new era in vaccine research as the basic goal of 
vaccination is to mimick an infection in order to stimulate a complete immune response 
(innate and adaptive, antibody- and cell -mediated) without inducing morbidity.  
The first contact with a pathogen/antigen triggers the innate immune response. Innate 
immunity is a primitive mechanism of defence that involves cells endowed with phagocytic 
and cytotoxic activity (i.e. polymorphonucleate granulocytes, mastocytes, Natural Killer cells, 
B lymphocytes, dendritic cells (DC) and macrophages) situated close to the physical barriers 
of the organism (mainly epithelia and mucosae) (Medzhitov and Janoway, 1997). The 
activation of innate immunity is induced by the recognition by these cells through the so 
called Toll-like Receptors (TLR) of Pathogen-Associated Molecular Patterns (PAMP), small 
molecular motifs consistently conserved among similar pathogens (i.e lypopolysaccharide, 
2 
 
peptidoglycan, DNA CpG motifs, flagellin) (Krishnan et al., 2007). In parallel to innate 
responses, pathogens activate specific long-lasting adaptive responses mediated by cells (B 
and T lymphocytes) expressing on their membranes highly specific antigen receptors. These 
receptors mainly bind to proteins or peptides (Garcia et al., 1999). The antigen-specific 
receptors of B lymphocytes are immunoglobulins. These composite glycoproteins block 
pathogens usually by interacting with portions of folded proteins (conformational epitopes -
groups of amino acids of the antigen not arranged as a straight chain in the primary structure-
). The antigen-immunoglobulin interaction activates the B cell and induces its proliferation 
and differentiation in a plasma cell, able to secrete immunoglobulins. As an alternative, the B 
cell can differentiate into a memory B cell able to persists for a long time in the lymph and 
blood streams, ensuring a quicker response in the case of a second pathogen attack 
(immunological memory). 
The antigen-specific receptors of T lymphocytes (T cell receptor, TCR) are structurally 
similar to immunoglobulins, but exist only in the membrane-associated form (Bentley and 
Mariuzza, 1996). Differently from immunoglobulins, TCR recognizes antigens only after they 
have been processed by specialized cells (Antigen Presenting Cells, APC) or by pathogen-
infected cells. The TCR recognizes a complex made of an antigen-derived peptide (linear 
epitope –group of amino acids arranged as a straight chain in the primary structure-) 
associated to a Major Histocompatibility Complex (MHC) molecule on the plasma membrane 
of these cells. APC take up antigen from the extracellular environment (for this reason named 
exogenous antigen), process and present derived fragments in association to MHC class II 
molecules. T lymphocytes that recognize epitopes associated to this class of MHC are defined 
as helper T lymphocytes, characterized by the presence of the co-receptor CD4 on the plasma 
membrane. These T cells show the distinctive feature of secreting soluble factors (cytokines) 
with regulatory functions on the immune response. The CD4+ helper T lymphocytes can be 
further divided in T helper 1 (Th1) and T helper 2 (Th2) on the basis of the pattern of 
cytokines they secrete.When epitopes are presented by cells that have been infected by the 
pathogen (endogenous antigens), they associate to MHC class I molecules. T lymphocytes 
that recognize epitopes associated to this class of MHC molecules are cytotoxic T 
lymphocytes (CTL), phenotypically characterized by the presence of the co-receptor CD8 on 
the plasma membrane. These cells are functionally characterized by the ability to kill 
pathogen infected cells through the secretion of cytolytic factors (perforins and granzymes). It 
is now becoming clear that the MHC class I and II pathways of antigen processing and 
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presentation are not so clearly disconnected and that some specialized APC are able to cross-
present exogenous antigens to CTL (Yewdell et al., 1999; Houde et al., 2003; Roy, 2003). 
 
1.1.2 Factors influencing vaccine efficiency 
Ideally, vaccines should elicit specific and long-lasting immune responses as much similar to 
those induced during pathogen infection both at systemic and mucosal level. Indeed, mucosae 
usually are access sites for pathogens and play a major role in protection due to the presence 
of a specialized lymphoid tissue compartment (MALT, Mucosal Associated Lymphoid 
Tissue) involved in the early steps of pathogen recognition and clearance (mucosal 
immunity). The activation of both systemic and mucosal compartments of the immune system 
by vaccination depends on several factors, but primarily on the delivery route and antigen 
immunogenicity. It is common notion that different compartments of the immune system are 
activated according to the vaccine delivery route. While delivery through the parenteral route 
elicit only systemic responses and is extremely effective in stimulating long-lasting immunity, 
delivery through mucosal routes (intranasal, oral, rectal, or vaginal) can elicit both systemic 
and mucosal immunity (Ryan et al., 2001; Holmgren and Czerkinsky, 2005). Nevertheless, 
different mucosal districts do not respond in the same way to vaccination. For example, 
intranasal is much more effective than oral immunisation in eliciting the activation of the 
different districts of the immune system, including those of distal mucosae (Mowat, 2003). 
Important determinants of the immunogenicity of a given antigen are primarily the molecular 
dimensions, that might become crucial in activating and addressing the elicited immune 
response. A “big” antigen for example, may contain more conformational and linear epitopes 
as compared to a “small” one, and has more chances to activate specific B and T cell clones. 
One of the strategies commonly used to increase the efficiency of a vaccine consists in 
coupling the antigen to a “carrier” (usually a protein) and/or in co-administering an adjuvant. 
Adjuvants are substances able to enhance the in vivo immunogenicity of antigens by helping 
to simulate the signalling cascade that promote the maturation of the APC and the optimal 
activation of adaptive immunity. They can be divided in two main groups on the basis of the 
mechanism of action (Pashine et al., 2005). A first group is composed of adjuvants able to 
activate innate immunity, the so called “immune potentiators”. A second group includes all 
those substances behaving as delivery devices by displaying antigens in repetitive patterns 
and inducing their targeting to APC. So far, pre-clinical studies have described several diverse 
compounds exhibiting adjuvant properties, but only a few have been approved for human use: 
i) alum (aluminium salt particles) highly effective in enhancing antibody responses, through 
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the elicitation of Th2-biased immune responses, but not in inducing the activation of cell-
mediated immunity; ii)  MF59, an oil-in-water squalene emulsion; iii) AS04, an alum 
formulation containing the Toll-like receptor 4 (TLR4) agonist monophosphoryl lipid A 
(Aguilar and Rodriguez, 2007). The efficiency of new generation adjuvants, based for 
example on liposomes (formulated with monophosphoryl lipid A) or on immuno-stimulating 
complexes incorporating the antigen (ISCOMS) is under evaluation in clinical trials.  
 
1.1.3 Vaccine types 
There are different types of vaccines licensed for human use. These include vaccines 
containing live-attenuated or inactivated/killed organisms and few subunit vaccines (Ulmer et 
al., 2006).  
 
1.1.3.1 Vaccines containing live, attenuated organisms  
The success of this approach depends on decoupling virulence from induction of protective 
immunity by the use for vaccination of live pathogen mutants less virulent than the wild type 
(w.t.) counterpart. The main feature of these vaccines is their ability to induce potent immune 
responses because of the preserved pathogen invasiveness and ability to replicate within host 
cells and also to the fact that pathogen surface molecules activate innate immunity. This 
vaccination approach has been adopted against the infection of several bacterial and viral 
pathogens, such as Vibrio cholerae, Mycobacterium tuberculosis, Salmonella typhi, yellow 
fever virus, measles virus, mumps virus, poliovirus, rubella virus, varicella-zoster virus, 
adenovirus and rotavirus. However, the use of vaccines containing live organisms have major 
limitations due to the fact that it is not always possible to identify sufficiently attenuated 
strains and there is a finite, underlying risk of reversion to virulence. 
 
1.1.3.2 Vaccine containing inactivated/killed organisms 
Vaccines containing inactivated or killed organisms despite including all the antigens of a 
pathogen able to induce the activation of the immune response, are generally much less 
efficient than live vaccines and require adjuvants co-delivery. This is due to the fact that 
pathogens are killed by chemical treatments (formaldehyde, β-propiolactone), that render 
them unable to access host cells and replicate. In this way they are active only as exogenous 
antigens, hence not competent to activate the whole-spectrum of immune responses. Several 
vaccines such as those against influenza virus, hepatitis A virus, rabies virus, and Bordetella 
pertussis are produced by this approach. 
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1.1.3.3 Purified or recombinant subunit vaccines 
Subunit vaccines contain microrganism-derived components selected on the basis of 
immunogenic properties and safety concerns. This vaccination strategy while being extremely 
valuable in terms of biosafety, is less advantageous in terms of effectiveness, mainly because 
isolated proteins by themselves are much less immunogenic than pathogens. Moreover, 
purified antigens may not retain their native conformation eliciting the production of 
antibodies that bind only weakly the native counterpart. These are the reasons why subunit 
vaccines require almost unavoidably the co-administration of adjuvants to be efficient. At the 
moment, subunit vaccines present on the market are those raised against tetanus, Hepatitis B 
(HBV) and Human Papillomavirus (HPV). While tetanus vaccine is produced by inactivating 
tetanus toxoid purified from the pathogen, HBV and HPV vaccines are manufactured by 
ectopically expressing the viral surface proteins in yeast and insect cells and purifying the 
virus like particles (VLP) generated by their self-assembly.  
 
1.1.4 Trends in vaccinology 
Despite considerable success of traditionally designed vaccines, sometimes these approaches 
are uneffective in preventing or treating infections induced by classical and emerging 
pathogens. The attempt to overcome these limitations, for example by identifying key 
antigens through ‘reverse vaccinology’ (a bioinformatics-based approach), is paving the way 
to next-generation vaccines (Rappuoli, 2004). 
 
1.1.4.1 Gene-based vaccines 
Gene-based vaccines have been mainly developed with the aim of eliciting the activation of 
CTL able to eliminate infected cells. By this approach, the sequence coding the antigen is 
delivered to cells in order to be expressed and further processed and presented by the immune 
system in association to MHC class I molecules, thus mimicking the events of a normal 
infection process. Gene-based vaccines can be delivered as plasmid DNA through gene gun or 
using recombinant viruses as vectors to enhance the potency of vaccination. Viral vectors 
based on adenovirus, poxviruses and alphaviruses, are more efficient in stimulating the 
immune response activation, probably because able to reproduce an infection-like 
environment. Despite their higher efficiency, manufacturing recombinant viral vectors is far 
more complicated than simple plasmid DNA. Moreover, pre-existing or vector-induced 
immunity that may limit the effectiveness of vaccination is a potential drawback.  
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1.1.4.2 Virus Like Particles  (VLP) 
VLP are particles that structurally mimic viruses, generated by self-assembly of viral capsid 
proteins when these are expressed in heterologous systems. VLP have several advantages over 
other vaccine types. They are particulate antigens and have the advantage to simulate the 
structure of the viral surface without carrying the viral genome. Therefore they are unable to 
induce infection while retaining all conformational epitopes usually targeted by neutralizing 
antibodies. The capsid proteins of several different viruses, including Human 
Immunodeficiency Virus type-1 (HIV-1), Norwalk virus and HPV, have been expressed to 
produce VLP that have been tested in human clinical trials. An anti-HPV VLP-based vaccine 
has been recently licensed for human use.  
 
1.1.4.3 Dendritic cell-based vaccines 
DC-based vaccines are individualized treatments that aim to exploit the central role of these 
cells in directing the adaptive immune responses against pathogens through antigen 
presentation. Manufacturing these vaccines implies recovery of a blood sample from an 
individual and isolation of DC from this sample. Cells are cultured, pulsed with the antigen of 
interest and finally re-injected to the original donor. At the present time, DC-based vaccines 
are under clinical trial to evaluate their efficacy in preventing and curing different pathologies 
and have been shown to induce both antigen-specific CD8+ and CD4+ T cell responses in 
vivo (Walsh et al., 2003).  
 
1.1.4.4 Peptide vaccines 
Molecular insights on the mechanisms of activation of adaptive immune responses indicate 
that peptides rather than whole proteins are responsible for the activation of T and B 
lymphocytes (even if at a lower extent). By using peptides it is possible to stimulate specific 
clones and bias the immune response towards an antibody or a cytotoxic response eliminating 
safety concerns. The selection of peptides to be included in vaccine formulations require an 
epitope mapping of the antigen of interest to identify immunodominant sequences. The 
identification of B cell activating peptides is complicated by the fact that often 
immunogloboulin recognize conformational epitopes. In the attempt to mimic conformational 
structures (particularly those of viral envelopes) cyclic peptides, branched peptides, 
peptomers (cross-linked peptide polymers) and other complex multimeric structures, as well 
as peptides conjugated to other molecules have been developed. Mix of peptides or 
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"mimotopes" identified in combinatorial peptide libraries that could mimic relevant structures 
and potentially inducing broad responses have been successfully used in some pre-clinical 
vaccination trials (respiratory syncytial virus, measles, hepatitis C, etc.). 
When the aim is to identify peptides activating CTL, the task is complicated by the fact that 
immunodominant peptides vary as a function of the individual immunogenetic background 
(MHC haplotype). Indeed, MHC molecules are encoded by a polygenic locus and each gene, 
particularly in humans, is characterized by an astounding allelic diversity. The differences 
among the MHC class I molecules encoded by each gene and by each allele of a gene, map in 
the region encoding the peptide binding pocket, so that different MHC molecules bind 
different peptides. To overcome the problem that different individuals respond to different 
peptides of a same antigen,  the possibility exists that a “cocktail” of peptides containing the 
immunodominant epitope for each haplotype can be used. The attempt to regroup the different 
haplotypes in a smaller number of supertypes, in a way to reduce the number of peptides to be 
included in the “cocktail”, has been performed (Sette and Sidney, 1999). Another major 
obstacle limiting the usefulness of peptide vaccines is the poor immunogenicity and the 
requirement of appropriate carriers and/or adjuvants to get a successful activation of the 
immune response.  
 
1.1.5 HIV-1 and influenza virus: open challenges to vaccine technologies 
Vaccination is the best strategy to prevent infections. Nonetheless, for several pathogens the 
development of efficient vaccination strategies has not yet succeeded. Among these pathogens 
are influenza virus and HIV-1. Indeed, despite the evident differences in their biology, 
starting from the fact that influenza causes an acute, while HIV-1, a chronic infection, both 
these pathogens are always “one step ahead” host neutralizing responses (Karlsson Hedestam 
et al., 2008). Although vaccination against influenza virus is effective as a single predominant 
variant circulates globally each year, the development of a vaccine against pandemic 
influenza represents a challenge because of the high number of variants deriving from the 
animal reservoir (usually birds) potentially able to generate the pandemic viral strain. This 
high variability somehow parallels the challenge of inducing broadly neutralizing antibody 
responses against HIV-1 by vaccination. However, the persistence of influenza virus occurs in 
the entire human population thanks to the infection of individuals with no or low protective 
immunity against new variants, while HIV-1 generates an enormous number of variants in 
each infected individual and these are simultaneously seeded and circulate in the population. 
Besides, HIV-1 has evolved many immune escape mechanisms that together with its high 
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variability represent the biggest challenge for vaccine development (Kwong et al., 2002; Wey 
et al., 2003). Because the main target of the neutralizing antibody response against both 
viruses are envelope proteins, the attempt to develop protective vaccines are mainly focused 
on these antigens and on the identification of conserved neutralizing elements within them. 
The precursor of the components of influenza virus envelope, haemagglutinin 0 (HA0), after 
translocation to the Endoplasmic Reticulum (ER) and trimerization, is targeted to the plasma 
membrane through the Golgi and is cleaved in HA1 and HA2 on released virus particles 
(Doherty et al., 2006). HIV-1 envelope (Env) is also composed by two glycoproteins, gp120 
and gp41 but, differently from influenza virus envelope components, they are both generated 
by proteolytic cleavage of a heavily glycosylated precursor (gp160) into the Golgi and the 
subsequent targeting to the plasma membrane for particles budding (Frankel and Young, 
1998). HA1 mediates the binding to the terminal sialic acid of glycoproteins and glycolipids 
on host cell surface while HA2 induce fusion. However, HA2 needs a low pH environment to 
get the permissive functional conformation and for this reason the fusion to the membrane 
occurs once the virus has been endocytosed by the target cell. Similarly, HIV-1 gp120 confers 
tropism towards CD4+ T lymphocytes while gp41 (the transmembrane domain of Env) 
mediates viral fusion to target cells.  
 
1.1.5.1 Current approaches to elicit protection against influenza 
To develop influenza vaccines based on the production of neutralizing antibodies against the 
viral envelope, the “predict and produce” approach is mainly applied at present. By this 
approach, all variants, most likely to spread across the globe, are identified and propagated in 
embryonated hen eggs. After detergent inactivation trivalent vaccines consisting of two 
subtypes of influenza A virus (H1N1 and H3N2) and one influenza B virus go into the market 
for intramuscular delivery. At present the main limitation of this commercialized influenza 
vaccine formulation is the narrow neutralizing activity of the elicited antibodies. One of the 
possible solutions to this problem and to the need of improving the efficiency of a pandemic 
influenza vaccine would be to enlarge the repertoire of cross-neutralizing antibodies by 
identifying conserved and exposed antigens among virus variants. It should also be envisaged 
to co-deliver adjuvants able not only to provide dose-sparing effects, but also to expand sub-
dominant B and T cell clones, otherwise remaining below the threshold of activation. 
Recently, a live-attenuated cold-adapted influenza vaccine based on viruses able to replicate 
efficiently at 25°C in the nasal passages but not at the high temperature occurring in the 
deeper respiratory tract, has also been licensed in USA. This vaccine, when administered 
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intranasally, induces a protection superior than that offered by the inactivated vaccine, 
possibly because the replicating virus express antigens longer and activates more 
compartments of the immune system. The identification of conserved antigens/epitopes is a 
complementing approach to the classic “predict and produce” methods for the development of 
a protective influenza vaccine as cross-neutralizing antigens could provide broader protection 
even to avian flu. In fact, it is extremely difficult to predict which flu strain might acquire the 
ability to infect and disseminate throughout the human population seasonally. Moreover, the 
existence of the avian flu reservoir represents a big challenge for vaccine development as it 
drives the “antigen shift” that has been responsible of pandemics in the past.  Recently, a 
comprehensive analysis of all the epitopes of influenza A proteins described in the  literature 
has been undertaken to inventory data available and to identify novel epitopes of interest for 
vaccine development (Bui et al., 2007). According to this analysis, the proteins forming the 
envelope (HA, Neuraminidase (NA), Matrix) are the most attractive as the antibody response 
seems to be crucial to control viremia. NA is interesting also because partially shared between 
human and avian variants, possibly providing cross-protection to viruses derived from the 
avian flu reservoir. Although the variability of the sequence of the epitopes recognized by 
antibodies is higher if compared to that of T-cell epitopes, appreciable conservation has been 
observed.  
Another problem relevant to influenza vaccine development concerns manufacturing. In fact, 
classic production systems based on the use of hen eggs are not valuable for the propagation 
of avian flu viral strains and alternative procedures must be envisaged.  
 
1.1.5.2 Current approaches to elicit protection against HIV-1 
As for the development of a vaccine inducing protective immunity against HIV-1 through the 
elicitation of neutralizing antibodies, experimental evidences obtained by analysing serum 
antibodies of infected individuals indicate that only a handful of sites on HIV-1 Env are 
conserved and vulnerable to antibody-mediated neutralization. These observations are 
confirmed by the fact that very few human monoclonal antibodies are able to neutralize a 
broad range of primary isolates of HIV-1 (Moore et al., 2001).  The paucity of neutralizing 
antibodies elicited against HIV depends on the high mutation rate and on the shielding of the 
viral surface through large N-linked glycans of host origin, able to render Env 
immunologically silent. The monoclonal antibodies b12 (Zhou et al., 2007) and 2G12 (Trkola 
et al., 1996), isolated in HIV-1 infected individuals, show specificity for different regions of 
gp120: b12 recognize the CD4 receptor binding site while 2G12 binds to a cluster of 
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conserved glycans on the outer domain, representing an exception to the masking role of 
glycans on HIV-1 particles. Two more neutralizing antibodies specific for the transmembrane 
glycoprotein gp41 (2F5 and 4E10; Muster et al., 1993; Stiegler et al., 2001) and a few others 
are under investigation to design effective immunogens (Zolla-Pazner et al., 2007). The 
epitopes recognized by 2F5 and 4E10 monoclonal antibodies are conserved and linear and this 
renders the region in which they are included on gp41 (the membrane proximal external 
region, MPER) an attractive target for the development of anti-HIV-1 vaccines (Zwick et al., 
2005). Due to the specificities of the described antibodies, many efforts aimed to develop an 
effective vaccine are focalized on the production of a form of gp120 conformationally closer 
to the natural counterpart therefore able to elicit similar antibody responses. Because the 
protein is extremely flexible and useless to elicit protective responses as a single isolated 
subunit, design efforts have been shifted to the engineering of soluble versions of oligomeric 
Env (containing full-length gp120 covalently linked to different versions of gp41 ectodomain) 
to form spikes resembling in their properties to the functional trimer. Recent data obtained by 
immunization with constructs encoding this complex (the gp140 molecule) showed a response 
with a wider cross-neutralizing spectrum (Phogat and Wyatt, 2007). Similarly, the attempt to 
structurally stabilize gp120 has been approached through the complexing to CD4 receptor, 
with the idea to obtain the release of the immunogenic site recognized by the b12 antibody. 
As b12 recognizes the CD4 binding site (BS), this epitope must be conserved, therefore 
representing a good candidate vaccine target. In the attempt to focus the antibody response on 
the CD4 BS, gp120 has been mutagenized by the introduction of new glycosylation sites, with 
the aim of focusing the immune response towards the region recognized by b12. It has been 
shown that, by this strategy, the binding of non-neutralizing and poorly neutralizing 
antibodies is inhibited, while leaving unmodified the broadly neutralizing properties of b12 
antibody (Pantophlet et al., 2003). Recently, the attempt to stabilize gp41-derived peptides 
through their insertion into a lipid context has also been described and a number of trials are 
ongoing to evaluate B- and T-cell responses against MPER-derived immunogens arrayed on 
carrier molecules (HB surface antigen) (Phogat et al., 2007) and heterologous lipid 
membrane. Approaches to develop vaccines based on the use of chemically inactivated 
virions or on the use of VLP are also under development (McBurney et al., 2006).  
 
1.1.5.3 Influenza and HIV vaccines: a possible role of CTL 
Since pathogen infection activate CTL responses beside eliciting neutralizing antibodies, the 
research in the field of vaccinology is trying to reproduce such a whole spectrum response. As 
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for the development of anti-HIV-1 vaccines, the elicitation of the CTL response is thought to 
be crucial for the clearance of the viral reservoir (infected cells) responsible for the chronic 
infection. Several studies have demonstrated that CTL play a central role in controlling HIV 
viremia in infected individuals. The appearance of HIV-specific CD8+ T cells is concomitant 
with the suppression of viral load during primary infection (Borrow et al., 1994; Koup et al., 
1994) and the loss of HIV-specific CD8+ T-cell activity is often associated with rapid 
progression to Acquired Immunodeficiency Syndrome (AIDS) (Klein et al., 1995). For the 
development of vaccines aiming to elicit cytotoxic response, several targets are under 
investigation. Nef (Negative factor)-, Vpr (Viral protein r)-, RT (Reverse Transcriptase)-, Tat 
(transactivator)- and Gag (Group-specific antigen)-based peptide vaccines have been tested in 
various forms. Deeper insights onto the mechanisms of CTL activation have demonstrated 
that just few peptides are responsible for virus clearance. These peptides are generally known 
as “immunodominant”. However, recent studies have reassessed the importance of CTL 
responses also against “subdominant” peptides (Zhong et al., 2003). These peptides, being not 
submitted to the immune response pressure, are less subjected to the onset of mutations and 
are therefore more conserved, ensuring the elimination of virus variants escaping CTL 
surveillance, as in the case of HIV-1. Moreover, evidences from studies on the murine model 
seem to indicate that the response to some immunodominant epitopes can be detrimental and 
sometimes does not correlate with virus clearance (Crowe et al., 2006). In general, it is 
assumed that T cell epitopes selected naturally by the immune system are good candidates for 
peptide-based vaccines. However, some of these epitopes may have limited efficacy in terms 
of anti-viral control and may even lead to delayed viral clearance. Two major problems have 
to be faced when trying to formulate efficient peptide-based vaccines able to elicit CTL 
responses. The first is that both immunodominant and subdominant peptides are different 
among individuals as a function of their haplotypes. The second is that the delivery system 
must be able to target peptides on MHC class I molecules. Very good results have been 
obtained using complex, conjugated peptides that include multiple CTL and helper epitopes 
(Alexander et al., 2002).  
 
1.2 Plants as vaccine factories  
 
Nowadays, subunit vaccines may be obtained either by purification from pathogen’s cultures 
or by expression in heterologous systems. A wide range of systems (bacteria, yeast, insect, 
mammalian) have been successfully developed to this aim (Baneyx and Mujacic, 2004; 
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Gerngross, 2004; Wurm, 2004; Kost et al., 2005). Bacteria and fungi represent robust 
production systems while mammalian cells are the favourite as in their environment even 
complex molecules such as antibodies fold properly and undergo post-translational 
modifications essential for their activity and their immunological and biochemical properties 
(glycosylation, methylation, acetylation, phophorylation, myroystilation). However, because 
yields and quality can be low due to product complexity, costs can be high due to the 
expensive and sensitive culture conditions and contamination from pathogens represents a 
sizeable risk for human health, it is sensible to consider alternative heterologous expression 
systems. Among the possible alternatives, plants have been considered as an efficient system 
to guarantee availability of bio-active, safe recombinant pharmaceuticals, in particular vaccine 
antigens that can be manufactured in a cost-effective manner (Ma et al., 2003). In fact, despite 
the major emphasis as to the relevance of transgenic plants was initially given to the 
possibility to confer traits of agronomic importance, such as disease resistance (Vaeck et al., 
1987; Broglie et al., 1991; Tavladoraki et al., 1993), in the past decade plants have also 
emerged as “factories” for the commercial production of valuable recombinant proteins and 
vaccines. The application of plants for the production of therapeutic proteins offers several 
advantages such as absence of mammalian pathogens, cost effectiveness, large-scale 
production and relative ease in expression and purification. In spite of the evident advantages 
of using plants as biofactories, this production platform has some limitations. In particular, the 
different glycosylation pattern as compared to mammals (Chrispeels and Faye, 1996). This is 
of particular importance for the production of human therapeutics, as many human proteins 
are glycosylated and their efficacy depends on their intrinsic biochemical features. Strategies 
aimed at addressing plant glycosylation have been developed to express proteins similar or 
identical to the cognate molecule (Cox et al., 2004; Bakker et al., 2006).  
 
1.2.1 Methods for antigen production in plants 
 
1.2.1.1 Stable transformation  
Different strategies and techniques have been deployed to construct stably transformed 
(transgenic) plants. Stable nuclear transformation is generally achieved by Agrobacterium-
mediated gene transfer (Graves and Goldman, 1986; Feldmann and Marks, 1987; Clough and 
Bent, 1998) and sometimes also by the less efficient direct-gene delivery methods (e.g., 
particle bombardment, electroporation) used especially to transform plant species recalcitrant 
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to Agrobacterium-mediated gene introduction (such as many monocotyledonous species) 
(Birch, 1997). Several antigens have been expressed in plants by this method (Tab. 1).  
Because expression levels obtained through nuclear transformation are not always 
satisfactory, due to interfering factors at different stages of the procedure, some basic 
shrewdness can be taken. The first forethought to prevent problems due to intrinsic features of 
the heterologous sequence consists in codon usage optimization and removal of cryptic 
signals that can negatively affect post-translational steps (Sullivan and Green, 1993; Koziel et 
al., 1996). Among basic interventions, the selection of suitable 5’- and 3’- regulatory elements 
able to ensure reproducible high-level and tissue-specific transgene expression is also 
important. In fact, it has been demonstrated that the activity of nominally constitutive 
promoters can vary as a function of the developmental stage, organ and plant species 
(Williamson et al., 1989; Malik et al., 2002; Samac et al., 2004).  
In the attempt to boost transgene expression in plants, viral promoters (Guilley et al., 1982), 
tissue-specific promoters (De Jaeger et al., 2002) and promoters of highly transcribed genes 
(Outchkourov et al., 2003) have been used. In a similar direction, efforts are oriented in 
attempting to adjust gene insertion into the genome by homologous recombination in order to 
induce the integration of the heterologous gene into a pre-determined genomic location in a 
single copy (Hanin and Paszowski, 2003; Srivastava and Ow, 2004). It has indeed been 
reported that the integration of several direct and inverted copies of the heterologous gene (De 
Neve et al., 1997; Tzfira et al., 2004), a fairly common event, can induce the accidental 
inactivation of genes fundamental for plant metabolism but, above all, transgene silencing 
(Hobbs et al., 1993; Jorgensen et al., 1996; Muskens et al., 2000; De Buck et al., 2001). 
Although single-copy transgenes can induce silencing as well (Elmayan and Vaucheret, 1996; 
Day et al., 2000), they generally have a uniform and stable expression (De Buck et al., 2004). 
In the attempt to enhance production efficiency of transgenic lines, plants stably encoding 
replicating viral vectors, the so-called replicons or amplicons, have also been developed, 
expressing uniformly and synchronously a foreign gene, thanks to the efficiency of viral 
replicases (Palmer et al., 1999; Mallory et al., 2002; Gleba et al., 2004; Zhang and Mason, 
2005). 
Alternative to nuclear transformation is the integration of the gene of interest into the plastid 
genome to produce stably genetically modified plants (Daniell, 2006). By this approach the 
foreign gene is inserted by homologous recombination into a specific site of the plastid 
genome, eliminating the “position effect” occurring in nuclear transformation. Despite the 
high levels of transgene transcription, no gene silencing has been described in plastid 
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transformed plant lines, and differences in the levels of expression occur only as a 
consequence of the activity of chloroplast proteases. Although this transformation technique 
is somehow laborious due to difficulties in obtaining homoplasmic plants (where the 
integration of the transgene occurs in every plastid genome), chloroplasts remain ideal 
“bioreactors” although closer to prokaryotic expression systems. Chloroplast genomes defy 
the laws of Mendelian inheritance in that they are maternally inherited and therefore minimize 
the outcross of transgenes via pollen, resulting in an environmentally friendly approach for 
the production of recombinant proteins. By the construction of transplastomic plants, having 
up to 10 000 plastid genomes per leaf cell, very high levels of expression have been obtained 
(Tregoning et al., 2003).  
As to the production of vaccines, a wishful thinking of plant biotechnologists is to use stably 
transformed plants not only as a measure to reduce production costs and improve product 
safety and stability, but also as a means to efficiently deliver vaccines at mucosal level, 
eliminating the purification steps and the use of needles (Kapusta et al., 1999; Tacket et al., 
2000; Tacket et al., 2004; Thanavala et al., 2005). Unfortunately, this dream is still far to 
come true mainly because antigen expression in plants through nuclear stable transformation 
still suffer limitations due to the low and variable expression levels of the heterologous gene 
among independent lines. This is a major drawback when direct oral delivery of the plant 
tissue is foreseen as this impairs a precise a priori definition of the vaccine dose. From this 
point of view transplastomic plants offer more realistic chances of success. Preliminary data 
have been recently published on the oral delivery of Nicotiana tabacum transplastomic tissues 
expressing two plague–derived antigens. However, data indicate that this oral boost, 
following a subcutaneous immunization, is efficacious in eliciting a systemic antibody 
response but induces only low IgA amounts at mucosal level (Arlen et al., 2008). Moreover, 
chloroplast transformation techniques of edible crops still need to be improved (Kanamoto et 
al., 2003; Zhou et al., 2008). 
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Table 1. Representative antigens stably expressed in plants 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Pathogen  Antigen  Plant platform References  
Hepatitis B Virus Surface antigen 
Lactuca sativa 
Lupinus luteus 
Nicotiana tabacum 
Solanum tuberosum 
Mason et al., 1992; Thanavala et 
al., 1995 ; Ehsani et al., 1997 ; 
Kapusta et al., 1999; Richter et 
al., 2000 ; Thanavala et al. 2005 
 
 
 
 
 
 
 
Norwalk Virus Capsid protein Nicotiana tabacum Solanum tuberosum 
Mason et al., 1996; 
Tacket et al., 2000 
 
 
 
 
 
Enterotoxic E. coli 
Heat-labile 
enterotoxin B 
subunit 
 
Fimbrial subunit 
protein FaeG 
 
Nicotiana tabacum 
Solanum tuberosum 
Zea mays 
Haq et al., 1995; Mason et al., 
1998 ; Tacket et al., 1998; 
Tacket et al., 2004; Joensuu et 
al., 2004 
 
 
 
 
 
 
 
 
Rabies Virus Glycoprotein Lycopersicon esculentum McGarvey et al., 1995 
 
 
 
Cytomegalovirus Glycoprotein B Nicotiana tabacum Tackaberry et al., 1999 
 
 
 
Vibrio cholerae Cholera toxin B subunit 
Solanum tuberosum 
Oryza sativa 
Arakawa et al., 1997; 
Arakawa et al.,1998; 
Oszvald et al., 2008 
 
 
 
 
 
Foot-and-mouth 
disease virus 
VP1 Structural 
protein 
Arabidopsis 
thaliana Carrillo et al., 1998 
 
 
 
 
Porcine 
transmissible 
gastroenteritis 
coronavirus 
Glycoprotein S 
Arabidopsis 
thaliana 
Nicotiana tabacum 
Zea mays 
Gomez et al., 1998; 
Tuboly et al., 2000; 
Streatfield et al., 2001 
 
 
 
 
 
 
Mannheimia 
haemolytica  
 
Mannheimia 
haemolytica GS60 
 
Medicago sativa Lee et al., 2008 
 
 
 
 
 
Rabbit 
haemorrhagic 
disease virus  
VP60 Structural 
protein 
Solanum tuberosum 
 Martìn-Alonso et al., 2003 
 
 
 
 
 
Canine parvovirus VP2 protein Arabidopsis thaliana Gil et al., 2007 
 
 
 
SARS-CoV spike protein (S1) 
Nicotiana tabacum 
Lactuca sativa 
Lycopersicon 
esculentum 
Li et al., 2006; Pogrebnyak et 
al.,2005  
HIV-1 Nef Nicotiana tabacum  
Marusic et al., 2007; Barbante et 
al., 2008; de Virgilio et al., 2008 
 
 
 
 
In bold characters are indicated references describing clinical trials of the plant-expressed antigens. 
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1.2.1.2 Transient antigen production in plants 
As an alternative to stable genetic transformation, plant viruses, mainly ss(+)RNA viruses 
(e.g. Tobacco Mosaic Virus (TMV), Cowpea Mosaic Virus (CPMV), Tomato Bushy Stunt 
Virus (TBSV), Plum Pox Virus (PPV), Potato Virus X (PVX), Alfalfa mosaic virus (AlMV)), 
(Pogue et al., 2000) or Agrobacterium tumefaciens (Kapila et al., 1997), have been exploited 
as vectors for transfer heterologous sequences destined to transient expression in plants. By 
this approach the transgene is not transmitted from the transformed plant to the progeny and, 
for this reason, repeated infection/transformation cycles are necessary. Nonetheless, the main 
advantage of this strategy of gene delivery to plant cells is that high yields of the product of 
interest can be obtained in relatively short periods of time. Several methods have been 
developed to transiently express heterologous proteins in plants using viral vectors. The 
foreign sequence can be integrated into the viral genome as an additional coding sequence or 
used to replace a viral gene (Canizares et al, 2005). A further strategy has been developed 
with the goal of using plant viruses not only as vehicles of the heterologous sequence but also 
as carriers of the encoded antigen in vaccine formulations from plants. This approach consists 
in inserting into the viral genome the sequence of interest so that in infected plant tissues 
chimeric virus particles are produced displaying on their surface as fusion to coat protein (CP) 
subunits the encoded polypeptide (Johnson et al., 1997). These modified virions that can be 
produced in large quantities using plants as biofactories, are attractive because, due to their 
structure, they can be used to safely and efficiently deliver antigens, with a significant 
increase in immunogenicity. According to the structure of the virus particles, some 
restrictions are imposed as to the size of the polypeptide, in that large sequences can create 
steric hindrance and interfere with virus particle assembly. The site of the insertion must be 
also selected on a structure-based analysis. For example, TMV tolerates peptide insertion at 
the C-terminus of the CP of a maximum of 23 amino acids. In addition to that, factors other 
than length have been identified as interfering with chimeric virus particles 
production/assembly (Bendhamane et al., 1999; Porta et al., 2003; Lico et al., 2006). When 
used in animal models, plant-derived chimeric virus particles have been demonstrated to 
confer antibody mediated immunity against a number of diseases. In most of the cases, this 
was obtained by parenteral immunization, but there are encouraging indications that also 
mucosal immunization is effective (Marusic et al., 2001). Recently, some data have been 
produced indicating that chimeric plant virus like particles produced in E. coli or plant virus 
particles chemically modified through the in vitro linking to antigens, can be effective in 
activating cytotoxic T cell immune responses (McCormick et al., 2006; Lacasse et al., 2008). 
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As for transient expression by Agro-infiltration, despite this technique has been mainly used 
to predict expression efficiency of constructs before nuclear stable transformation, it is 
currently considered also as an efficient means for large scale production. Recently, Icon 
Genetics Inc. has developed a system (magnICON) for the over-expression of foreign genes 
that conjugates the efficiency of Agrobacterium-mediated transformation with viral rate of 
expression. (Marillonet et al., 2005) To pursue this goal, TMV genome has been optimized, 
by the removal of cryptic sequences that, if recognized by the plant machineries, could affect 
viral replication/spreading, and splitted into 5’ and 3’ modules. The 5’ module includes the 
viral polymerase and the movement proteins genes while the 3’ module carries the gene of 
interest in place of the viral CP gene. The two modules, inserted into binary vectors are used 
to transform A. tumefaciens, that are then used to infiltrate plant tissues together with a third 
strain of A. tumefaciens carrying a vector encoding a recombinase. When the three different 
sequences are transferred into plant cells, the recombinase recognizes specific target-
sequences artificially added to each module inducing their recombination, hence the 
expression of the heterologous gene. This “deconstructed” virus system is unable to spread 
systemically as TMV needs the CP to move throughout the plant and in the environment. 
Moreover, it is not influenced by the dimension of the inserted gene due to the absence of the 
packaging process, while it drives the plant cell machinery to the production of heterologous 
protein. Using this strategy, high yields of several Yersinia pestis antigens have been 
expressed in Nicotiana benthamiana plants, and used to efficiently induce protective immune 
responses against the pathogen, when administered subcutaneously to guinea pigs (Santi et 
al., 2006).  
 
1.2.2 Considerations on antigen purification from plant tissues  
Plants are a cheap and reliable system for the production of recombinant molecules. 
Nonetheless, the downstream processing of plant material may involve expensive and time-
consuming methods, heavily affecting the final cost of good (Menkhaus et al., 2004). The 
intended final use of the recombinant product dictates special processing requirements. For 
example, pharmaceutical applications, including vaccine formulations, require an accurate 
downstream processing with a final product purity of at least 95-98%. This could change in 
the future if the transformed plant tissues will be used not only as a production but also as a 
delivery system, turning the processing minimal or unnecessary. Many research efforts are 
devoted to develop and improve downstream processing methods with the aim to reduce 
associated costs and to improve the feasibility for commercial application. In general, 
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processing and purification procedures consist in plant tissue harvesting and fractionation 
along with particle size reduction, extraction of the target protein into an aqueous medium, 
clarification of the crude extract and final purification (Menkhaus et al., 2004). The first issue 
to be considered to achieve high yield of the product of interest is the stability of the 
recombinant protein, keeping the notion that protein degradation does not occur only in the 
extraction buffer but also within cells. For this reason it is important to target the protein to 
proper cellular compartments as this may facilitate high yields of recovery. Different 
subcellular compartments may be eligible to accumulate different recombinant proteins. For 
example, the highest accumulation of complete antibodies has been reported by targeting into 
the apoplastic space while, the stability of single-chain Fv antibody fragments (scFv) is 
increased by the retention in the lumen of the ER (Conrad and Fiedler, 1998). Another 
example of the importance of protein targeting to the proper compartment for stabilization has 
been provided in the case of HIV-1-derived protein Nef (Marusic et al., 2007). The expression 
of Nef in the cytoplasm or in the ER lumen of tobacco cells showed that the targeting to the 
cytoplasm has a stabilizing effect on the protein that accumulates up to 0.4% Total Soluble 
Protein (TSP), while ER targeting  and introduction into the secretory pathway has a 
detrimental effect leading to protein degradation. The stability of Nef in the cytoplasm has 
been further increased by its fusion to a sequence  derived from the C5 cytochrome (Tail 
Anchor, TA), promoting  targeting to the cytosolic side of the ER membrane (Barbante et al., 
2008). By this approach Nef accumulated in tobacco cells to over 0.7% TSP. However, 
alternative approaches as targeting to Nicotiana tabacum protein bodies through zeolin fusion 
(de Virgilio et al., 2008) or plastid expression (Zhou et al., 2008) resulted in higher 
accumulation levels of Nef (1% and 40% TSP, respectively). Targeting recombinant proteins 
accumulation in various subcellular compartments or tissues involves the development of 
appropriate extraction protocols. A recent work compares the efficiency of different 
procedures in extracting from plant tissues a monoclonal antibody accumulating in different 
cell compartments (apoplast,  ER or plasma membrane) (Hassan et al., 2008). The data 
indicate that harsher techniques (mechanical shearing or manual grinding) and presence of 
detergents in the extraction buffer are required to purify the membrane-bound antibody, while 
gentler procedures are suitable to extract the antibody from apoplast or ER. From the point of 
view of costs and purification, protein accumulation in the apoplast by fusion to ER targeting 
signals is the strategy of choice in that the scale-up would be simplified. Recombinant 
proteins accumulating in this extracellular space can indeed be purified without the need of 
tissues fractionation and by simply recovering the liquids from the extracellular spaces 
19 
 
through buffer infiltration. In the case of expression in cultured plant cells, apoplast targeting 
results in protein secretion directly into the culture medium. Secretion through the roots 
(rhizosecretion) transformed with secretory versions of heterologous sequences under the 
control of either the constitutive (CaMV) 35S, or the modified Agrobacterium mannopine 
synthase (mas2’) promoter, preferentially active in roots (Ni et al., 1996) allows an easy 
recovery of large amounts of recombinant protein directly from the medium of hydroponically 
grown plants (Borisjuk et al., 1999). Several approaches have been suggested for the 
stabilisation of the recombinant protein either by the addition of gelatine (Drake et al., 2003) 
or the co-secretion of protease inhibitors (Komarnytsky et al., 2006). An advantage of this 
approach is that the protein can be continually collected along over the plant lifetime, 
reducing time, costs and labour.  
The purification procedure to be followed to separate the recombinant protein from a complex 
plant extract is of course dictated by its targeting to a specific subcellular compartment/tissue 
but also by unique physicochemical properties of proteins, such as the isoelectric point or 
affinity to a particular ligand. Reports published on recovery and purification of recombinant 
products from plant tissues are typically based on chromatographic approaches that typically 
exploit affinity. The easiest way to render the protein affine to some molecule is to fuse the 
sequence to a molecular tag (Kusnadi et al., 1998; Terpe, 2003). Recombinant proteins with 
tags bind to columns packed with the affinity ligand so that contaminants in the crude plant 
extract are removed. Protein tags are generally represented by small peptides (His-, poly-Arg-, 
FLAG-, c-myc-, S-, and Strep II-, ELP-tag) or also by whole proteins (glutathione S-
transferase, maltose-binding protein). It has been shown that the use of tags may have a 
positive effect on the biochemical properties of the target protein by improving yields, 
preventing proteolysis, facilitating refolding and increasing solubility (Arnau et al., 2005). 
When the recombinant protein is an antibody or an antibody fragment the purification can be 
performed by exploiting the high specificity of the interaction with the antigen or by using 
Protein A or Protein G (Chargelegue et al., 2000). Although chromatographic methods are 
really efficient in obtaining highly pure proteins, they usually correlate with low yield of the 
final product especially because to prevent column clogging preliminary purification steps are 
necessary. This increases the possibility to waste the protein in intermediate steps. Recently, a 
very efficient alternative purification method, requiring the fusion of the protein of interest to 
elastin-like peptides (ELP), has been used to purify an antibody expressed in Nicotiana 
tabacum plants (Floss et al., 2008). The purification of proteins fused to ELPs can indeed be 
achieved by a simple procedure called ‘inverse transition cycling’ as these peptides are highly 
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soluble in aqueous solutions below their transition temperature (Tt) while collapsing, 
aggregating and altering protein solubility, when the temperature is raised above Tt (Meyer 
and Chilkoti, 1999). Therefore, this approach may be suitable to significantly enhance the 
accumulation of recombinant proteins in plant (Patel et al., 2007). 
 
1.2.3 Seed-based production platforms 
Seeds are an eligible plant tissue for the large-scale expression of recombinant proteins. The 
main reason is that they have evolved to constitute a stable environment for the accumulation 
of storage proteins in a reduced volume. Recombinant protein targeting to mature seeds 
results in its accumulation in a sort of natural cellular ‘warehouse’ where it can be stockpiled 
for several years until recovery (Stoger at al., 2000). This provides an evident advantage over 
targeting to sporophytic tissues that require, after harvesting, an immediate processing or 
storage at very low temperature to prevent proteolysis. Heterologous protein restriction to the 
seed do not normally interfere with vegetative plant growth and limits adventitious contact 
with non-target organisms such as microbes in the biosphere and leaf-eating herbivores. 
Moreover, the small complexity of the seed proteome facilitates the purification and 
downstream processing of the protein of interest. Cereals, legumes and oilseeds have been 
largely investigated to be used for heterologous protein production (Stoger et al., 2005). The 
cereal crops are all potentially good production systems as their grains have high protein 
content and are produced in very large amounts each year. Among them, maize, despite being 
a cross-pollinating species, seems to be the most interesting for several reasons: i) it gives the 
highest annual grain yield; ii) it has the shortest generation interval; iii) it benefits of a 
relatively easy in vitro manipulation and transformation procedures and of several seed-
specific and seed-restricted promoters that can be used to drive transgene expression. Maize 
has been used to produce the first two commercial plant-derived recombinant proteins, avidin 
and β-glucuronidase (Hood et al., 1997; Witcher et al., 1998) and represents, at the moment, a 
good candidate as a commercial platform for the production of pharmaceutical and technical 
proteins, including recombinant antibodies, vaccines and enzymes. Also rice, a self-
pollinating species, is an interesting crop as protein content per grain is high. Barley and 
wheat have lower producer price as compared to maize and rice but it is not yet clear why 
they do not accumulate recombinant proteins at high levels. Legumes have also been explored 
as potential production platforms due to the high protein content (>40% in soybean). 
However, transformation procedures are time-consuming compared to maize and in some 
cases, such as soybean, the high oil content of the grains might interfere with downstream 
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processing steps. Pea has a similar annual grain yield and seed protein content to soybean. 
However, the producer price is about 50% higher than that of soybean. 
The most obvious approach to get protein accumulation in seeds is to put the expression of the 
sequences under the control of one of the seed-specific promoters discovered in association to 
seed storage protein genes. One of the promoters most frequently used in monocots is the rice 
glutelin promoter Gt-1, which confers endosperm-specific expression both in rice and maize 
(Yang et al., 2003). Several other monocot seed-specific promoters have been identified, 
including the embryo-specific maize globulin-1 promoter (Belanger and Kriz, 1991), the 
maize endosperm-specific 27-kDa zein promoter (Russell and Fromm, 1997) and the barley D 
hordein (Horvath et al., 2000) and aleurone-specific promoters (Hwang et al., 2003). The 
expression levels achieved in monocots seed tissues using these promoters have exceeded 
those obtained using constitutive promoters (Hood et al., 2003). For heterologous genes 
expression in dicots, the novel seed-specific promoter bean arc5-I from the common bean 
(Phaseolus vulgaris) has been characterized. The expression in Arabidopsis thaliana of a 
ScFv antibody under the control of this promoter resulted in antibody levels higher than 36% 
of TSP in homozygous seeds (De Jaeger et al., 2002).  
Another approach followed to accumulate proteins in seeds is the targeting to the protein 
storage organelles (i.e. the protein bodies and protein storage vacuoles), as these 
compartments have evolved to facilitate stable protein accumulation. Several recent studies 
have shown that conventional targeting strategies might not work as expected when applied in 
seeds. In fact, recombinant proteins tagged with the secretory pathway targeting peptide 
KDEL in rice endosperm were mainly found in protein bodies rather than in the apoplast 
(Nicholson et al., 2005), probably because, to reach the apoplast, proteins have to pass 
through the endomembrane system, which is generally well articulated in storage cells and 
“specialised” at targeting proteins to storage organelles.  This abnormal behaviour has effects 
on the glycosylation pattern of proteins expressed in seeds (Stoger et al., 2005).  
 
1.2.4 Organelle coupling-based purification  
An innovative approach to perform a preliminary cost-effective purification of the 
recombinant protein from plant tissues, removing the bulk of native proteins, consists in its 
coupling to plant cell organelles (in particular, chloroplasts and oil bodies) that can be easily 
separated from the other cellular components by centrifugation on sucrose density gradients.  
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1.2.4.1 Chloroplast targeting  
Protein coupling to chloroplasts can be obtained by the fusion with PAP-fibrillins 
(plastoglobulins), a family of proteins coating the low density lipoprotein particles attached to 
the thylakoid membranes called plastoglobules. The PAP/fibrillin family proteins are highly 
conserved in the plant kingdom and plastoglobules are ubiquitously found in all types of 
plastids, mainly in leaf chloroplasts. In leaf crops producing high biomass, plastoglobule 
targeting would allow accumulation of large amount of the recombinant proteins and easy 
downstream processing of leaf material. As for chloroplast targeting of recombinant proteins, 
this approach may limit the toxicity of foreign proteins to plant cells and facilitate the 
downstream processing. In particular, sequestration of the recombinant proteins in particles 
such as plastoglobules (Fig. 1) minimizes the deleterious effects on photosynthetic light and 
dark reactions due to the accumulation of the foreign protein into the chloroplasts.  
 
 
 
 
Figure 1. Plastoglobules in chloroplasts. 
Schematic representation of a chloroplast (left side) highlitghing  the 
thylakoid-associated plastoglobules lipoprotein particles (Kessler and 
Vidi, 2007). 
 
 
The expression of the Yellow Fluorescent Protein (YFP) as fusion to these proteins 
demonstrated the advantages of this approach in terms of recombinant protein purification 
from leafy crop plants such as tobacco (Vidi et al., 2007). In fact, chloroplasts were 
previously fractionated from other cellular components and later plastoglobules were easily 
separated from thylakoid membranes and from the chloroplast envelope by floatation 
centrifugation on density sucrose gradient. This approach provided a 250 fold enrichment of 
the recombinant protein.  
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1.2.4.2 Oil body targeting 
Oil body targeting of recombinant proteins is an oilseed-based production and recovery 
technology successfully developed at SemBioSys Genetics Inc. (http://www.sembiosys.com/) 
(Fig. 2).  
 
 
Figure 2. The oleosin-fusion technology.  
Schematic representation of heterologous proteins targeting to oil bodies 
through oleosin sequence fusion (envisaged by SemBioSys, 
http://www.sembiosys.com/).   
 
 
Owing to their physicochemical properties, oil body coupling can be exploited to simplify 
downstream processing of transgenic seeds accumulating recombinant proteins. In fact, oil 
bodies easily separate from other seed components by liquid–liquid phase separation as they 
tend to float. This mild process eliminates the need for refolding and can reduce the number 
of chromatography steps required to obtain a purified product, thereby reducing consistently 
the overall cost of good (Deckers et al., 2004). Exploratory studies performed by fusing 
Arabidopsis oleosin to β-glucuronidase (GUS) have shown that the enzymatic activity of the 
recombinant protein is preserved (van Rooijen and Moloney, 1995a). Similarly, by oleosin 
fusion to Green Fluroescent Protein (GFP) it has been demonstrated that the chimeric oleosin 
is correctly targeted to and tightly associated with oil bodies as shown in tobacco leaf cells 
(Wahlroos et al., 2003). Few pharmaceuticals have been produced in plants using the oleosin 
fusion technology. As a proof of concept, the recombinant human precursor insulin has been 
expressed and recovered as an active molecule from transgenic A. thaliana seeds (Nykiforuk 
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et al., 2006). When analysed by reverse phase high-performance liquid chromatography (RP-
HPLC), oil body-targeted insulin showed a peak with a retention time almost identical to that 
of the standard insulin (yeast recombinant human insulin). The expression of insulin in 
transgenic seeds through the fusion to A. thaliana oleosin was approximately six times higher 
that obtained in potato tubers by the fusion to cholera toxin B (CTB) (Arakawa et al., 1998). 
The fusion accounted for 0.1% TSP present in the tubers, corresponding for mature insulin to 
0.022% TSP. A further example is provided by the expression of hirudin in B. napus seeds. 
Hirudin is an anticoagulant peptide used to treat thrombosis, originally isolated from the 
medicinal leech Hirudo medicinalis. Its expression in plants and targeting to the oil bodies 
through fusion to Arabidopsis oleosin guarantees high levels accumulation and provide a 
mean for the easy purification (Parmenter et al., 1995). Both insulin and hirudin bound to oil 
bodies undergo a further processing to free the active molecule from the organelle. This is 
achieved by inserting an endoprotease cleavage site between the oleosin and the recombinant 
product sequences. Beside the use of recombinant protein coupling to oil bodies aimed to 
improve the purification procedure, in the patent of SemBioSys, the use of this method to 
produce innovative vaccine formulations is envisaged. This application considers the 
possibility of using the purified chimeric oil bodies as carriers to efficiently deliver antigens 
in innovative vaccine formulations. The immunogenic properties of oil bodies, mainly due to 
their corpuscular nature, could be potentiated owing to their lipid nature. The patent describes 
also different procedures that can be used to couple antigens to oil bodies surface, other than 
fusion to a heterologous oleosin, such as cross-linking by biotin-streptavidine interaction. 
Moreover, the patent describes the possibility to deliver chimeric oil bodies not only through 
“classical” immunization routes but also transdermally, an easy non-invasive delivery strategy 
that provides a prolonged stimulation of the immune system and may lead to self 
administration by reducing health care system costs. Results concerning this kind of potential 
applications have never been published up to now. 
 
1.3 Oil body protein composition and biogenesis 
 
Oilseeds accumulate lipids to supply the energy requirements for the growth of the seedling 
after germination. Such lipids are generally stored as triacylglycerols (TAG) in spherical 
compartments referred to as spherosomes (Frey-Wyssling et al., 1963), oleosomes (Murphy, 
1990) or, most frequently, oil bodies. Oil bodies are found in the endosperm and embryo cells 
of oilseeds and pollen. They have variable diameters with a narrow range between 0.5 and 2.0 
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µm and a hydrophobic TAG core surrounded by a half-unit phospholipid (PL) membrane and 
an outer shell of specialized proteins (Tzen et al., 1993). Chemical analyses reveal that 1 to 
4% (by weight) of seed oil bodies is composed of proteins (Tzen and Huang, 1992). Oil 
bodies have been analysed biochemically due to the economic importance of oilseeds. Among 
the oil body proteins, oleosins are the most abundant (Jolivet et al., 2004). They are relatively 
low molecular weight proteins of about 16-24 kDa that accumulate on the surfaces of lipid 
bodies in desiccation tolerant seeds. Their distribution is consistent with an active role in oil 
mobilization as it has been proposed they could act as binding site for lipase (Huang, 1996). 
Oleosins form a family with similar structural properties. They include a long hydrophobic 
core of about 70 residues organized around a unique 12–amino acid motif (proline knot) and 
two polar N- and C-terminal domains flanking the hydrophobic region (Abell et al., 1997). A 
high degree of similarity is located in, but not restricted to, the hydrophobic domain and 
proline knot motif, both of which are essential for the correct targeting to oil bodies (van 
Rooijen and Moloney, 1995b; Beaudoin and Napier, 2000). Sixteen oleosin genes have been 
characterized in the A. thaliana genome (Kim et al., 2002). According to their tissue specific 
expression, these genes have been divided into three groups: those specifically expressed in 
maturing seeds (5), those expressed in both maturing seeds and floral microspores (3) and 
those specifically expressed in the floral tapetum (8). Oleosins are responsible for the 
stabilisation of oil bodies, preventing these organelles from coalescing during seed 
desiccation. Several observations suggest that they are also involved in ensuring the 
maintenance of the appropriate size and surface volume/ratio to balance the conflicting needs 
for efficient storage and ease of TAG mobilization (Napier et al., 1996). Higher TAG-to-
oleosin ratios result in larger oil bodies. To this purpose it has indeed been observed that: i) 
species containing higher amounts of oleosins (i.e. Brassica napus) have smaller oil bodies 
compared with those with lower oleosins content; ii) oleosins are not present in fruit oil 
bodies, such as avocado (Persea americana) and olive (Olea europaea) (Ross et al., 1993) 
typically containing larger oil bodies; iii) manipulating oleosin expression and accumulation 
levels modulates the size of oil bodies (Siloto et al., 2006).  
How and when oleosin accumulates on oil bodies is a matter of debate. The finding that oil 
body biogenesis can occur in the absence of oleosins (Ross et al., 1993) supports a model in 
which TAG droplets surrounded by a PL monolayer accumulate in ER subdomains later 
acquiring their oleosin coat. An alternative model suggests that accumulation of TAG, oleosin 
and PL is concomitant during oil body assembly (Peng and Tzen, 1998). Besides abundant 
oleosins, other three minor proteins of 27, 37 and 39 kDa have been identified in sesame oil 
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bodies (Chen et al., 1998). The gene encoding 27 kDa protein has been cloned. Sequence 
analysis revealed the presence in this protein, named caleosin, of a putative calcium-binding 
motif (Chen et al., 1999). Similarly to oleosin structure, caleosin contains three structural 
domains: an N-terminal hydrophilic domain including the calcium-binding motif, a central 
hydrophobic anchoring domain with a proline knot and a C-terminal hydrophilic domain 
containing a potential phosphorylation site (Chen et al., 1999). Caleosin function is 
presumably modulated by calcium binding and phosphorylation state. It has been suggested 
that it could be involved in calcium-mediated fusion of oil bodies (Frandsen et al., 2001). Also 
the gene encoding the 37 kDa polypeptide has been cloned (Lin et al., 2002) revealing that the 
encoded protein, named steroleosin, possesses an N-terminal hydrophobic segment anchoring 
to the oil body surface a soluble domain homologous to sterol-binding 
dehydrogenases/reductases, normally involved in signal transduction in diverse organisms. 
Steroleosin could be involved in diverse signal transduction (Jolivet et al., 2004). 
 
1.4 Organelle proteome analysis by mass spectrometry approach 
 
Recently, the development of fine mass-spectrometry (MS) techniques has lead to more 
comprehensive studies on eukaryotic cells allowing to address many biological questions. The 
availability of an ever-increasing number of sequenced genomes and advances in MS 
technology enables acquisition of information on protein identity, abundance, subcellular 
localization, post-translational modifications, interactions, and ultimately, function. The aim 
of organelle proteomics is first to establish the protein repertoire of various subcellular 
compartments. At its simplest, organelle proteomics involves isolating the organelle of 
interest and producing a catalogue of the proteins present in that organelle by some form of 
separation of proteins or their proteolytic fragments followed by identification utilizing MS. 
Subcellular fractionation and biochemical enrichment of these proteins are required to 
overcome the abundance issues and detect even low abundance proteins. The majority of 
studies on plant organelle proteomic have been focused on the chloroplast and mitochondria, 
which can be isolated rather easily. However, plant research is nowadays focusing on 
developing procedures to purify new plant organelles and characterize them through the MS 
approach. Using these sensitive techniques few catalogues of proteins have been obtained for 
vacuoles (Jaquinod et al., 2007), plastids (Jain et al., 2008) and oil bodies (Jolivet et al., 
2004). However, organelle protein catalogues may contain a high number of false positives 
because of the difficulty or near impossibility of isolating cellular organelles to 100% 
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homogeneity. Moreover, the high sensitivity of the new generation mass-spectrometer means 
that even low abundance contaminants may be detected. The problem with contaminants in 
such catalogues is that they cannot be distinguished from true residents, hence calling into 
question the reliability of the entire catalogue. One approach to address the problem of 
contaminants is known as subtractive proteomics. In this approach, a preparation of the 
organelle is compared against a “control” sample to correct for background contamination. 
Manipulating or interfering with the accumulation of a true resident protein to its subcellular 
localization and analysing the sample by quantitative MS, true resident proteins would 
modify, meanwhile contaminants would stay at same level as the control (Borner et al., 2006). 
By this method a set of 241 true lipid raft residents has been identified by comparing 
membrane protein sets derived from control and cholesterol-disrupting drugs treated samples. 
Membrane associated proteins decreased in treated samples, meanwhile no variations were 
observed for non-specific proteins (Foster et al., 2003). On the other hand, dynamic studies 
may be performed on organelles as proteins that are stably associated may change their 
distribution according to the cellular growth conditions (Andersen et al., 2005). While the 
subtractive approach can be useful for studying a single organelle, it still requires high level 
enrichment and this is not always achievable. Moreover, analysis of dynamic cell 
compartments as ER and Golgi apparatus and characterization of proteins trafficking between 
them and their budding vesicles require a more global survey. In fact, many proteins are 
shared between these compartments and recently, several methods have been developed to 
survey protein localization in multiple organelles. It has been suggested that a true resident 
has a characteristic distribution pattern within a gradient and that it was not restricted to a 
single fraction. Proteins which are co-resident in organelles will co-fractionate upon 
biochemical separation (De Duve, 1971). In this way, the location of a protein of unknown 
residency can be identified by matching to specific marker proteins. The quantitative profiling 
of protein levels in the different fractions is carried out and statistical analysis is used to 
identify co-varying proteins. The first of these methods, Protein Correlation Profiling, was 
initially developed to identify contaminants in a purified preparation of centrosomes 
(Andersen et al., 2003). Centrosomes were first purified on a sucrose gradient and peptides 
derived from five fractions of the gradient were analysed by consecutive Liquid 
Chromatography (LC)-MS runs by a label-free approach. The peak intensity of the peptides 
were utilised to profile the relative abundance of proteins in different fractions. The 
centrosomal proteins showed a different distribution profile compared to that of contaminants 
along the gradient.  A recently developed method which works on similar principles is the 
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Localization of Organelle Proteins by Isotope Tagging (LOPIT). LOPIT was used to map 
proteins to multiple organelles in A. thaliana. Organelles were first partially separated on a 
density gradient, and gradient fractions were labeled for relative quantitation of protein levels 
in order to profile each protein distribution in the gradient. Stable isotope tags ( Isotope-
Coded Affinity Tag (ICAT) and iTRAQ reagents) were used to distinguish proteins from the 
different fractions (Dunkley et al., 2004; Dunkley et al., 2006). In particular the use of iTRAQ 
reagents for labelling increased considerably the proteome coverage. The multivariate 
statistical methods (Principal Components Analysis (PCA), Partial Least Squares-
Discriminant Analysis (PLS-DA)) applied to this quantitative MS technique allows proteins 
to be clustered based on their co-variation. A given protein which shows a similar distribution 
to a known organelle marker clusters with it on a PCA scatter plot and is likely to reside in the 
same organelle. Proteins from different organelles form separate clusters. In particular, using 
this approach, 527 proteins have been localised confidently to the ER, Golgi apparatus, 
vacuolar membrane, plasma membrane, mitochondria and plastids (Dunkley et al., 2006). 
Localizations were confirmed by immunofluorescence microscopy of GFP-fused proteins. 
The increasing need of developing procedures to prepare highly purified organelles and 
sensitive techniques to detect either low abundant true organelle residents or contaminants 
find an answer in organelle proteomics investigation.  
 
1.4.1 Mass spectrometry-based proteomics workflow  
The typical workflow for an MS-based proteomics experiment involves a preliminary protein 
extraction step followed by a pre-fractionation phase (biochemical fractionation, affinity 
purification, two-dimensional or one-dimensional gel separation) aimed to reduce sample 
complexity. Afterwards, proteins are digested to peptides with a sequence specific protease, 
usually trypsin, to generate samples easier to handle and solubilize and with mass spectra 
easier to interpret. After the digestion peptides are separated by one or more steps of high-
pressure liquid chromatography (HPLC) to be then identified. When peptide mixtures derive 
from less then 2 or 3 proteins, peptide mass fingerprinting (PMF) can be easily and quickly 
achieved without sequencing or fragmentation of peptide ions using a tandem MS approach. 
During PMF, peptides generated by the tryptic digest of an isolated protein are analyzed by 
MS giving a set of peptide masses which are unique to that protein. By matching the tryptic 
peptide masses to a database of proteins that has been digested in silico, the protein can be 
identified. When more complex peptide mixtures have to be analyzed, tandem MS (MS/MS) 
must be performed. Column eluted peptides are ionised at the ion source by the process of 
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ElectroSpray Ionization (ESI). At this stage, peptides ionize under the application of a strong 
electric potential and the co-eluting solvent evaporates. Alternatively, peptides can be ionized 
by matrix-assisted laser desorption ionization (MALDI), in which analyte is mixed with a 
solid crystalline matrix, typically an organic acid, and bombarded with a laser to bring about 
ionization. A mass spectrum of the peptides is recorded, followed by parent ions 
fragmentation in order to yield peptide sequence information. Fragmentation can be induced 
in several ways: by collision with an inert gas in a process known as collision-induced 
dissociation (CID) or by radical directed cleavage in electron transfer dissociation (ETD) or 
electron capture dissociation (ECD). Resulting MS/MS spectra contain fragment ions giving 
information on peptide sequences and allowing protein identification. 
The final stage in a proteomics workflow is protein identification. With MS/MS data, it is 
possible to interpret spectra to obtain peptide sequences using the mass differences between 
consecutive fragment ions. This is known as de novo sequencing, but it depends highly on 
manual interpretation and is usually used only if the genome sequence of the study organism 
is not available. The most common method of identifying proteins in high-throughput studies 
is by database searching. The MS/MS spectra are used to generate peak lists which are 
searched by matching against theoretical MS/MS spectra derived from in silico digestion of 
protein databases. The MS/MS spectra are assigned to peptides with probability scores to 
indicate how likely the match is to be true. The identified peptides are then ‘assembled’ into a 
list of proteins that are likely to have been present in the sample. In this way, a large number 
of proteins can be identified from a complex sample in a single experiment. Several 
commercial algorithms exist for database searching, such as SEQUEST (Yates et al., 1995) 
and Mascot (Perkins et al., 1999). 
 
1.4.2 Principles for Mass Spectra interpretation 
In LC-MS/MS the peptide mixture is first loaded onto the reversed-phase HPLC (RP-HPLC) 
columns and peptides are separated according to their hydrophobicity. The most hydrophilic 
peptides elute first. The eluted peptides are directly coupled to the ion source and a mass 
spectrum of the eluting peptides is recorded (MS survey scan). The records of the intensity of 
the peptide ions are displayed on the spectra as related to their mass to charge ratio (m/z). 
Peptides are often protonated during electrospray ionization, giving rise to (M+nH)n+ ions, 
where M is the mass of the peptide and n is usually 2 or 3. The MS survey scan can be used to 
determine the charge state of a peptide using the isotope envelope. Due to the natural 
abundance of 13C, a peptide gives rise to several isotopic peaks consisting of no 13C atoms, 
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one 13C atom, two 13C atoms and so forth. These isotopic peptides are 1 Da apart from each 
other, but because the mass spectrometer measures the ratio m/z, the corresponding peaks are 
separated by an m/z value dependent on the charge state. Hence, a doubly charged peptide 
will have isotope peaks 0.5 Da apart. This can therefore be used to determine the peptide 
charge state. Knowing the charge state and m/z value in turn allows one to calculate the mass 
of the peptide. Following the survey scan, ions are selected for fragmentation to yield 
sequence information. In CID, peptide ions of a particular m/z are isolated (this is known as 
the precursor ion), and bombarded with inert gas molecules which transfer their kinetic 
energy and induce peptide bond cleavage. The mass spectrum of the fragment or product ions 
is recorded and this forms the MS/MS spectrum. The selection of ions for MS/MS can be 
controlled by the user if there is a particular interest in certain species. This is known as 
Selected Ion Monitoring (SIM). More commonly though, the instrument is operated in data-
dependent acquisition mode, whereby the 2 or 3 (or more) most abundant peptide species 
eluting at a given time are automatically selected for MS/MS. The instrument then returns to a 
survey scan and selects the next ions for MS/MS. Usually a dynamic exclusion is set up so 
that once a peptide of a certain mass has been selected and sequenced, it is excluded from re-
selection to allow for other peptides to be sampled. Cycling between MS and MS/MS modes 
in this way is known as the duty cycle and allows one to maximize the number of peptides 
that are sampled, even including those of lower abundance.   
 
1.4.3 Quantitative mass spectrometry 
Recently, several high throughput methods have emerged involving quantitative strategies 
that allow comparative or quantitative analyses of proteomes. Quantitative data come in two 
forms, the absolute amount of protein in the sample or the relative change in protein amount 
between two states. The traditional approach to protein quantitation has been to first separate 
proteins by two-dimensional gel electrophoresis, stain the gels (or label the proteins with 
fluorophores before gel separation) to obtain a measure of spot intensity and hence protein 
level, then excise differentially expressed spots of interest for identification by MS. This is 
both labour intensive and restricted by the limitations of 2-D gel electrophoresis such as bias 
against proteins that are hydrophobic or are too basic or acidic (Lilley et al., 2002). Hence in 
recent years the community has shifted to MS-based approaches which overcome these 
shortcomings. However, MS is not inherently quantitative in that the signal intensity of a 
peptide is not a direct read-out of the protein abundance. This lack of a direct relationship is 
because other factors such as size, charge and hydrophobicity of the peptide affect its 
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ionization and mass-spectrometric response. Hence, two peptides derived from the same 
protein, though present at the same stoichiometry, can give rise to different signal intensities 
in MS. MS-based quantitation must therefore compare chemically identical peptides. This can 
be achieved in two main ways: using a label-free approach or by differential labelling of 
peptides with stable isotopes. Label-free quantification approaches have the advantage that 
they can be performed with any type of sample. Clear disadvantages are the multiple 
occasions for experimental variation to occur during sample processing and analysis. Some 
quantitative information can be extracted from lists of protein identifications (qualitative 
experiments). Although protein and peptide identification scores provide a poor estimate of 
protein abundance as scores are based on the number of matching sequence fragments with 
the database rather than their absolute intensities, more accurate indices may be utilised for 
quantification as spectral counting and exponentially modified Protein Abundance Index 
(emPAI). The spectral counting is based on the idea that the number of MS/MS spectra 
assigned to a protein is a reflection of the protein abundance in the sample (Liu et al., 2004). 
Hence, by comparing the number of assigned spectra per protein in two different sample runs, 
one can obtain an estimate of the relative protein abundance. The emPAI value-based 
quantification relies on the observation that the number of peptides observed for a protein 
increases in relation to its abundance. The PAI value is obtained by normalizing the number 
of observed peptides to the number of observable peptides for the protein under consideration. 
Ishihama et al. (2005) viewed that the number of peptides observed correlated logarithmically 
with the protein amount. This observation led to the concept of an exponentially modified 
PAI (emPAI). An additional method for free-label quantification considers the peak area in 
the chromatogram describing the intensity of the signal related to the eluting peptides. This 
value is known as extracted ion current (XIC) and although the MS detector response to 
different peptides of the same protein is also very different because of the peptide extraction 
and ionization properties, the peak area is linearly related to the amount for the same peptide 
between two different samples over several orders of magnitude (typically 3). The intensities 
of the same peptides between two states of the proteome can be compared to determine their 
relative abundance.  
Besides label-free approaches, other methods have been developed for stable isotope-based 
quantification in proteomics which are mainly distinguished by the way stable isotopes are 
introduced into the peptide or the protein. Methods for labelling fall into these categories: i) 
spiking in an isotopically labelled analogue; ii) having cells incorporating the label 
metabolically; iii) incorporating through an enzymatic reaction during protein digestion; iv) 
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introducing a chemical, isotopically labelled tag into the peptide or protein. Labelling is 
carried out using non radioactive isotopes such as 13C, 15N, 2H. Although they can be 
equivalently incorporated in peptides, they can modify peptide properties. For example, 
deuterated peptides are cheaper to synthesise than 13C, 15N-labelled peptides, but they behave 
differently in RP-chromatography as compared to the unlabelled counterpart. The simplest 
approach to introduce isotope-labelled peptides in a quantitative experiment is to chemically 
synthesise them and spike a known amount into the protein sample as internal standard. The 
AQUA (Absolute Quantification) internal standard peptides are synthesized with an amino 
acid sequence that exactly mimics the corresponding native peptide produced during 
proteolysis. The heavy stable isotopes incorporate 13C- and/or 15N- labelled amino acids as 
they do not show chromatographic retention shifts. The synthetic and the native peptides 
share the same physicochemical properties including chromatographic elution, ionization 
efficiency, and relative distributions of fragment ions, but are differentially detected in a mass 
spectrometer due to their mass difference. An absolute quantification of the analyte is 
achieved by calculating the amount of the native peptide, hence the protein it came from, by 
direct comparison with the peak intensity of the internal standard spiked at a known 
concentration (Kirkpatrick et al., 2005). To reduce interference from the background ions, 
quantification can be performed on specific fragments of the peptide generated in the mass-
spectrometer using selected- or multiple-reaction monitoring (SRM or MRM, respectively). In 
these methods the MS is set to detect pre-programmed precursor-fragment combination with 
very high sensitivity and specificity. The internal peptide standard is introduced at a late stage 
in the sample processing workflow during or after protein digestion. Early incorporation of 
the label is favorable as it allows different samples to be combined earlier in the process, 
minimizing variation resulting from sample preparation procedures. The earliest stage at 
which differential incorporation of stable isotopes can be achieved is during growth. Cells can 
be metabolically labeled by growing them in culture with isotopically enriched 15N medium. 
15N is incorporated into every amino acid in the protein in this approach, originally pioneered 
in bacteria (Oda et al., 1999) but also applicable to higher organisms by feeding them on a 
diet of 15N-labeled bacteria, yeast (Krijgsveld et al., 2003) or algae (Wu et al., 2004). 
However, since peptides contain variable numbers of nitrogen atoms, matching light and 
heavy peptide pairs for relative quantitation is a challenge. An alternative technique achieves 
metabolic labeling of proteins by Stable Isotope Labeling of Amino Acids in Cell culture 
(SILAC) (Ong et al., 2002). In the most common approach, lysine and arginine are replaced 
with 13C6-lysine and 13C6-arginine respectively, so that every tryptic peptide is labeled and 
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peptide pairs always differ in mass by the same amount, making matching very easy. 
Alternatively, labelling through an enzymatic reaction, consists in digesting protein in the 
presence of H218O resulting in peptides labeled with 18O at their C-termini.  
Finally, proteins or peptides can be chemically labeled with isotopically coded tags. There is a 
wide variety of commercially available tags with a number of specificities for labeling 
different functional groups, hence allowing selective tagging of proteins or peptides of a 
specific class of interest. For example, ICAT are biotinylated tags that label cysteine residues 
in proteins (Gygi et al., 1999), while isotope-coded protein labels (ICPL) label free amino 
groups in proteins and peptides (Schmidt et al., 2005). With most of these tags, the relative 
abundance of the labeled peptides is measured in MS. However, the iTRAQ reagent (Ross et 
al., 2004) works on quite a different principle. In fact, the iTRAQ reagents label peptides at 
their N-termini and lysine residues. They are a set of four tags that are isobaric in MS mode, 
but produce isotopically distinct reporter fragment ions in MS/MS, hence allowing relative 
quantitation during MS/MS. Chemical labeling approaches can be used on any type of sample 
and some tags, such as iTRAQ, are useful for simultaneous analysis of multiple samples. 
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2. THE AIM OF THE PROJECT 
 
One of the main goal of research in the vaccine field is the identification of new delivery 
strategies are able to elicit not only humoral but also innate and cytotoxic responses. Although 
antibody responses are those preventing pathogen from entering the host, the cytotoxic 
responses are crucial for the clearance of infected cells. Vaccine preparations based on 
pathogen subunits and peptides, despite being safe, do not normally elicit the immune system 
activation without the co-delivery of immune-potentiators as they are poorly immunogenic 
antigens by themselves. Moreover, their administration preferentially elicit antibody 
responses as they behave as exogenous antigens being presented in association to MHC class 
II molecules and activating CD4+ T cells. This is a major limitation as vaccine-induced 
responses should resemble as much as possible to pathogen-induced responses therefore be 
able to evoke CTL responses. Among delivery systems capable to overcome this limitation, 
lipid-based antigen formulations have been identified. By this approach the effective 
activation of naïve CTL is induced by exogenous antigens uptake and processing via the 
phagosome-cytosolic pathway.   
The present PhD project is aimed at devising Arabidopsis thaliana plants stably expressing 
antigenic peptides in association to oil bodies as oleosin fusions and successive 
characterization of these organelles for biochemical and immunological properties. The 
exploitation of oil bodies for the production and easy purification of pharmaceuticals from 
plants has been largely documented in literature (Parmenter et al., 1995; Nykiforuk et al., 
2006). The lipid core and the particulate nature of oil bodies have suggested that these 
organelles may be exploited also in vaccine formulations. After extraction and purification 
from seeds oil bodies, chimeric and wild type organelles are going to be fine characterized by 
mass spectrometry before being tested as antigen carriers.  
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3. MATERIALS AND METHODS 
 
3.1 Biological Materials 
 
3.1.1 Bacterial Strains 
Escherichia Coli XL10-Gold (Stratagene): TetrΔ(mcrA)183 Δ(mcrCB-hsdSMR-mrr)173 
endA1 supE44 thi-1 recA1 gyrA96 relA1 lac The [F’ proAB lacIqZΔM15 Tn10 (Tetr) Amy 
Camr] 
 
Agrobacterium tumefaciens GV3101: VirG+ Rifr pMP90 (Gmr) 
 
3.1.2 Plasmids 
pET3d (Novagen): is an expression vector derived from pBR322 and contains a  T7 
transcription cassette. 
 
pKMS2: is a cloning vector derived from pBlue Script KS that contains the promoter and 
terminator sequences of Glycine max cv Century 84 p24 oleosin isoform A gene and the Not I 
restriction site between the two regulatory sequences.  
 
pTOPO TA vector (Invitrogen) is a cloning vector that is provided linearized with a single 3’-
thymidine (T) overhangs and 3’-covalently bound topoisomerase I. This vector is really 
efficient for PCR products cloning as Taq polymerase adds a single deoxy-adenosine (dA) to 
the ends of the PCR products because of its non-template dependent terminal transferase 
activity, providing the insert with a compatible ends for cloning. The presence of 
topoisomerase I promotes the ligation between the 3’ ends of the vector and 5’ end of the 
insert.  
 
pOBP: is cloning vector derived from pET3d and containing the sunflower oleosin coding 
sequence (Oil body Binding Protein, OBP). 
 
pBIN19: is a binary vector that can replicate in both E. coli and A. tumefaciens. In this vector 
the Transferred DNA (T-DNA) region is replaced by a multiple cloning site (MCS). As the 
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cloning site is inserted within the T-DNA border sequences (Left Border, LB, and Rigth 
Border, RB) the transfer of a foreign DNA into the nuclear genome of dicotyledonous plants 
is allowed. The vector contains the neomycin phosphotransferase II (nptII) gene conferring 
kanamycin resistance (Kmr) for bacterial selection as well as the β−galactosidase gene 
(LacZ’) for E. coli screening. 
 
pBIN19-35S: is a binary vector derived from pBIN19. It contains the 35S promoter sequence 
of the Cauliflower Mosaic Virus (CaMV) upstream the MCS; this promoter allows the 
constitutive expression of the foreign DNA in plant tissues. 
 
3.1.3 Oligonucleotides 
Oligonucleotide primers were designed to anneal to the required target sequence template 
(Tab. 1). The primers were used to generate the DNA inserts for the cloning procedures, for 
PCR screening of positive bacteria clones and plants and for sequencing. Suitable restriction 
sites were introduced into the 5’ and 3’ ends of the primers utilised for PCR amplification of 
DNA inserts subsequently cloned into several vectors. The GC dinucleotide was added to 
both primer ends to allow efficient cleavage by restriction enzymes. All primers were 
purchased from Genosys Biotechnologies LTD (London). 
 
3.1.4 Plant material 
Arabidopsis thaliana plants, cv Columbia, were grown in large pots filled with damp Fison F2 
and covered with polythene. Individual plants were grown for 4-6 weeks in green house with 
a photoperiod of 16 hours light at 22°C and 8 hours night at 15°C.  
 
3.2 Non-Biological Materials 
 
3.2.1 Bacterial Media 
2YT  1.6% w/v Bactotryptone (Oxoid Ltd., Basingstoke, UK), 1% Bacto Yeast Extract 
(Oxoid), 0.5% w/v NaCl, pH 7.0 
 
SOC  2% Bactotryptone (Oxoid), 0.5% w/v Bacto Yeast extract (Oxoid), 5 mM NaCl, 2.5 
mM KCl, 20 mM glucose, 10 mM MgCl, pH 7.0 
 
37 
 
In the case of cultures on solid medium in Petri dishes, 1.6% w/v Bactoagar was also 
included. For vectors carrying ampicillin resistance gene as selection marker, the working 
concentration of ampicillin was 100 µg/ml for both solid and liquid media. E. coli 
transformed with the binary vectors were selected on solid medium and grown in liquid 
culture containing 50 µg/ml kanamycin. Meanwhile, A. tumefaciens GV3101 transformed 
with the binary vectors were selected on solid medium and grown in liquid culture containing 
50 µg/ml kanamycin, 100 µg/ml rifampicin, 25 µg/ml gentamycin. 
 
3.2.2 Buffer and solutions 
3.2.2.1 Tris-Tricine buffers 
10X Anode Buffer  
 
2 M Trizma Base pH 8.9  
 
10X Cathode Buffer  
 
 
 1 M Tris, 1 M Tricine, 1%  SDS  pH 8.25  
3X Gel Buffer  3 M Tris-HCl, 0.3 % (w/v) SDS pH 8.45 
 
2X TSB (Tricine 
Sample Buffer)  
100 mM Tris-HCl pH 6.8 , 24 % (w/v) Glycerol, 8 % (w/v) 
SDS, 5 % (v/v) Mercaptoethanol, 0.02 % (w/v) 
Bromophenol Blue 
 
3.2.2.2 Tris-glycine buffers 
1X Separating buffer  
  
0.4 M Tris-HCl pH8.8 
1X Stacking buffer  0.125 M Tris-HCl pH6.8 
5X SDS running buffer  0.95 M glycine, 0.1 M Trizma Base, 5% 
SDS, pH8.3 
 
3X Protein loading buffer  24% glycerol, 0.15 M Tris-HCl pH6.8, 
0.1% BPB, 1.6% SDS, 3% β-
mercaptoetanolo 
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3.2.2.3 Western blot buffers 
1X Transfer buffer  20% v/v methanol, 0.2 M glycine, 25 
mM Trizma Base and 0.02% SDS.  
 
Blocking solution 1% BSA (Bovin Serum Albumin) in TBS 
or 5% milk/PBS 
 
1X TBS (Tris buffered saline)  150 mM NaCl, 10 mM Trizma Base, pH 
8.0. 
 
1X T-TBS (Tween-Tris buffered saline)  0.05% v/v Tween 20, 150 mM NaCl, 10 
mM Trizma Base, pH 8.0 
 
10X PBS (Phosphate buffered saline)  1.5 M NaCl, 0.015 M Na2HPO4·H2O, 
0.09M NaH2PO4X 12H2O, pH 7.2 
 
1X T-PBS  
 
PBS 1X, 0.1% Tween 
1X Alkaline phosphate buffer  
 
100 mM NaCl, 5 mM MgCl2, 100 mM 
Tris-HCl, pH 9.5 
 
3.2.2.4 Southern blot solutions and buffers 
Depurination buffer 
 
0.25 M HCl 
 
Denaturation solution  
 
1.5 M NaCl, 0.5 M NaOH 
 
Neutralising buffer  1.5 M NaCl, 0.5M Trizma base, pH7.2 
 
20X SSC  3 M NaCl, 0.3 M tri-sodium citrate pH7.0 
50X Denhardts 
 
1% w/v ficoll, 1% w/v PVP, 1% BSA 
 
 
hybridization solution  
 
6X SSC, 50% formamide, 5X Denhardts, 0.5% SDS 
 
3.2.3 Plant transformation and selection media 
Dipping medium: 5% sucrose solution (autoclaved or prepared fresh), 0.05% Silwett L-77. 
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Selection medium: 4.4 g/l MS salts, 0.5 g/l MES, 1% w/v Agar (Technical Nb 3, Sigma) and 
50 µg/ml kanamycin. 
 
3.3 Enzymes 
Enzymes were obtained from Promega and New England Biolabs Corporations. 
 
3.4 Immunochemicals 
The oleosin polyclonal antiserum was raised at Rothamsted Research Institute immunizing 
rabbits with urea washed oil bodies isolated by Dr. D. Lacey (IACR-Long Ashton Research 
Station).The monoclonal antibody (mAb) 2F5 was provided by the National Institute of 
Health (NIH) AIDS Research and Reference Reagent Program; catalog no.1475. Secondary 
antibodies were provided by Sigma. 
 
3.5 Sterilisation  
All liquids, glassware and heat stable plastics were sterilised by autoclaving at 15 psi and 
120°C for 20 minutes. Solutions intolerant to these conditions were sterilised by filtration 
through 2 µm Acrodisks (Gelman Sciences, Ann Arbour, MI, USA).  
 
3.6 Methods  
 
3.6.1 Epitope selection 
Peptide sequences including or perfectly matching to T and B cell epitopes for expression on 
oil bodies surface as oleosin-fusions were selected using available epitope maps and referring 
to literature. The on-line algorithm SYFPEITHI for epitope prediction developed by the 
Department of Immunology of the University of Tubingen (Rammensee et al., 1999; 
http://www.syfpeithi.de/) was additionally utilised. The SYFPEITHI database is based on 
published T-cell epitopes and MHC ligands and predicts putative T-cell epitopes within a 
specified polypeptide sequence according to the MHC aplotype. The score values for each 
peptide are predicted considering the amino acids in the anchor and auxiliary anchor positions 
of a selected MHC molecule (as well as other frequent amino acids) and evaluating the 
frequency of the respective amino acid in natural ligands, T-cell epitopes, or binding peptides. 
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The score is calculated according to the following rules: amino acids have a specific value 
depending on whether they are anchor, auxiliary anchor or preferred residue in the selected 
peptide. Ideal anchors are given 10 points, unusual anchors 6-8 points, auxiliary anchors 4-6 
and preferred residues 1-4 points. Amino acids supposed to have a negative effect on the 
binding ability are given values between -1 and -3. 
 
3.6.2 Small scale purification of plasmid DNA 
A single colony was used to inoculate 3-5 ml of 2YT media and grown overnight with 
appropriate antibiotic selection. Bacteria were then transferred to 1.5 ml Eppendorf tubes and 
pelleted at 20000g, 4°C, 1 minute. Plasmid DNA extractions were carried out using Qiagen 
Plasmid Mini kit. 
  
3.6.3 Large scale purification of plasmid DNA  
A single colony was used o inoculate 3 ml of 2YT media and grown for 8 hrs with appropriate 
antibiotic selection (preculture). One ml of the preculture was inoculated in a 2 L flask 
containing 500 ml growing media and appropriate antibiotic selection. The culture was grown 
overnight at 37°C (E. coli) or 28°C (Agrobacterium tumefaciens), 250 rpm. Then, bacterial 
cultures were transferred into Oak Ridge tubes and pelleted at 6000Xg, 4°C for 10 minutes. 
Plasmid DNA extractions were carried out using the Qiagen Plasmid Maxi kit. The final DNA 
pellet was resuspended in water and analysed on 0.8% agarose gel. 
 
3.6.4 Plasmid DNA restriction 
One µg plasmid DNA was digested according to the supplier instructions using 5 units of 
suitable enzymes. The linearization of the plasmid was assessed by analysis on 0.8% w/v 
agarose gel. 
 
3.6.5 Oligonucleotide annealing 
Ten µl of 5’ oligonucleotide (1µg/µl) mixed with 10 µl of 3’ oligonucleotide (1µg/µl) have 
been denatured at 95°C for 2 minutes and then let to anneal at 25°C for 1 hr. 
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3.6.6 Ligation reactions 
The ligation of purified PCR products or purified DNA fragments obtained after restriction 
was carried out using the ligase supplied by Promega according to the suppliers instructions. 
Finally, ligase was inactivated at 65°C for 15’. 
 
3.6.7 DNA electrophoresis 
DNA samples were analysed on 1-2% agarose gel prepared in TAE 1X (TAE 50X: 2 M 
Trizma Base, 0.05 M EDTANa2, glacial acetic acid, pH8.2). DNA samples were added with 
loading buffer 5X (25.5% glycerol, 0.05% bromophenol blue (BPB), 0.05 M EDTANa2 
pH8.0) prior to electrophoresis. DNA separation was carried out at a constant voltage about 
10 V/cm (gel 5x7.5 cm) o 6 V/cm (gel 15x20 cm). DNA molecules were finally visualized on 
gel using the fluorescent dye ethidium bromide, at a final concentration 0.5 µg/ml.  
 
3.6.8 Polymerase chain reaction 
Amplification of specific DNA fragments was performed by Polymerase chain reaction 
(PCR). This method employed a heat-stable polymerase derived from Termophilus aquaticus 
(Taq) to exponentially amplify the DNA template of interest through thermal cycling of 
denaturing and synthesis steps. PCR was performed under the following conditions: an 
initiation step at 94°C for 2’ for DNA double strands denaturation, 25-30 thermal cycles 
(involving a denaturation step (94°C for 45’’), a primers annealing step (54°C for 45’’) and an 
elongation step (72°C for 1’)) and a final elongation step at 72°C for 10’. The thermal cycles 
were repeated several times (25-30 cycles) in order to amplify the DNA sequence between the 
primers to 2n, where n indicates the number of cycles. The reaction mix was prepared as 
following: 3 µl Taq Buffer 10X (160 mM (NH4)2SO4, 670 mM Tris-HCl pH8.8, 0.1% 
Tween-20) (Euroclone), 200 µM dATP, 200 µM dCTP, 200 µM dGTP, 200 µM dTTP, 
forward and reverse primers at a final concentration of 6.6 ng/µl each, 1.6 mM MgCl2, 15-20 
ng DNA template, 1 unit (U) DNA Taq polymerase (EuroTaq, Euroclone), sterile bdH2O in a 
final volume of 30 µl. The amplification of DNA was performed using a Peltier Thermal 
Cycler-200 (PTC-200). PCR method has also been applied to screen bacterial colonies 
transformed with ligation products (Sandhu et al., 1989). Briefly, each colony was picked 
with a sterile tip and the tip was then immerged into a 0.2 ml PCR tube containing the PCR 
reaction mix. The remaining cells were then spread onto a plate containing the appropriate 
antibiotic selection in order to keep the clone under screening. PCR was performed under the 
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following conditions: 94°C for 7 minutes for cell disruption, 33 thermal cycles involving a 
denaturation step (94°C for 45’’), an annealing step (54°C for 45’’), an elongation step (72°C 
for 1’) and a final elongation step at 72°C for 10’. 
 
3.6.9 PCR site-directed mutagenesis  
Site-directed mutagenesis was used to create a new restriction site into the pOBP vector. This 
method uses “mutagenic” primers containing the desired mutation that bind to the template 
DNA and represent the starting point for DNA amplification performed by the high fidelity, 
non-strand displacing Pfu turbo DNA polymerase. The two primers 5’-AvrII and 3’-AvrII 
(Tab.1) were designed for the mutagenesis encoding the AvrII restriction site and annealing at 
the 5’ end of the sunflower oleosin sequence in the pOBP vector. The forward primer was 
flanked by sequences homologous to the 3’end of OBP (5’-AvrII, Tab.1) while the reverse 
primer was flanked by sequences homologous to the vector portion downstream OBP (3’-
AvrII, Tab.1). The amplification reactions were carried out using the QuikChange XL Site-
Directed Mutagenesis Kit (Stratagene) and the Peltier Thermal Cycler-200 (PTC-200). A 
reaction mixture was prepared as follows: 1X reaction buffer, 1µl dNTP mixture (Stratagene), 
300 ng of each primer, 50 ng template DNA, 2.5 U Pfu Turbo polymerase (Stratagene) in 50 
µl final volume. Three different annealing temperatures (45°C, 50°C or 55°C) were tested for 
amplification. Then, the PCR method was as follows: initial denaturing step at  95°C for 1’, 
18 thermal cycles (involving a denaturing step at 95°C for 30’’, an annealing step performed 
at 45°C, 50°C or 55°C for 5’’, an elongation step at 68°C for 30’’) and a final elongation step 
at 68°C for 7’. Finally, the methylated, non-mutated parental DNA was removed from the 
amplification products by digestion with DpnI restriction enzyme. Ten units of DpnI were 
added to each reaction and samples were incubated at 37°C for 1 h. Five µl of the PCR 
reaction were then analysed on 1% agarose gel. Two µl of amplification products were used 
to transform Stratagene XL-10 Gold competent cells following the suppliers instructions. 
 
3.6.10 Sequencing and sequence analysis 
Sequencing service has been provided by Geneservice DNA Sequencing Facility, (Oxford, 
UK). DNA for sequencing was prepared adding specific primers and lyophilising the DNA 
samples using a Speedvac (Savant) (30°C for 15’). The analysis of the sequences was 
performed on-line using the T-COFFEE server (http://www.igs.cnrs-
mrs.fr/Tcoffee/tcoffee_cgi/index.cgi). 
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3.6.11 Transformation of bacteria competent cells  
Bacterial competent cells were transformed either by the heat-shock or the electroporation 
method.  
Aliquots of E. coli competent cells were added with 5% β-Mercaptoethanol (β-ME) and DNA 
(either Dpn I treated-DNA (2 µl), ligation products (7.5 µl) or plasmid DNA (2 µl)) and were 
chilled on ice for 30’. Afterwards, cells were incubated in a 42°C water bath for 30’’ (heat-
pulse) and immediately transferred to ice for 2’. Five hundred µl of preheated SOC medium 
were added to the tubes. The transformed cells were incubated at 37°C with shaking at 250 
rpm for 1 h. Finally, they were spread onto selective media and incubated overnight at 37°C. 
As an alternative method for competent cells transformation electroporation was performed. 
By this method an aliquot of competent cells was mixed either with the ligation products (7.5 
µl) or plasmid DNA (2 µl) and placed in a pre-cooled cuvette (0.1 mm electrode). The 
ligation products were de-salted by spin column chromatography through Sephadex CL-6B 
before electroporation. An electric pulse was applied to the mix using a GenePulser (BioRad 
Laboratories) set to 200 Ω, 1.8 kV, 2.5 µF. Immediately after the pulse, 0.5 ml of SOC media 
were added and cells gently resuspended and incubated at the appropriate temperature for 45 
minutes. The cells were then plated on selective media and incubated overnight at the required 
temperature.  
 
3.6.12 Preparation of Agrobacterium competent cells 
A single colony of the Agrobacterium GV3101 was picked to inoculate 5 ml of 2YT 
containing 50µg/ml rifampicin and 25µg/ml gentamycin in a 15 ml snap-cap tube (Falcon 
tube). The culture was grown overnight at 30°C with shaking at 250 rpm. The day after, two 1 
L flasks, each containing 250 ml of 2YT, were inoculated with 2.5 ml (1/100 volume) of the 
overnight culture and grown at 30°C with vigorous shaking until mid-log (O.D.600 =1-1.5). 
Cells were transferred to two pre-cooled 250 ml Oak ridge bottles and placed on ice for 20’. 
The bottles were centrifuged at 9000Xg for 10’ at 4°C. The supernatant was poured off and 
the cells were resuspended in 150 ml of cold sterile water and centrifuged again. The cells 
were washed four times more with cold sterile water. Finally, cells in each tube were 
resuspended with 15 ml of cold sterile 10% glycerol, pooled together in a cold 50 mL 
polypropylene Falcon centrifuge tube and centrifuged at 3000Xg for 10’ at 4°C. The 
supernatant was poured off and cells were resuspended very gently in 1 ml of cold sterile 10% 
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glycerol. Fifty µl aliquots of cells were prepared and quick-freezed in liquid nitrogen. 
Agrobacterium competent cells were finally stored at -80°C.  
 
3.6.13 Transformation of A. thaliana plants by floral dip 
Arabidopsis plants were grown as described (see section 3.1.4) for 4-6 weeks until the main 
bolts were about 10 cm. The main bolts were then clipped leaving about 2.5 cm of bare stem. 
The clipping procedure removed apical dominance encouraging growth of multiple secondary 
bolts. After a week the plants were ready for Agrobacterium-mediated transformation of the 
multiple bolts. A single colony of Agrobacterium carrying the appropriate construct was 
grown in 200 ml of selective medium (see section 2.2.2) overnight (16-20 hours) to a 
stationary phase (OD550 =1,3) on a rotary shaker (250-300 rpm). After centrifugation cells 
were resuspended in 250 ml of dipping medium (see section 3.2.3) and placed into a glass 
bowl. One pot was inverted into the solution making sure that all flowers and buds were 
immersed into the bacterial solution for 15’’. After dipping transformed plants were kept in 
dark for two days and then put back into greenhouse with regular watering for 4-6 weeks. 
Finally, plants were dried and seeds were harvested. 
 
3.6.14 Selection of T0 plants integrating the transgene and isolation of T1 
isogenic lines 
Seeds were harvested separately for each construct and weighted (1g= about 50,000 seeds). 
Four hundred mg of seeds per construct were soaked in 70% v/v ethanol  for 1’ and then in a 
solution prepared with 10% v/v Sodium Hypocloride and 0.05% v/v Tween 20 for 15‘ for 
sterilization. Seeds were rinsed 6 times with sterile water and resuspended in 0.8% melted 
sterile agarose (50°C) to spread evenly onto selective medium (see section 2.2.2) in 20 cm 
Petri dishes (0.1 g of seed per dish). Dishes were left to dry under the flow hood and kept in 
dark in the cold room for 2-3 days for seed vernalization. Then plates were moved to the 
growth chamber set at 22°C with 24 hours light. After 1-2 weeks T0 transformants were 
distinguished as healthy green plants compared to pale yellow seedlings (non positive). Once 
T0 transformants were identified, individual plants were transplanted to pots and grown for 4-
6 weeks until seeds could be harvested. For each T0 plant a determined number of seeds was 
plated onto selective medium and grown as before, for 1-2 weeks. As transformants T0 plants 
obtained with floral dip are usually hemyzigous for the T-DNA insertion (Clough & Bent, 
1998) and being Arabidopsis an autogamous plant, a segregation ratio of 3 resistant vs 1 
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sensitive plants in T1 generation indicated that a single copy of the T-DNA was present in the 
corresponding T0 plant (higher ratios indicated more than one copy of the T-DNA was 
inserted). T1 plants generated from a single copy T0 plant (3/4 resistant) were transplanted and 
grown as described. Seeds were collected and plated on selective medium, as described 
previously, to assess homozygous plants (integrating the transgene in the same locus on both 
chromosomes). The isogenic T1 plants were identified by 100% resistant plants in their T2 
lineage and were maintained as “homozygous” lines bearing each transgene construct. 
 
3.6.15 Plant Genomic DNA miniprep with CTAB/chloroform/isopropanol 
One hundred mg of leaf tissue were grinded in 200 µl 2X CTAB extraction buffer (0.1M 
Trizma Base pH 9.0, 2% Cetyl Trimethyl Ammonium Bromide (CTAB), 1.4 M NaCl, 20 mM 
EDTA pH.8.0) supplemented with RNase A (0.5 µg/100µl extraction buffer). Samples were 
incubated at 65°C for 20 minutes to favour disruption of the plant cell wall. Then, 200 µl 
chloroform (CHCl3) were added. Samples were mixed vigorously and centrifuged for 2 
minutes, 14000 rpm at room temperature. The supernatant was transferred to a new tube and 
added with 100 µl 100% isopropanol. After incubating the samples for 1-2 minutes at room 
temperature, DNA was pelleted by centrifuging for 5 minutes, 14000 rpm at room 
temperature. An additional wash of the pellet was performed using 70% ethanol. Dry DNA 
pellets were finally resuspended in 50 µl water. 
 
3.6.16 Southern blot  
This technique allows the identification of a specific DNA sequence separated by gel 
electrophoresis within a genome using a specific radiolabeled probe (Southern 1975). On day 
one, 1 µg genomic DNA from leaves was digested using the restriction enzyme BamH I 
(10U). Restriction reactions were performed at 37°C for 4 hrs, in a 50 µl final volume. 
Digestions were run on 0.8% agarose gel, at 25V overnight. On day two, DNA molecules 
separated on gel were first depurinated (formation of apurinic sites) and then denatured (in a 
strongly alkaline solution the apurinic sites in DNA molecules are hydrolysed and double 
strand hydrogen bonds are removed) by soaking the gel for 15’ with gentle agitation in 
depurination buffer and denaturation buffer, respectively. The denaturation step was repeated 
twice to achieve a better transfer of small, single-stranded DNA molecules to nylon 
membranes. A neutralisation step was carried out to bring the gel pH down to neutral and 
improve the DNA transfer to the membrane by incubating the gel twice in the neutralising 
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buffer for 15’. For the blotting, a positively charged Nylon membrane (Hy-bond, Amersham) 
and 4 pieces of 3MM Whatman paper were cut to size of the gel. One piece of 3MM 
Whatman paper was cut longer to act as a wick. Both ends of the wick dipped into 20X SSC 
and two sheets of 2X SSC pre-wetted 3MM paper were placed centrally onto the wick. The gel 
was rinsed with distilled water and placed onto the 2 pieces of 3MM paper. Parafilm was used 
to mask the edges and prevent SSC by-passing the gel. Pre-wetted nylon membrane was 
placed on gel and covered with the other two sheets of 3MM pre-wetted paper. A 5-10 cm 
stack of absorbent paper towels was placed on top followed by a gel tray and a weight. The 
DNA transfer took place overnight by capillarity. On the third day, the membrane was briefly 
rinsed in 2X SSC and the DNA molecules transferred were cross-linked to the membrane 
using the Stratalinker UV crosslinker for 1’ following the suppliers instructions. A pre-
hybridization step of the membrane was followed by hybridization with a specific probe 
incubating the membrane at 65°C in a rotisserie oven overnight. The probe was prepared by 
labelling 1 µg pOBP linearized plasmid using the “Prime it II” Random Primer kit 
(Stratagene). This labelling procedure relies on the ability of random hexanucleotides to 
anneal to multiple sites along the length of a DNA template. The primer–template complexes 
formed represent a substrate for the Klenow fragment of DNA polymerase I. The newly 
synthesized DNA is made radioactive by adding a radiolabeled nucleotide ([α−32P]dATP or 
[α−32P]dCTP) in the reaction mixture. To remove unbound radiolabeled nucleotides from the 
probe mix “NucTrap” columns (Stratagene) were used, according to the suppliers instructions. 
The purified probe was denatured in a boiling water bath for 10’ before adding to the 
hybridization solution (6X SSC, 50% formamide, 5X Denhardts, 0.5% SDS). On the fourth 
day, the membrane was washed twice (0.5% SDS, 2X SSC) from the probe solution in a 42°C 
shaking bath and let to dry on a 3MM Whatman paper. The membrane was then placed in a 
developing cassette with an X-ray film. The film was exposed overnight at -20°C and 
developed on the day after using an automatic developer.  
 
3.6.17 Total protein extraction from leaves and siliques 
Fifty mg of leaves tissue or 50 mg mature siliques (mature seeds before desiccation) were 
grinded in liquid nitrogen using mortar and pestle. The homogenous powder was transferred 
to a 1.5 ml sterile Eppendorf tube and resuspended in 200 µl of Tricine Sample Buffer (Bio-
Rad) added with 0.1 M DTT. Cell debris were pelleted by centrifuging the samples for 5’ at 
maximum speed in a table top microcentrifuge. The supernatants were transferred to fresh 
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tubes and heated at 65°C for 15’ to unfold proteins and break protein secondary structures. 
Twenty µl each sample were analysed by Coomassie staining and Western blot. 
 
3.6.18 Protein quantification 
Protein from plant crude extracts or oil body total soluble protein (TSP) were quantified by 
Bradford assay (Bradford, 1976) that relies on the modification of the absorbance maximum 
for an acidic solution of Coomassie Brilliant Blue G-250 dye (from 465, red to 595, blue) 
after binding to proteins. The Micro assay kit (Bio-Rad) and the Bovine Serum Albumin 
(BSA) standard curve as reference were used to determine the protein concentration. 
 
3.6.19 SDS-PAGE  
Proteins and polypeptides were separated on the basis of their molecular weight in 1mm 
denaturing polyacrylamide gels consisting of a stacking phase (4% polyacrilammide 
(acrilamide/bisacrilammide 29:1), 0.1% Sodium Dodecyl Sulfate (SDS), 0.06% Ammonium 
persulfate (APS), 0.2% TEMED in 1X stacking buffer or 3X Gel buffer) and a separating 
phase (12% polyacrilammide, 0.1% SDS, 0.05% APS, 0.1% TEMED in 1X separating buffer 
or 3X gel buffer). Both Tris-Glycine and Tris-Tricine buffer systems were used. Gels were 
immerged in 1X running buffer or 10X Anode and Cathode buffer and run vertically using the 
Mini-Protean 3 (Bio-Rad) apparatus. Protein samples were prepared for running adding 3X 
protein loading buffer or 2X TSB and denaturing at 100°C for 5’. Runs were performed at a 
constant voltage of 130V until the outcome of the dye.  
 
3.6.20 Coomassie staining 
Polypeptides separated on polyacrilammide gels were visualized by staining with Coomassie 
brilliant blue G250 dye. Gels were fixed for at least 20 minutes in methanol: acetic acid: 
water (45:1:54), then stained for 12-18 hours using 17% (w/v) ammonium sulphate, 34% 
methanol, 0.5% acetic acid, 0.1% (w/v) Coomassie G250. The day after gels were destained 
in distilled water until desired contrast. 
 
3.6.21 Western blot 
This technique allows the identification of a specific polypeptide blotted onto a nitrocellulose 
membrane using an antibody. After separation on polyacrilammide gel polypeptides were 
transferred onto 0.2 µm Hybond nitrocellulose membrane (Whatman), pre-soaked in 1X, 
48 
 
transfer buffer using a “Trans-Blot SD” semi-dry blotting apparatus (BioRad) set at 13V for 
30’. After blotting the membrane was immerged in 5% skimmed milk (SIMILAC formula 
PLUS, Abbott) in 1X PBS or 1% BSA (Bovin Serum Albumin) in TBS overnight at 4°C for 
blocking. The day after the membrane was rinsed three times with 1X T-PBS and twice with 
1X PBS and then incubated with a solution of 2% milk in PBS containing the primary 
antibody (1:5000 dilution of rabbit serum raised against sunflower urea-washed oil bodies; 
1:100 dilution of mAb 2F5 (EVA3063) for 2 hrs. Rinses in T-PBS and PBS were repeated. 
The membrane was then incubated with an alkaline phosphatase-conjugated secondary 
antibody (1:5000 dilution of anti-rabbit whole IgG; 1:200 anti-human IgG) resuspended in 2% 
milk in PBS for 1 h. Finally, the membrane was rinsed and the immobilized antibody detected 
by the alkaline phosphatase reaction to the substrate (NBT/BCIP purple solution (Sigma)).  
 
3.6.22 Oil body purification according to Tzen  (Tzen et al., 1997) 
One gram of A. thaliana seeds were grinded in 40 ml grinding medium (0.6 M Sucrose, 10 
mM sodium phosphate buffer pH 7.5, 1mM EGTA, 1 mM PMSF) at 4°C. Cell debris were 
pelleted by centrifuging the sample at 5000Xg for 15 min and the supernatant was placed at 
the bottom of a 38 ml centrifuge tube. The centrifuge tube was topped up with 15 ml flotation 
medium (0.4 M Sucrose, 10 mM sodium phosphate buffer pH7.5) and spun at 10000Xg for 20 
min in a swinging-bucket rotor. The fat pad (floating unwashed oil bodies, Step 1, S1) was 
skimmed from the top (~5 ml) and resuspended in 20 ml detergent washing solution (0.1% 
Tween 20, 0.2 M Sucrose, 5 mM sodium phosphate buffer pH 7.5). The sample was topped 
up with 10 ml of 10 mM sodium phosphate buffer pH 7.5 and spun at 10000Xg for 20 min. 
The fat pad (detergent washed oil bodies, Step 2 Tzen, S2T) collected on top (~5 ml) was 
resuspended in 15 ml ionic elution buffer (0.6 M Sucrose, 10 mM sodium phosphate buffer 
pH 7.5, 2 M NaCl) and topped up with 15 ml  floating medium (0.25 M Sucrose, 10 mM 
sodium phosphate buffer pH 7.5, 2 M NaCl). The sample was centrifuged at 10000Xg for 20 
min. The fat pad (salt washed oil bodies, Step 3 Tzen, S3T) was resuspended in 1-2 ml 10 
mM sodium phosphate buffer pH 7.5 and mixed with 10 ml 8 M urea. Urea washing of the oil 
bodies took place for 10’, at room temperature at 60 rpm. Ten ml grinding medium was mixed 
with urea washed oil bodies and the mix placed at the bottom of a 35 ml centrifuge tube and 
layered on the top with 15 ml of 10 mM sodium phosphate buffer pH 7.5. The sample was 
centrifuged again and urea washed oil bodies (~10 ml) skimmed from the top. Oil bodies were 
finally resuspended in 1.5 ml 10 mM sodium phosphate buffer pH 7.5 and stored at 4°C (Step 
4 Tzen, S4T). 
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3.6.23 Oil body purification according to Deckers (Deckers et al., 2004) 
One gram of A. thaliana seeds were grinded in 5 volumes cold grinding buffer (50 mM Tris-
HCl pH 7.5, 0.6 M Sucrose, 0.5 M NaCl) and the mix was centrifuged 5000Xg  for 30’ to 
remove solids. The oil body fat pad was skimmed from the top of the tube with a metal 
spatula and resuspended in one volume of grinding buffer. The oil bodies were then layered 
underneath 5 volumes of cold 50 mM Tris-HCl pH 7.5 in a centrifuge tube and centrifuged. 
The washing procedure was repeated twice (Step 2 and 3 Deckers, S2D and S3D). A further 
washing to remove seed protein contaminants was carried out incubating oil bodies with 0.1 
M Na2CO3 pH 11 for 30’, at room temperature with shaking at 60 rpm. Later, the mixture was 
layered underneath 5 volumes of water and centrifuged. Finally, the washed oil bodies were 
resuspended in cold 50 mM Tris-HCl pH 7.5 (Step 4 Deckers, S4D). 
 
3.6.24 Treatment to remove lipid contaminants from oil body preparation 
(de-lipidation)  
Protein samples that were analysed by SDS-PAGE and Mass Spectrometry (MS) were 
previously treated to remove lipid contaminants forming the oil bodies core. One hundred µl 
chloroform/methanol (2:1 v/v) and 100 µl 10% TCA/Acetone were added to the samples 
(Wang at al., 2004). Samples were incubated on ice for 5’ and centrifuged at maximum speed 
for 1’. Two washes were performed with 500 µl cold 10% TCA and one using 1ml cold 
water. Proteins were finally precipitated by adding 1ml cold acetone and incubating at -20°C 
for at least 1hr. After precipitation  protein pellet was resuspended in 1% SDS buffer (1% 
SDS, 0.1 M sodium phosphate buffer pH 7.5) containing or not containing 6 M urea.  
 
3.6.25 Treatment with trypsin of oil body associated proteins for MS 
analysis 
Twenty to fifty µg of a pellet containing oil body total soluble protein (TSP) were 
resuspended in 50 mM ammonium bicarbonate pH 7.5 to a final concentration of 0.1-0.5 
µg/µl. Acetonitrile was added to a final concentration of 5% to promote protein resuspension. 
Denaturation of proteins was carried out by reduction with 10 mM DTT and incubation of the 
sample for 1hr at room temperature and alkylation by adding 10 mM iodoacetamide, to 
prevent proteins to fold back. Incubation with iodoacetamide was carried out in the dark for 
15’ at room temperature. Trypsin (Sequence Grade Modified Trypsin, Promega) protease was 
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added to the protein sample to a final ratio substrate to enzyme of 20:1 (w/w) and the reaction 
was incubated overnight at 37°C. Samples were centrifuged twice at maximum speed to 
remove the non-digested pellet. Formic acid was added to the supernatant to a final 
concentration 0.1% to improve the protonation of the tryptic peptides at the ion source. 
 
3.6.26 LC-MS/MS analysis of oil body total proteins 
The qualitative and quantitative analysis of oil body TSP Liquid Chromatography Mass 
Spectrometry (LC-MS) analysis was carried out on in-gel tryptic digests (GeLC). Tryptic 
digestions of proteins separated on polyacrilammide gels were carried out on protein bands 
excised from Coomassie-stained 1D-gels (50 µg of oil body total proteins loaded on a 12% 
SDS-PAGE) and stored in a 96 well plate. The gel pieces were washed in 25 mM ammonium 
bicarbonate in 50% acetonitrile, subjected to reduction (25 mM DTT) and alkylation (12.5 
mM.iodoacetamide) in order to break disulphide bridges between cysteine residues and 
prevent reforming. Fifty µl trypsin (Sequence Grade Modified Trypsin, Promega) solution (15 
ng mL-1 in 25 mM ammonium bicarbonate) was added to the dehydrated gel piece and 
allowed to digest overnight at 37°C. Salts and buffers in the digest mixtures were removed 
using ZipTips  (Millipore Corporation) composed of a plug of C18 packing material. The 
samples were then loaded from a 96 well plate onto a pre-column for 3 minutes (0.1% formic 
acid, 30 mL min-1) to concentrate. After 3 minutes, the peptides were eluted from the pre-
column by 5-40% acetonitrile gradient flow over 40 minutes and bound to the PicoFrit 
column (75 mm, 50mm, New Objective Inc) for separation. Peptides were finally sprayed 
directly from the column into the source region on an LTQ XL Linear Ion Trap Mass 
Spectrometer (Thermo Finnigan). Tandem MS (MS/MS) spectra were searched using the 
Mascot search engine version 2.2 and a modified A. thaliana FASTA database downloaded 
from the National Center for Biotechnology Information FTP site including the sunflower 
oleosin and the chimeric sunflower oleosins sequences.  
 
3.6.27 Enzyme-Linked ImmunoSorbent Assay (ELISA) for epitope 
detection and quantification  
This technique allows the detection of a specific protein in a mixture by adhesion of the 
protein to a polypropylene surface and antibody detection. The presence and quantification of 
the chimeric oleosin on the oil body surface by detecting 2F5e or the sunflower oleosin was 
determined by direct ELISA, coating Nunc immunomodule plates (Maxisorb) with serial 
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dilutions (5, 4, 3, 2, 1 µl) of oil body preparations in a final volume of 50 µl overnight at + 
4°C. As for quantification of 2F5e on chimeric oil body surface a group of wells was coated 
with different amounts (0.5, 1, 2, 4 and 8 ng) of a synthetic polypeptide containing 2F5e 
(QTQQEKNEQELLELDKWASL; NIH AIDS Research and Reference Reagent Program, 
catalog no.2030) as positive control/internal standard. As negative control, a group of wells 
was coated with oil bodies extracted from the seeds of plants transgenic for the non-chimeric 
sunflower oleosin. As for quantification of the sunflower portion of the chimeric oleosin a 
group of wells was coated with serial dilutions (5, 4, 3, 2, 1 µl) of oil bodies carrying the non 
chimeric sunflower oleosin as a standard. After coating, wells were washed three times with 
PBS containing 0.1% Tween 20 (PBS-T) and two times with PBS. After 2 h of blocking at 
37°C with PBS containing 5% skimmed milk and washing as above, wells were  incubated 
with 2F5 monoclonal antibody (EVA3063; Buchacher et al., 1994) (1:500 dilution in PBS 2% 
milk at 37°C for 2 h) or sunflower oleosin-specific polyclonal antibody (1:5000 dilution in 
PBS 2% milk at 37°C for 2 h). Wells were then washed, and the presence of bound antibodies 
was detected by the application of a peroxidase-conjugated anti-human IgG antibody (1:200) 
or a biotin-conjugated anti-rabbit IgG antibody (1:5000) mixed with streptavidin-peroxidase 
(1:2000) (37°C for 2 h). Afterwards the chromogenic substrate 2,2'-azino-bis(3-
ethylbenzthiazoline-6-sulphonic acid) (ABTS) (Kirkegaard & Perry Laboratories, 
Gaithersburg, MD) was added and the colorimetric reaction measured with an automated 
ELISA reader (ELISA SUNRISE (Tecan)) at 405 nm after 1h. 
 
3.6.28 Animals and Immunization 
Six week-old C57BL/6J female mice in groups of 4 (Charles River Laboratories Italia Spa, 
Lecco, Italy) were maintained under standard housing conditions in the ENEA Casaccia 
Animal Care Unit. The experimental procedures were approved by the ENEA ethical 
committee and performed according to the current Italian law.  
 
3.6.29 ELISPOT assay 
A mouse IFN-γ ELISPOT kit was used according to manufacturer's instructions (eBioscience, 
San Diego, CA). Briefly, 19 days after the last immunization, spleens were harvested from 
mice and single splenocyte suspensions prepared by mechanical disruption. After red blood 
cells lysis, 0.5 x 106 splenocytes were distributed in triplicate wells of PVDF-bottomed 96 
well plates (Millipore, Billerica, MA) previously coated overnight at 4°C with a rat anti-
mouse IFN-γ antibody. Cells were left unstimulated (negative control) or stimulated with 
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either ASNENMETM or TYQRTRALV synthetic peptides (0.4 µg/well). As positive internal 
control, 0.4 x 104 splenocytes were stimulated with 1 ng Phorbol Myristic Acetate (PMA) - 
0.5 mg ionomycin /ml (Sigma, St. Louis, MO). After 20 h at 37°C in atmosphere with 0.5 % 
CO2 and 95% relative humidity, plates were washed and incubated with a biotinylated rat 
anti-mouse IFN-γ antibody followed by avidin-Horse Radish Peroxidase (HPR). The binding 
of the antibody was then visualised by adding the substrate 3-amino-9-ethyl carbazole (AEC). 
Spots were counted using an automated ELISPOT reader (Aelvis, Hannover, Germany). The 
frequency of peptide-specific T cells present in the responding population was calculated by 
subtracting the mean number of spots obtained in unstimulated wells from the mean number 
of spots obtained in stimulated wells, and reported as number of specific spot-forming cells 
(SFC)/spleen. Statistical analysis was performed using the unpaired Student’s t-test. 
Differences were considered statistically significant when P<0.05.  
 
3.6.30 Antibody titration in animal sera  
Individual mouse serum samples, obtained by tail bleeds, were analyzed by enzyme-linked 
immunosorbent assay (ELISA) to determine the concentrations of anti-2F5e antibodies. 
Briefly, individual wells of 96-well microtiter Maxisorp ELISA plates (Nunc, Roskilde, 
Denmark) were coated overnight at 4°C with 50 µl PBS containing 4 ng/µl synthetic 
polypeptide containing 2F5e (QTQQEKNEQELLELDKWASL; NIH AIDS Research and 
Reference Reagent Program, catalog no.2030). After coating, wells were washed three times 
with PBS containing 0.1% Tween 20 (PBS-T) and two times with PBS. After 2 h of blocking 
at 37°C with PBS containing 5% skimmed milk and washing as above, 50 µl of individual 
mouse serum dilutions (in PBS with 2% milk) were added to triplicate wells, and incubated 
overnight at 4°C. Wells were then washed, and the presence of bound antibodies was detected 
using an Horse Radish Peroxidase (HRP)-labelled sheep anti-mouse IgG polyclonal antibody 
(1:2500) (Amersham Bioscience, General Electrics, New Brunswick, NJ) and 2,2'-azino-
bis(3-ethylbenzthiazoline-6-sulphonic acid) (ABTS) (Kirkegaard & Perry Laboratories, 
Gaithersburg, MD) as substrate. The colorimetric reaction was measured with an automated 
ELISA reader (ELISA SUNRISE (Tecan)) at 405 nm, and antibody levels were expressed as 
optical density values at 405 nm (OD405). Endpoint titers were defined as the reciprocal of the 
highest serum dilution giving an absorbance ≥0.1 OD unit above the blank (absorbance of the 
pre-immune sera). Geometric mean titers (GMT) were determined for each group, including 
non-responder mice.  
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4. RESULTS 
 
4.1. Epitope selection 
To direct the expression on oil bodies surface of amino acid sequences including or 
corresponding to T and B cell epitopes derived from HIV-1 (Nef and Env) and influenza virus 
proteins (Nucleoprotein, NP)  we have adopted an oleosin-fusion strategy. Nef is a 
phosphorylated and N-terminally myristoylated protein of about 27 kDa (206 aa) fundamental 
for HIV-1 pathogenesis (Arora et al., 2002). As with many other HIV-1 regulatory proteins, it 
is considered as a possible target of an anti-HIV-1 vaccine formulation for the activation of 
CTL mediated responses. Nef peptides to be expressed as oleosin fusions have been selected 
referring to Nef CTL experimentally-based epitope-mapping available on the HIV-1-
dedicated NIH website (National Institute of Health of Bethesda, USA; 
http://www.hiv.lanl.gov/content/immunology/maps/ctl/Nef.html) and considering the 
haplotypes of the murine models available to test the immunological potential of chimeric oil 
bodies (Balb/c, C57BL/6 and H2 knock-out/HLA-A2 transgenic mice). After the two 
polypeptides were identified on this basis, Nef125 (aa sequence 125-
QNYTPGPGIRYPLTFGWCYKLVPVEPE-151) (Fig. 3) was further analysed using the on-
line algorithm SYFPEITHI for epitope prediction (Rammensee et al., 1999; 
http://www.syfpeithi.de/). By this approach 33 peptides, either 9mer or 10mer, fitting the 
binding site on MHC class I molecules in animal models (HLA-A2, H2-d, H2-b) were 
identified (Tab. 2).  
As Env protein of HIV-1 is the only structural protein able to induce neutralizing antibodies 
(Moore J.P., 2001), a highly conserved and immunogenic 6 amino acid spanning gp41-
derived epitope (2F5e) is the other HIV-1-derived sequence selected for fusion to oleosin. 
This peptide (aa position 662-668, sequence ELDKWA) is recognized by the human 
monoclonal antibody 2F5 and represents one of the few epitopes able to induce neutralizing 
antibodies in humans (Muster et al., 1993).  
NP is a major structural protein in the ribonucleoprotein complex of influenza virus and is a 
major target structure for cross-reactive CTL. The epitope for oleosin fusion was derived from 
NP of the influenza virus strain A/PR/8/34. The selected 9 amino acid spanning peptide (aa 
position 366-374, ASNENMETM) is the immunodominant epitope in C57BL/6J mice (H2-
Db haplotype) able to elicit CTL responses responsible for virus clearance in this murine 
model (Flynn et al., 1998). 
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Figure 3. Nef CTL epitope map of the region including the Nef125 polypeptide (pink box) selected to be 
expressed as oleosin fusion.   
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Table 2. List of the epitopes binding to MHC/HLA class I molecules (H2-d, H2-b, HLA-A2) predicted by the SYFPEITHI algorithm as 
included in the Nef125 polypeptide sequence 
 
Peptide sequence 
 
 Haplotype Score* 
Q N Y T P G P G I R Y P L T F G W C Y K L V P V E P E     
    
 P G P G I R Y P L 
              9mer Db 14 
      
 P G I R Y P L T F 
            9mer Db 14 
Q N Y T P G P G I   
                 9mer Db 11 
           
 
 L T F G W C Y K L       9mer Db 10 
    T P G P G I R Y P               
 9mer Ld 16 
     P G P G I R Y P L              
 9mer Ld 12 
       P G I R Y P L T F            
 9mer Ld 12 
      G P G I R Y P L T             
 9mer Ld 11 
           Y P L T F G W C Y        
 9mer Ld 11 
           
  L T F G W C Y K L       9mer Ld 11 
    P G P G V R Y P L                9mer Dd 31 
             T F G W C Y K L V       9mer Kd 19 
Q N Y T P G P G I                    9mer Kd 19 
   T P G P G I R Y P                 9mer Kd 16 
   T P G P G I R Y P L                10mer Kd 12 
                  C Y K L V P V E P E 10mer Kd 12 
        
 
 R Y P L T F G W C Y         10mer Kd 11 
        
 
    L T F G W C Y K L V      10mer Kd 11 
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Table 2. Continued 
 
Peptide sequence 
 
 Haplotype Score* 
 N Y T P G P G I R Y   
               10mer Kd 10 
           
 P L T F G W C Y K L    
   10mer Kd 10 
   
 T P G P G I R Y P L 
              10mer Db 12 
     
 G P G I R Y P L T F 
            10mer Db 11 
        
 
      F G W C Y K L V P V    10mer Db 11 
           
 P L T F G W C Y K L    
   10mer Db 8 
            L T F G W C Y K L       9mer HLA-A*0201 22 
               G W C Y K L V P V    9mer HLA-A*0201 17 
       G I R Y P L T F G            9mer HLA-A*0201 13 
Q N Y T P G P G I                   9mer HLA-A*0201 12 
    
 P G P G I R Y P L         
      9mer HLA-A*0201 10 
           P L T F G W C Y K L       10mer HLA-A*0201 18 
            L T F G W C Y K L V      10mer HLA-A*0201 18 
              F G W C Y K L V P V    10mer HLA-A*0201 18 
   T P G P G I R Y P L               10mer HLA-A*0201 13 
          Y P L T F G W C Y K        10mer HLA-A*0201 12 
 
* For score definition refer to Materials and Methods section. 
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4.2 Gene engineering for plant expression of HIV-1 and influenza-
derived peptides as oleosin fusions  
 
4.2.1 pOBP vector modification  
The sunflower oleosin cDNA sequence (oil body binding protein, OBP) inserted into a pET-
3d vector (pOBP) (Fig. 4a) was modified by site-directed mutagenesis PCR to introduce an 
additional restriction site at the 3’ end. Primers encoding the Avr II restriction site were 
designed. The forward primer was flanked by sequences homologous to the 3’end of OBP 
(5’-Avr II oligonucleotide) while the reverse primer was flanked by sequences homologous to 
the vector portion upstream OBP (3’-Avr II oligonucleotide) (Tab.3). The PCR reactions were 
performed in a temperature gradient to assess the best annealing conditions. PCR products 
analysis on 0.8% agarose gel showed that the amplification of the vector occured only at an 
annealing temperature of 55°C. XL10 GOLD competent cells (Stratagene) were transformed 
using this PCR product and correctly mutagenized plasmids (pOBP/Avr II) (Fig. 4b) were 
identified by Avr II restriction and sequence analysis.  
 
4.2.2 Cloning of sequences encoding Nef, Env or NP epitopes into pOBP/Avr II  
vector 
The double-stranded DNA fragments encoding the peptides Nef 125, 2F5e and NP were 
obtained by in vitro annealing of synthetic oligonucleotides (5’-Nef125 and 3’-Nef125; 5’-
2F5 and 3’-2F5; 5’-NP and 3’-NP) (Tab. 3). Prior to annealing, oligonucleotides were 
phosphorylated using T4 Polynucleotide Kinase. The DNA fragments were then ligated to the 
Avr II-linearized and dephosphorylated pOBP/Avr II vector. Cells transformed with the 
ligation reaction products were screened by PCR using T7 and epitope-specific (3’-
Nef125PCR, 3’-2F5 or 3’-NP) primers. By this approach, only clones carrying plasmids 
where sequences encoding the epitope were inserted in the correct orientation, were 
identified. The plasmids pOBP/Avr II-Nef125, pOBP/AvrII-2F5e and pOBP/Avr II-NP (Fig. 
4c) were further analysed by Avr II-restriction and sequencing.  
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4.2.3 Transferring of the chimeric oleosin coding cassettes into pKMS2 
vector  
To generate DNA fragments encoding chimeric oleosins and having Not I-compatible ends, 
the chimeric oleosin sequences into pOBP/Avr II-Nef125, pOBP/Avr II-2F5e or pOBP/Avr II-
NP vectors were amplified with appropriate pairs of primers (5’NotOleoF and 3’-Not125R, 
3’-Not2F5R or 3’-NotNPR; Tab. 3). PCR products were cloned into Topo-TA vectors for 
sequencing prior to transfer into the vector pKMS2. The vector pKMS2 (kindly provided by 
Dr. E.Cahoon) carrying the Glycine max cv Century p24 oleosin promoter and terminator 
sequences and between them a multicloning site including Not I was utilised to add regulatory 
sequences to the chimeric oleosin coding cassettes. Colony PCR screening, performed using 
appropriate up- and downstream primers (5’-pKMS2F and 3’-Not125R, 3’-Not2F5R or 3’-
NotNPR; Tab. 3) identified the clones carrying the chimeric oleosin inserted in the correct 
orientation.  
 
4.2.4 Transfer of the chimeric oleosin coding cassettes with the oleosin 
specific regulatory sequences to the binary vector pBIN19 
The chimeric oleosin coding cassettes, flanked by the oleosin promoter and terminator 
sequences into pKMS2-derived plasmids (pKMS2-Nef125, pKMS2-2F5e and pKSM2-NP) 
(Fig. 4d), were excised using the restriction enzymes Kpn I and Sac I. To skip gel purification 
procedures, a further digestion with the restriction enzyme Pvu I was also performed, to 
modify pKSM2 backbone ends prior to the set-up of a ligation reaction with Kpn I and Sac I 
digested pBIN19. After E. coli transformation, positive clones were identified by PCR using 
5’-pKMS2F and 3’-pKMS2R primers.  
 
4.2.5 Cloning of Nef125-, 2F5e- or NP-oleosin fusions into the binary vector 
pBIN19-35S  
The chimeric oleosin coding cassettes were excised from Topo-TA vectors using Not I and 
their sticky ends were filled-in with DNA Polymerase I (Klenow fragment) prior to the 
insertion into Sma I-linearized pBIN19-35S binary vector. Transformed E. coli cells were 
screened by PCR using 5’-35S and 3’-Not125R, 3’-Not2F5R or 3’-NotNPR primers (Tab. 3). 
Positive clones with the insert in the correct orientation were used for plasmids extraction and 
restriction analysis. 
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Figure 4. Constructs. 
Schematic representation of (a) pOBP), (b) pOBP/AvrII, (c) pOBP/AvrII-Nef125, -2F5e, -NP, (d) pKMS2-Nef125,-2F5e,-NP, 
(e) pBIN19-GM-Nef125, -2F5e, -NP, (f) pBIN19-35S-Nef125, -2F5e, -NP constructs.  
White box: sunflower oleosin c-DNA (OBP); black arrow: T7 promoter; dashed arrow: 5’-NotOleoF and 3’-Not125R or 3’-
Not2F5R  or 3’-NotNPR primers; OleoP: Glycine max p24 oleosin promoter; OleoT: Glycine max p24 oleosin terminator; 
black trapeziums: T-DNA left (LB) and right (RB) borders; green boxes: Pnos (nopaline synthase gene promoter) and nosA 
ter (nopaline synthase gene terminator); yellow box: CaMV 35S constitutive promoter; blue box: nosA ter; nptII: neomycin 
phosphotransferase II gene; red box: Nef125-, 2F5e- or NP-peptide encoding sequence; black boxes: G. max p24 oleosin 
promoter and terminator. 
a  
NcoI Bam HI  
b  
NcoI Bam HI  
AvrII 
NcoI Bam HI  
c  
NotI NotI  KpnI SacI 
OleoP 
OleoT 
d  
e 
KpnI SacI  
 
nptII 
5’ 3’ 
nptII 
5’ 3’ 
f 
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Table 3. Oligonucleotide sequences 
 
 
5’-AvrII 
 
5’-GAAGGGGGGAAACCTAGGTAAGGTGAGAAA-3’ 
 
3’-AvrII 
 
 
5’-TTTCTCACCTTACCTAGGTTTCCCCCCTTC-3’ 
 
 
5’-Nef 125 
 
 
5-CTAGGCAAAATTATACTCCTGGACCTGGAATTCGTTATCCTCTTACTTTTGGATGGTGTTA 
TAAGCTTGTTCCTGTTGAACCTGAATAACTCGAGC-3’ 
 
 
3’-Nef125 
 
5’-CTAGGCTCGAGTTATTCAGGTTCAACAGGAACAAGCTTATAACACCATCCAAAAGTAAGA 
GGATAACGAATTCCGGATCCAGGAGTATAATTTTGC-3’ 
 
 
5’-NP 
 
5’-CTAGCGCTTCTAACGAGAACATGGAGACTATGTAAC-3’ 
 
 
3’-NP 
 
 
5’-CTAGCTTACATAGTCTCCATGTTCTCGTTAGAAGCC-3’  
 
 
5’-2F5 
 
5’-CTAGCGAACTTGATAAGTGGGCTTAAC-3’ 
 
 
3’-2F5 
 
5’-CTAGGTTAAGCCCACTTATCAAGTTCG-3’ 
 
 
3’-Nef125PCR 
 
 
5’-CTAGGCTCGAGTTATTCAGG-3’ 
 
 
T7 Promoter 
 
 
5’-TAATACGACTCACTAT-3’  
 
 
5’-pKMS2 F 
 
 
5’-ATATAACAACACCCCCGT-3’ 
 
 
5’-pKMS2 R 
 
 
5’-CCTACATAGGCAAGAGGT-3’ 
 
3’-Not125R 
 
5’-GGCCGCGGCCGCTTATTCAGGTTCAACAGGAA-3’ 
 
 
3’-NotNPR 
 
5’-GGCCGCGGCCGCTTACATAGTCTCCATGTTCT-3’ 
 
 
3’-Not2F5R 
 
5’-GGCCGCGGCCGCTTAAGCCCACTTATCAAGTT-3’ 
 
 
5’-NotOleoF 
 
5’-AATTGCGGCCGCATGGCCACCACAACCTACGA-3’ 
 
 
5’-35S 
 
5’-CTATCCTTCGCAAGACCCTTC-3’ 
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4.3 A. thaliana transformation and characterization of transgenic 
plants 
 
4.3.1 A.  thaliana plants transformation by floral dip 
Competent A. tumefaciens cells (strain GV3101) were transformed by electroporation with the 
binary vectors pBIN19- or pBIN19-35S carrying the chimeric oleosin sequences (pBIN19-
GM-Nef125, pBIN19-GM-2F5e, pBIN19-GM-NP, pBIN19-35S-Nef125, pBIN19-35S-2F5e 
or pBIN19-35S-NP) (Fig. 4e and f). Transformed  Agrobacterium cultures were used to 
transfer gene constructs to 5 weeks old A. thaliana plants by floral dip (Clough and Bent, 
1998). About three weeks later, seeds were collected and sowed on selective kanamycin solid 
medium (100 mg seeds /plate) to identify T0 plants. 
 
4.3.2 Analysis of T0 resistant plants to verify transgene expression  
Expression of the fusion protein was verified on crude leaves and mature siliques extracts by 
Western blot using a polyclonal antibody specific to sunflower oleosin, without cross-reaction 
to endogenous A. thaliana oleosins. By this approach three major bands were evidenced on 
the blotted membrane together with minor bands probably resulting from the aspecific 
binding of the antibody. The major band with the predicted molecular mass (20-23 kDa) was 
clearly visible in the leaves and siliques extracts of plants transformed with pBIN19-35S 
vectors (constitutive promoter) (Fig. 5) and only in the siliques extracts of the plants 
transformed with pBIN19-GM vectors (seed-specific promoter) (Fig. 6 and Fig. 7). The other 
two major bands were 15 and 19 kDa for plants expressing the Nef125 chimeric oleosin (Fig. 
5 and Fig. 6), 12 and 16 kDa for plants expressing the 2F5e and NP peptide chimeric oleosin 
(Fig. 7). The analysis of the expression of the chimeric oleosins in leaves and siliques of both 
plants transformed with pBIN19-35S or pBIN19-GM demonstrated that the Glycine max 
oleosin derived regulatory sequences induced tissue-specific expression of foreign oleosin at 
higher levels than those obtained by the 35S promoter in mature siliques. Moreover, for plants 
expressing the chimeric oleosins under the control of the 35S promoter a higher accumulation 
was observed in siliques than in leaves (Fig. 8). The presence of the peptide as oleosin fusion 
was indicated in the extracts of the plants transformed with Nef125 fusion by a shift in the 
migration of the oleosin band as compared to the band identified in the extracts of transgenic 
plants transformed with non-chimeric sunflower oleosin. The presence of the 2F5e peptide  
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Figure 5. Analysis of the 35S-driven expression of chimeric oleosin in a representative group of A. thaliana 
transgenic plants (T0). 
                                                                                                                                   
Western blot analyses of crude extracts of leaves (panel a: lane 1-8) and siliques (panel b: lane 1-9) from T0 
plants transformed with pBIN19-35S-Nef125 performed with an antibody specific for the sunflower oleosin.                                                                                
M: Pre-stained Molecular Weight Marker (the arrows indicate the molecular weight of the marker bands of 
interest); WT: leaf protein extracts of w.t. plants. 
 
60K 
25K 
20K 
1 2 M 4 5 3 6 7 WT 
a 
8 
1 2 3 4 5 6 M 7 8 9 
60K 
25K 
20K 
b 
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Figure 6. Analysis of the G. max oleosin promoter-driven expression of chimeric oleosin in a 
representative group of A. thaliana transgenic plants (T0).  
                                                                                                                                  
Western blot analyses of crude extracts of leaves (panel a: lane 1-5) and siliques (panel b: lane 1-9) from T0 
plants transformed with pBIN19-GM-Nef125 performed with an antibody specific for the sunflower oleosin.                                                                                
M: Pre-stained Molecular Weight Marker (the arrows indicate the molecular weight of the marker bands of 
interest); WT: leaf protein extracts of w.t. plants. 
 
M 1 2 3 4 5 WT 
a 
60K 
25K 
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b 
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25K 
20K 
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1 2 M 3 4 5 WT FL 
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Figure 7. Analysis of the G. max oleosin promoter-driven expression of chimeric oleosin in a 
representative group of A. thaliana transgenic plants (T0).  
                                                                                                                                 
 Western blot analyses of crude extracts of siliques from T0 plants transformed with pBIN19-GM-NP (panel a: 
lanes 1-7) or with pBIN19-GM-2F5e (panel b: lanes 1-7) performed with an antibody specific for the sunflower 
oleosin.                                                                                
M: Pre-stained Molecular Weight Marker (the arrows indicate the molecular weight of the marker bands of 
interest); FL: protein extracts from A. thaliana plants transformed with the non-chimeric sunflower oleosin gene 
driven by 35S promoter; WT: siliques protein extracts of w.t. plants. 
a 
1 2 M 3 4 5 6 7 FL 
25K 
20K 
15K 
M 1 2 3 4 5 6 7 FL WT 
b 
25K 
20K 
15K 
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Figure 8. Analysis of the accumulation of chimeric oleosins driven by 35S or G. max oleosin promoter in 
leaves and siliques of a representative group of A. thaliana transgenic plants (T0). 
SDS-PAGE (panel a) and Western blot analyses (panel b) of crude extracts of leaves (lanes 1 and 3) and siliques 
(lanes 2 and 4) from T0 plants transformed with pBIN19-35S-Nef125 (lanes 1 and 2) or pBIN19-GM-Nef125 
(lanes 3 and 4). 
M: Pre-stained Molecular Weight Marker (the arrows indicate the molecular weight of the marker bands of 
interest); FL: protein extracts from A. thaliana plants transformed with the non-chimeric sunflower oleosin gene 
under the control of 35S promoter; WTL and WTS: leaf and siliques protein extracts of w.t. plants, respectively. 
60K 
25K 
20K 
a 
M 1 2 3 4 FL WTS WTL 
60K 
25K 
20K 
b M 1 2 3 4 FL WTS WTL 
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was instead verified by the use of the monoclonal antibody 2F5 (Buchacher et al., 1994) (Fig. 
9). No reagents were available to reveal the expression of the NP peptide.  
 
4.3.3 Genetic analysis of T0 plants to verify transgene integration 
Leaves from T0 plants were used to extract genomic DNA and perform PCR analysis using 
transgene specific primers (5’-NotOleoF and 3’-Not125R, 3’-Not2F5R or 3’-NotNPR primers, 
Tab. 3). The integration of the transgene was confirmed by the presence of a 800 base pair 
(bp) band (Fig. 10a). Transgene integration was verified also through Southern blot analysis 
of BamHI-digested genomic DNA using as probe the linearized pOBP plasmid. After 
digestion the genomic DNA samples were run on 0.8% agarose gel. Then, the gel was blotted 
and the membrane hybridised. The hybridization with the probe showed the presence of a 
single band as expected for the plants integrating a single copy of the transgene (Fig. 10b). 
The segregation test performed sowing the seeds collected from T0 plants confirmed the 
results obtained with southern blot. By these analyses 3 independent T1 lines of A. thaliana 
plants for each construct integrating a single copy of the transgene were identified (not 
shown) and grown to T2 generation. 
 
4.4 Wild-type and chimeric oil bodies characterization 
 
4.4.1 Comparison of the efficiency of different oil body purification 
procedures  
Oil bodies were purified from the seeds of w.t. and transgenic T2 plants. To this aim the two 
protocols available in the literature were compared to define the most effective in removing 
seed protein contaminants (Tzen et al.,1997; Deckers et al., 2004). Oil bodies were initially 
extracted from seeds by grinding with pestle and mortar in a cold 0.6 M Sucrose, 10mM 
sodium phosphate buffer (Step 1, S1) and purified by centrifugation through a 0.4 M sucrose 
cushion. This is a step common to both protocols and is used to separate the buoyant oil 
bodies from other cellular components. The extracted oil bodies present in a white fat pad on 
the top of the cushion were then sequentially washed with 0.1%Tween (Step 2 Tzen, S2T) , 2 
M NaCl (Step 3 Tzen, S3T), and 8M urea (Step 4 Tzen, S4T) (Tzen et al, 1997); or following 
Deckers’ protocol twice with Tris-HCl  pH 7.5 (S2D and S3D) and once with 0.1 M Na2CO3 
pH 11 (S4D). The quality of the two preparations was analysed by SDS-PAGE. The results 
clearly showed that the protocol developed by Tzen was much more effective in removing  
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Figure 9. Analysis of the expression of the 2F5e-chimeric oleosins in A. thaliana transgenic plants (T0).  
Western blot analysis of crude extract of siliques from T0 plants transformed with pBIN19-GM-2F5e (lanes 1-7) performed 
with the 2F5 monoclonal antibody.  
M: Pre-stained Molecular Weight Marker (the arrows indicate the molecular weight of the marker bands of interest); FL: 
protein extracts from A. thaliana plants transformed with the non-chimeric sunflower oleosin gene under the control of 35S 
promoter; WT: siliques protein extracts of w.t. plants. 
 
Figure 10. Genetic analysis of representative T0 lines of transformed A. thaliana plants. 
a) PCR analysis performed on genomic DNA extracted from the leaves of Nef125 and 2F5e T0 plants using transgene 
specific primers (lanes 1-3; top: 5’-NotOleoF and 3’-Not125R; bottom: 5’-NotOleoF and 3’-Not2F5R)(M1:100bp DNA 
ladder Fermentas (10 fragments: 1000, 900, 800, 700, 600, 500, 400, 300, 200, 100 bp); +:pKMS2-Nef125 (top) or pKMS2-
2F5e (bottom); -: PCR performed without template.  
b) Southern blot analysis performed on BamHI-digested genomic DNA extracted from the leaves of Nef 125 (lanes 1 and 2) 
and 2F5e (lane 3) lines of PCR-positive plants or w.t. A. thaliana cv Columbia plants (w.t.), using as probe the linearized 
pOBP plasmid carrying the cDNA sequence of the sunflower oleosin. The arrows indicate the molecular size of the marker 
bands (4361, 2322, 2027, 564 bp).  
M 1 2 3 4 5 6 7 FL WT 
25K 
20K 
a b 
M 1 2 3 + - 
M 1 2 3 + - 1 2 3 WT 
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contaminants compared to the protocol of Deckers that gave a protein profile similar to the 
total seed extract (S1) (Fig. 11 and 12). The SDS-PAGE analysis of the intermediate steps of 
purification obtained using the protocol of Tzen showed that the 8 M urea treatment was 
crucial to remove proteins migrating between 21 and 50 kDa and that only six bands were 
clearly visible at the final step within the 6–55 kDa range (Fig. 12).  
 
4.4.2 Characterization of protein composition of w.t. and chimeric oil bodies 
by MS 
The identification of the proteins associated with w.t. oil bodies using the protocol of Tzen 
(sample S4T) was initially performed by MS analysis of the proteins separated through SDS-
PAGE. Before SDS-PAGE protein samples were treated to remove the lipid contaminant that 
would interfere with protein migration. The gel was sliced as shown in Fig. 13 and the 
proteins within each slice, along each lane, digested with trypsin. Each peptide mixture was 
then submitted to LC–MS/MS. The results obtained by the analysis of most evident 
Coomassie-stained bands led essentially to the identification of six isoforms of oleosins 
(slices 12 and 13, S4T) with molecular mass ranging from 14.8 to 21.2 kDa (Tab. 4) together 
with proteins previously annotated as associated to oil bodies (Jolivet et al., 2004) (two A. 
thaliana seed gene (ATS) isoforms (At4g26740; At5g55240) (slice 9, lane S4T); 11-β-
hydroxysteroid dehydrogenase-like protein (At5g50600) (slice 6, lane S4T); predicted GPI 
(Glycosylphosphatidylinositol)-anchored protein (At1g54860) (slice 12, lane S4T); β-
Tonoplast Intrinsic Protein (TIP) (At1g17810) (slice 11, lane S4T)). However, a more 
comprehensive study revealed that the sample was more complex than expected when also 
slices not visibly stained by Coomassie were analysed. The merging of all the results obtained 
by Mascot searching (www.matrixscience.com) of the spectra corresponding to the tryptic 
peptides generated across S4T lane identified 75 proteins with a score sufficient for protein 
identification (at least two unique peptides with an ion score >35 for each protein) (Tab. 5). 
Among these proteins structural components of the ribosome as well as proteins involved in 
embryonic development (Late Embryogenesis Abundant protein isoforms, LEA; Arabidopsis 
thaliana Seed protein isoforms, ATS), enzymatic activity (oxidoreductase, dehydrogenase, 
disulfide isomerase activity), transmembrane transporter activity (β-TIP; Pore Homologue 
protein; Adenylate translocator) and GTP-binding proteins were identified. A comparison 
between the list of the total proteins identified in S1 and S4T was carried out to monitor 
proteins that were removed or enriched across the purification procedure. The number of total  
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Figure 11. SDS-PAGE analysis of wild type and chimeric oil bodies prepared according to the protocols 
developed by Deckers and Tzen. 
Protein analysis by SDS-PAGE and Coomassie-staining of w.t. (lanes 1 and 2) or chimeric (lanes 3 and 4) oil 
bodies prepared according to Deckers (lane 1 and 3) or Tzen (lane 2 and 4). 
M: Novex Sharp Protein Standard (Invitrogen). 
 
 
 
 
 
Figure 12. SDS-PAGE analysis of proteins associated to w.t. oil bodies purified according to the procedure 
developed by Tzen. 
Total seed extracts (S1) (lane 1) were centrifuged through a sucrose cushion to isolate oil bodies according to the 
protocol developed by Tzen. These were sequentially  washed with 0.1% Tween (S2T) (lane 2), 2M NaCl (S3T) 
(lane 3) and finally 8M urea (S4T) (lane 4). 
M: Precision Plus All blue Protein Standard (Bio-Rad). 
M 1 2 3 4 
40K 
30K 
20K 
M 1 2 3 4 
37K 
25K 
20K 
50K 
75K 
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Figure 13. Shematic representation of SDS-PAGE slicing for MS analysis of w.t oil bodies protein 
composition. 
 
 
 
 
Table 4. List of oleosin isoforms identified by MS analysis in the w.t. oil  body 
preparation 
 
 
 
 
 
 
 
 
 
 
 
 
 
MW: Molecular Weight; pI: Isoelectric point; n.i.: not identified by Jolivet et al., 2004. 
a Nomenclature used by Kim et. al, 2002 and Jolivet et al., 2004. 
 
 
Accession 
Number 
 
Protein description 
 
Protein 
MW 
Protein 
pI Rename
a 
At3g27660 
 
oleosin isoform 
 
20300 
 
6.92 
 
S2 
At4g25140 
 
oleosin 18.5K 
 
18558 
 
9.43 
 
S3 
At3g01570 
 
putative oleosin 
 
19742 
 
7.11 
 
S1 
At5g40420 
 
oleosin 
 
21266 
 
9.36 
 
S4 
At5g51210 
 
oleosin-like 
 
14843 
 
9.86 
 
n.i. 
At1g48990 
 
 
oleosin like protein 
 
18432 
 
9.89 
 
n.i. 
M 1 2 3 4 
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proteins decreased from 361 (S1) to 75 (S4T), with 44 proteins shared between the two 
samples (Tab. 5). The shared proteins were grouped in 6 categories (structural constituents of 
ribosome; enzyme activity; nutrient reservoir; embryonic development; oleosins; other 
function) referring to the Gene Ontology (GO) database 
(http://www.ncbi.nlm.nih.gov/sites/entrez). To quantify the changes in the profiles of common 
proteins the “exponentially modified Protein Abundance Index” (emPAI) was utilised 
(Ishihama et al., 2005). The emPAI value, calculated as the ratio between the number of 
experimentally observed peptides for a protein to the number of peptides generated by its in 
silico digestion, is a valuable index for protein quantification in a complex sample. Indeed, it 
has been established that the number of unique peptides of a protein detected by MS correlate 
with the abundance of that protein. Protein abundance, expressed as molar fraction 
percentages (% mol), was calculated as the ratio between the emPAI value for each protein 
and the summation of emPAI values for all the identified proteins within each sample 
((emPAI/ΣemPAI) X 100). From this analysis 12 proteins out of 44 at least doubled their 
content (Tab. 6). These proteins included oleosins and the embryo-specific protein 3. The 
majority of the proteins decreasing in abundance were the seed-storage proteins (12S 
cruciferins α and β sub-units) and the structural constituents of the ribosome. The remaining 
proteins, unmodified between the two samples were mainly those classified as enzymes and 
those involved in embryonic development. A schematic representation of protein content 
variation is reported in Fig. 14. The 31 proteins identified only in S4T, apart for the 14.8 kDa 
(At5g51210) oleosin isoform, were mainly derived from the nucleus (histone 2 and histone 4), 
from the endomembrane system (cytochrome b5, GDSL-motif lipase/hydrolase-like protein, 
calnexin-like protein) and from plastids. Besides the characterization of the total protein 
content in w.t. oil body preparations, LC-MS/MS analysis was also performed to sequence the 
sunflower oleosin present in the oil bodies preparations obtained from transgenic seeds. 
Lipids were removed from the protein samples and proteins were separated by SDS-PAGE. 
The gel was Coomassie-stained and sliced across the whole lane. Tryptic digestion of the 
proteins in each band was then performed and the peptide mixture was sprayed into the mass 
analyser. The spectra obtained were searched with Mascot using a modified A. thaliana 
FASTA database in which the sunflower oleosin and the chimeric sunflower oleosins 
sequences were included. The presence of the epitope sequence was verified in one gel band 
for the Nef125 polypeptide and for NP. In particular, for Nef 125 2 tryptic peptides mapping 
in the Nef-derived polypeptide were identified, as well as 6 peptides from the sunflower 
oleosin sequence with a protein coverage of 38% (Fig.15). The NP peptide was also detected  
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Table 5. List of proteins identified by MS analysis in purified oil bodies (S4T) 
 
 
Protein description 
 
Protein Mass Protein score Protein pI emPAI 
11-beta-hydroxysteroid dehydrogenase-like 39518 4471 5.92 25.57 
oleosin isoform 20300 4082 6.92 11.79 
oleosin, 18.5K 18558 659 9.43 9.54 
GTP binding / phospholipase activator/ protein binding 20667 294 6.43 3.68 
putative oleosin 19742 1110 7.11 4.01 
oleosin 21266 2209 9.36 3.47 
embryo-specific protein 1 (ATS1) 28134 630 5.81 2.63 
oleosin-like 14843 100 9.86 1.88 
CRU3 (CRUCIFERIN 3) 58541 2614 6.53 1.84 
ATHSD5 (HYDROXYSTEROID DEHYDROGENASE 5) 43528 343 6.41 1.79 
histone H4 11402 97 11.48 1.77 
40S ribosomal protein S14 16304 131 10.60 1.63 
40S ribosomal protein s14 like 16320 124 10.60 1.63 
 ribosomal protein S14 like protein 16285 111 10.60 1.63 
CRA1 (CRUCIFERINA) 52905 917 7.68 1.51 
40S ribosomal like protein (S18) 17591 165 10.54 1.47 
ribosomal protein L9, putative 22118 55 9.48 1.47 
embryo-specific protein 1; Ca2+-binding EF-hand protein-
like 
27972 635 5.62 1.37 
cupin family protein 55200 485 6.64 0.94 
oleosin like protein  18432 95 9.89 0.91 
pore protein homolog 18574 250 6.97 0.90 
hypothetical protein, 3~ partial 27687 146 4.53 0.79 
Putative 40S ribosomal protein S15A 14852 61 9.90 0.70 
cytochrome b5  15132 53 5.11 0.68 
embryo-specific protein 3 (ATS3) 23410 201 6.27 0.67 
putative ribosomal protein s19 or s24 15363 66 10.70 0.67 
oxidoreductase 31596 111 6.11 0.66 
putative cruciferin 12S seed storage protein 50869 525 6.52 1.05 
histone H2B like protein  15723 148 10.05 0.65 
LEA domain-containing protein 32653 82 5.28 0.64 
ras-related small GTP-binding protein RAB1c 22532 145 5.27 1.03 
putative 40S ribosomal protein S15 17118 117 10.34 0.59 
40S ribosomal protein S3 27612 117 9.57 0.55 
putative aspartic protease  56397 1013 5.97 0.54 
AWPM-19-like membrane family protein 19947 59 9.74 0.49 
benzodiazepine receptor-related 21277 87 9.34 0.45 
predicted GPI-anchored protein 21897 57 6.08 0.44 
GTP-binding protein, ara-5 22805 61 5.02 0.42 
40S ribosomal protein - like 23079 83 10.17 0.41 
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Table 5. Continued 
 
 
pI: Isoelectric point; emPAI: exponentially modified Protein Abundance Index; in bold characters are indicated S1 and S4T shared 
proteins 
Protein description 
 
Protein Mass 
 
Protein score Protein pI emPAI 
GTP-binding RAB2A like protein 23378 79 6.96 0.41 
GAPC-2 37004 112 6.67 0.39 
LEA76 homologue type2 24172 77 8.83 0.39 
GTPase AtRAB8 24095 61 8.35 0.39 
putative aspartic proteinase 55320 362 5.37 0.34 
ribosomal protein S3a homolog 27503 113 9.57 0.34 
RNA recognition motif (RRM)-containing protein 27218 80 5.46 0.34 
translocon-associated protein alpha (TRAP alpha) family 
protein 
28264 136 5.08 0.33 
globulin-like protein 56983 131 5.44 0.33 
β-Tonoplast Intrinsic Protein 28222 90 6.54 0.33 
Photosystem II chlorophyll-binding protein PsbS 27990 77 9.25 0.33 
calnexin - like protein 60790 137 4.81 0.31 
putative histone H2B 15072 146 10.05 0.30 
histone H2B - like protein 15215 146 10.08 0.30 
prohibitin, putative 30619 81 6.93 0.30 
FLA15 48157 96 6.22 0.29 
FLA16 49184 87 6.35 0.28 
putative histone H2B 16519 146 10.00 0.27 
hypothetical protein (Chloroplast, mitochondrion, membrane) 17932 80 8.54 0.25 
AtHVA22b-like protein (regulatory protein) 18730 84 6.40 0.24 
GDSL-motif lipase/hydrolase-like protein 37039 72 5.83 0.24 
putative vacuolar sorting receptor 71762 79 5.30 0.19 
40S ribosomal protein S5 23090 65 9.69 0.19 
putative 40S ribosomal protein S5 23021 65 9.66 0.19 
Soul-1 23700 71 7.74 0.18 
unknown protein (endoplasmic/plasma membrane) 24549 61 9.32 0.18 
putative seed maturation protein 23869 58 6.97 0.18 
FLA18 50988 81 6.72 0.17 
FLA17 50491 75 6.21 0.17 
manganese superoxide dismutase-like protein 26932 84 6.25 0.16 
putative seed storage protein (vicilin-like) 55898 67 5.83 0.16 
putative disulfide isomerase 55852 67 4.81 0.16 
putative prohibitin 31617 54 9.65 0.14 
late embryogenesis abundant domain-containing protein  67155 76 5.78 0.13 
putative non-green plastid inner envelope membrane protein 36735 82 7.00 0.12 
-chloroplast genome- cytochrome f 35449 61 8.34 0.12 
Putative vicilin storage protein (globulin-like) 84041 53 6.39 0.10 
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Figure 14. Characterization of protein content of oil bodies before and after Tzen purification procedure.  
Variation of the abundance of protein groups (referring to Gene Ontology database) associated to oil bodies 
before (a) and after (b) purification.  
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Table 6. List of the proteins shared between the two set of data S1 and S4T and doubling 
their content 
 
 
 
 
 
Accession N° Protein  description Protein  MW 
S1 Protein 
content   
(% mol) 
S4T Protein 
content 
(% mol) 
 
 
 
At3g52580 ribosomal protein S14 like protein 16285 0.8084 1.9759 
 
 At1g48990 oleosin like protein 18432 0.1190 1.103 
 
 At4g25140 oleosin, 18.5K 18558 5.9815 11.5650 
 
 At3g01570 putative oleosin 19742 2.5394 4.8611 
 
 At3g27660 oleosin isoform 20300 4.716 14.2926 
 
 At5g40420 oleosin 21266 2.1773 4.2065 
 
 
 
At2g47770 benzodiazepine receptor-related 21277 0.1041 0.5455 
 
 
 
At5g07190 embryo-specific protein 3 (ATS3) 23410 0.4860 0.8122 
 
 At1g17810 β-TIP 28222 0.1636 0.4 
 
 
 
 
 
 
 
At2g21160 
alpha subunit precursor TRAP 
complex/Signal sequence 
receptor alpha subunit (SSR-
alpha) 
28264 0.1636 0.4 
 
 
 
 
 
At4g10020 
ATHSD5 
(HYDROXYSTEROID 
DEHYDROGENASE 5) 
43528 1.334 2.16 
 
 
 
At1g62290 putative aspartic protease 56397 0.3273 0.6546 
 
MW: Molecular Weight;  % mol: Protein content expressed as (emPAI/Σ emPAI) X 100 
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a 
Peptide sequence 
Monoisotopic ion 
[M] 
[M+H]+ [M+H]++ 
EGGKPR 642.34 643.34 322.17 
LTHPQR 750.41 751.41 376.205 
LVPVEPE 781.41 782.41 391.705 
QQQGPSTGK 929.45 930.45 465.725 
MATTTYDR 957.42 958.42 479.71 
HDQHTGDR 964.4 965.4 483.2 
STMSVPVQR 1003.5 1004.5 502.75 
QNYTPGPGIR 1101.55 1102.55 551.775 
LQDVGEYTGQK 1236.59 1237.59 619.295 
YPLTFGWCYK 1276.59 1277.59 639.295 
HHVTTTQPQYR 1366.67 1367.67 684.335 
IQHTAHEMCDQGQGQGQGGGK 2165.93 2166.93 1083.965 
 
 
 
b 
 
 
 
 
 
 
 
 
 
c 
OBP-Nef125 
MATTTYDRHHVTTTQPQYRHDQHTGDRLTHPQRQQQGPSTGKIMVIMALLPITGILFGLAGITLVGTVI
GLALATPLFVIFSPVIVPAMIAIGLAVTGFLTSGTFGLTGLSSLSYLFNMVRRSTMSVPVQRDYVKGKL
QDVGEYTGQKTKDLGQKIQHTAHEMCDQGQGQGQGGGKEGRKEGGKPRQNYTPGGIRYPLTFGWCYKLV
PVEPE  
 
 
 
Figure 15. Identification by LC-MS/MS analysis of peptides generated by tryptic digestion of Nef125 
chimeric oleosin associated to oil bodies. 
a) List of the peptides generated by in silico digestion with trypsin of the Nef125 chimeric sunflower oleosin. b) 
List of tryptic peptides experimentally identified by LC-MS/MS. c)  Amino acid sequence of Nef125 chimeric 
oleosin showing in red sunflower oleosin-derived and in blue Nef125 polypeptide-derived fragment peptides 
identified by LC-MS/MS. M: Monoisotopic ion; [M+H]+, [M+H]++: protonated and doubly protonated ions. 
Protein description Peptide sequence Ion score 
Sunflower oleosin LQDVGEYTGQK 59 
 GKLQDVGEYTGQK 60 
 HHVTTTQPQYR 32 
 STMSVPVQR 44 
 HDQHTGDR 57 
 IQHTAHEMCDQGQGQGQGGGK 75 
Nef125 polypeptide QNYTPGPGIR 36 
 YPLTFGWCYK 49 
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(although it contained one or both the methionines in an oxidised form), as well as 5 peptides 
bearing into the sunflower oleosin sequence (Fig.16). The sequence coverage for this chimeric 
protein was 34%. No fragment peptides including 2F5e were found by MS/MS analysis (Fig. 
17). However, 5 peptides derived from the sunflower oleosin sequence were identified giving 
a protein coverage of 28%. The in silico analysis of the tryptic peptides that can be generated 
by digestion with trypsin of 2F5e chimeric sunflower oleosin was also performed confirming 
that the fragment peptides bearing the epitope sequence are quite small and probably 
undetectable by the MS analyser.  
 
4.5 Evaluation of the immune responses elicited by immunisation 
with chimeric oil bodies 
 
4.5.1 Preparation and characterization of oil bodies for immunisation 
As urea is toxic for mice, oil bodies preparations for in vivo experiments were carried out 
using a protocol similar to that developed by Deckers, using sterile 0.9% NaCl for washing 
instead of sodium carbonate buffer. The protein profile of the oil body preparations, analysed 
by SDS-PAGE, showed a pattern of bands similar to that obtained with Deckers protocol (Fig. 
18). To prevent bacterial contamination all the procedure was performed under sterile 
conditions and oil body preparations were aliquoted and flash-frezeed. Quantification of the 
total proteins in oil body preparations was performed after lipid removal by using the 
Bradford assay solution and BSA (Bovine Serum Albumin) as a standard. Due to the 
unavailability of reagents able to detect the presence of the peptide in the preparation, it was 
not possible to determine the NP peptide doses injected with these oil bodies quantities.  
The attempt to detect and quantify 2F5e associated to purified chimeric oil bodies was carried 
out by direct ELISA performed using the Mab 2F5 for the detection. Four different dilutions 
of the chimeric and non chimeric oil bodies preparation were distributed in triplicates into the 
wells of Maxisorp plates in parallel to different dilutions of a synthetic polypeptide 
(QTQQEKNEQELLELDKWASL) that embodies 2F5e in the sequence. From this analysis a 
positive signal could be detected only in the chimeric oil bodies sample. However, looking at 
the two regression lines obtained by titrating the chimeric oil body sample and the HIV-1 
Env-derived synthetic peptide, it was evident that they were not parallel (Fig. 19a). In order to 
evaluate if this could be due to the interference of some components of the oil body 
preparation, a second ELISA was performed by titrating chimeric and non chimeric oil bodies  
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a 
 
Peptide sequence 
Monoisotopic 
ion [M] 
[M+H]+ [M+H]++ 
LTHPQR 750.41 751.41 376.205 
QQQGPSTGK 929.45 930.45 465.725 
MATTTYDR 957.42 958.42 479.71 
HDQHTGDR 964.4 965.4 483.2 
STMSVPVQR 1003.5 1004.5 502.75 
LQDVGEYTGQK 1236.59 1237.59 619.295 
HHVTTTQPQYR 1366.67 1367.67 684.335 
EGGKPSASNENMETM 1580.64 1581.64 791.32 
IQHTAHEMCDQGQGQGQGGGK 2165.93 2166.93 1083.965 
 
 
 
b 
 
Protein description Peptide sequence Ion 
score 
Sunflower oleosin STMSVPVQR 48 
 LQDVGEYTGQK 49 
 HHVTTTQPQYR 37 
 IQHTAHEMCDQGQGQGQGGGK 80 
 DLGQKIQHTAHEMCDQGQGQGQGGGK 25 
NP peptide EGGKPSASNENMETM 61 
 EGGKPSASNENMETM 35 
 
 
 
c 
OBP-NP 
MATTTYDRHHVTTTQPQYRHDQHTGDRLTHPQRQQQGPSTGKIMVIMALLPITGILFGLAGITLVGTVIGL
ALATPLFVIFSPVIVPAMIAIGLAVTGFLTSGTFGLTGLSSLSYLFNMVRRSTMSVPVQRDYVKGKLQDVG
EYTGQKTKDLGQKIQHTAHEMCDQGQGQGQGGGKEGRKEGGKPSASNENMETM 
 
 
 
Figure 16. Identification by LC-MS/MS analysis of peptides generated by tryptic digestion of NP chimeric 
oleosin associated to oil bodies. 
of the peptides generated by in silico digestion with trypsin of the NP  chimeric sunflower oleosin. b) List of 
tryptic peptides experimentally identified by LC-MS/MS. c)  Amino acid sequence of NP chimeric oleosin 
showing in red sunflower oleosin-derived and in blue NP polypeptide-derived fragment peptides identified by 
LC-MS/MS. M: Monoisotopic ion; [M+H]+, [M+H]++: protonated and doubly protonated ions. 
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a 
 
 
 
 
 
 
 
 
 
 
 
b 
 
Protein description Peptide sequence Ion score 
Sunflower oleosin STMSVPVQR 36 
 LQDVGEYTGQK 53 
 HHVTTTQPQYR 26 
 IQHTAHEMCDQGQGQGQGGGK 68 
 
 
 
 
c 
OBP-2F5e 
MATTTYDRHHVTTTQPQYRHDQHTGDRLTHPQRQQQGPSTGKIMVIMALLPITGILFGLAGITLVGTV
IGLALATPLFVIFSPVIVPAMIAIGLAVTGFLTSGTFGLTGLSSLSYLFNMVRRSTMSVPVQRDYVKG
KLQDVGEYTGQKTKDLGQKIQHTAHEMCDQGQGQGQGGGKEGRKEGGKASELDKWA 
  
 
 
Figure 17. Identification by LC-MS/MS analysis of peptides generated by tryptic digestion of 2F5e 
chimeric oleosin associated to oil bodies. 
a) List of the peptides generated by in silico digestion with trypsin of the 2F5e chimeric sunflower oleosin. b) 
List of tryptic peptides experimentally identified by LC-MS/MS. c)  Amino acid sequence of 2F5e chimeric 
oleosin showing in red sunflower oleosin-derived fragment peptides identified by LC-MS/MS. M: Monoisotopic 
ion; [M+H]+, [M+H]++: protonated and doubly protonated ions. 
 
 
 
Peptide sequence 
Monoisotopic ion 
[M] 
[M+H]+ [M+H]++ 
ASELDK 661.32 662.32 331.66 
LTHPQR 750.41 751.41 376.205 
QQQGPSTGK 929.45 930.45 465.725 
MATTTYDR 957.42 958.42 479.71 
HDQHTGDR 964.4 965.4 483.2 
STMSVPVQR 1003.5 1004.5 502.75 
LQDVGEYTGQK 1236.59 1237.59 619.295 
HHVTTTQPQYR 1366.67 1367.67 684.335 
IQHTAHEMCDQGQGQGQGGGK 2165.93 2166.93 1083.965 
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using the sunflower oleosin-specific polyclonal antibody. As expected, the two regression 
lines were parallel in this case (Fig. 19b). However, this result just indicated that the two 
samples contained the same amount of sunflower oleosins. Unfortunately, up to now it has not 
been possible to estimate the non-chimeric sunflower content.  
 
4.5.2 Enhanced frequency of ASNENMTEM-specific IFN-γ  secreting cells 
after in vivo administration of plant-produced NP peptide chimeric oil 
bodies     
Six week-old C57BL/6J female mice in groups of 4 were immunized subcutaneously (s.c.) 
into the tail base at day 0 and 14 with a single dose of chimeric oil bodies carrying the 
sunflower oleosin fused to the NP-derived peptide ASNENMETM containing a total of 75 µg 
of proteins. Control mice were immunized with sterile saline alone, with the synthetic peptide 
ASNENMETM (50 µg/inoculum) (>95% purity; Sigma, St. Louis, MO), or with oil bodies 
preparations carrying the non chimeric sunflower oleosin containing a total of 75 µg of 
proteins. Immonogens were emulsified in Incomplete Freund’s Adjuvant (IFA), and 
administered in a final volume of 50 µl. An additional group of mice was immunized with the 
same dose of chimeric oil bodies in 50 µl sterile saline, to evaluate if oil bodies have intrinsic 
adjuvant properties. Nineteen days after the second immunisation mice were sacrificed, single 
cell suspensions prepared from spleens, and IFN-γ ELISPOT performed to measure the 
responses to the NP peptides ASNENMETM and TYQRTRALV. The TYQRTRALV peptide 
is the CTL immunodominant peptide of NP in Balb/c mice (H2-Dd haplotype) and is not able 
to induce the activation of CTL-mediated immune responses in C57BL/6J mice. Figure 20 
shows results demonstrating that a good peptide-specific response was induced in mice 
immunized with the oil bodies preparation carrying the NP chimeric oleosin. The number of 
spot forming cells (SFC) is comparable to that obtained by classical immunization with a high 
peptide dose in IFA (P<0.05). No peptide-specific responses were obtained by immunizing 
mice with the chimeric oil bodies preparation without adjuvant and by immunizing mice with 
the non-chimeric preparation.  
 
4.5.3 Detection of 2F5e-specific antibodies elicited by immunization with 
chimeric oil bodies in mice sera 
Eight week-old C57BL/6J female mice in groups of 4 were immunized subcutaneously (s.c.) 
into the tail base at day 0 and 14 with a single dose of chimeric oil bodies carrying the  
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Figure 18. SDS-PAGE analysis of the oil body preparations used to immunize mice. 
SDS-PAGE analysis of the oil body preparations washed with 0.9% NaCl used for in vivo experiments (lane 1: 
non chimeric oil bodies; lane 2: chimeric oil bodies). M:Protein Standard RPN5800 (Amersham). 
 
 
 
 
Figure 19. Detection of 2F5e and of sunflower oleosin associated to oil body preparations by ELISA.  
a) Regression lines obtained by titrating HIV-1 Env-derived synthetic peptide (green squares) and the 2F5e 
chimeric oil bodies preparations (red triangles). b) Regression lines obtained by titrating the non chimeric (blue 
diamonds) and 2F5e chimeric oil bodes (red triangles).  
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sunflower oleosin fused to 2F5e ELDKWA corresponding to a total of 75 µg proteins with or 
without IFA. Control mice were immunized with non-chimeric oil bodies containing a total of 
75 µg proteins with or without IFA in a final volume of 50 µl. Blood samples were collected 
from each mouse at day 0 (pre-immune mice), 14, 21 and 42. Direct ELISA coating wells 
with the HIV-1 Env-derived synthetic peptide was performed to titrate 2F5e specific 
antibodies in the sera. However, no responder mice could be identified. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 20. Enhanced frequency of ASNENMTEM-specific IFN-g secreting cells after in vivo 
administration of plant-produced NP peptide chimeric oil bodies.  
Evaluation by IFNg ELISPOT assay of the in vivo induction of ASNENMETM specific T cell responses by the 
s.c. immunization with IFA emulsions of apyrogen saline, ASNENMETM peptide (pep), non chimeric or 
chimeric oil body preprations. An extra-group of mice was immunized with the chimeric oil bodies without IFA 
(no IFA). Results are expressed in terms of spot forming cells (SFC)/106 of splenocytes in culture on the y-axis. 
Each value represents the mean of triplicate wells after subtraction of the SFC counted in the respective negative 
control (unstimulated cells) ± SD . Cells were considered responsive only when the number of SFC in the wells 
stimulated with the peptide was at least two times that counted in the corresponding unstimulated control. The in 
vitro response to the H-2d-restricted peptide TYQRTRALV is not shown because for all the groups the number 
of SFC counted in the stimulated wells was equal to that counted in negative controls. Mice immunized with 
saline, with non chimeric oil bodies or with chimeric oil bodies without IFA do not show a peptide-specific 
response.  
*t-student p<0.05 
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5. DISCUSSION 
 
Several proteins of pharmaceutical interest have been successfully expressed in plant cells 
through the covalent coupling to proteins within the oil-storing organelles known as oil bodies 
(Van Roijen and Moloney, 1995a; Parmenter et al., 1995; Nykiforuk et al., 2006). Owing to 
their physico-chemical properties, these organelles facilitate the purification which leads to 
good yields of the final product and allows seed-targeted expression of the pharmaceutically 
important proteins. A similar strategy has been recently developed that is based on the use of 
plastoglobules i.e. lipo-proteic complexes found into choloroplasts bound to thylakoids. At 
present, this technology is still in its infancy but could represent a valuable alternative to the 
use of oil bodies especially when the recombinant protein has to be produced in leaf crops 
(Vidi et al., 2007).  
Studies devoted to the characterization of oil bodies identified in oleosins the main protein 
component of these organelles. These proteins form a shield around the TAG lipid core. 
Different oleosin isoforms have been identified in plants and their expression is usually time- 
and tissue-specific (Kim et al., 2002). Oleosins accumulate at very high levels on the oil body 
surface and thus to achieve successful targetting of the protein to oil bodies, the gene 
sequence encoding the heterologous protein/peptide must be fused to the gene sequence 
encoding an oleosin. Investigations of oleosin topology and mechanisms of targeting to oil 
bodies through the ER suggest that the hydrophobic central domain of these proteins is highly 
conserved among different species (Abell et al., 1997; Beaudoin and Napier, 2000). The 
surface-exposed C-terminus, as well as the N-terminus however, is highly variable and thus 
amenable to fusion with heterologous protein (Van Roijen and Moloney, 1995b; Beaudoin 
and Napier, 2000).  
The primary goal of the present PhD thesis was to establish Arabidopsis thaliana (cv. 
Columbia) lines genetically modified to independently express three immunogenic peptides 
derived from human immunodeficiency and influenza viruses (Nef125 polypeptide, 2F5e 
peptide, NP peptide) as C-terminus fusions with the 19 kDa isoform of the sunflower oleosin. 
The selected oleosin sequence is one of the two major isoforms present in sunflower, reported 
to be expressed earlier during seed development and oil deposition (Thoyts et. al, 1995). The 
selected epitopes are known to be inducers of B cell- or T cell- mediated immune responses in 
humans and/or mice (Yedwell et al., 1985; Muster et al., 1993; Billaut-Mulot et al., 2001; 
Crowe et al., 2006). 
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A. thaliana plants were transformed with pBIN19-based binary vectors in which the chimeric 
oleosin sequences were under the control of regulatory sequences promoting the expression in 
all plant tissues (pBIN19-35S) or only in the seeds (pBIN19-GM). The reason for using both 
vectors was to allow comparison of the efficacy of the regulatory sequences both in terms of 
expression levels and tissue-specificity. Western analysis with a polyclonal antibody specific 
to the sunflower oleosin of crude protein extracts of leaves and siliques from plants 
transformed with pBIN19-35S-based constructs showed that, despite the fact that these 
constructs should guarantee transgene expression in the entire plant, the expression was more 
pronounced in siliques. Previous studies on transgenic A. thaliana plants ectopically 
expressing the wild type sunflower oleosin demonstrated that varying levels of protein 
accumulation in different tissues do not correlate with the corresponding levels of transcript, 
but do correlate with the diverse accumulation of TAG (Beaudoin and Napier, 2000). On 
these premises, it may be postulated that in leaves oleosins accumulate in the ER but fail to be 
transferred to oil bodies that are formed to a lower extent in this non-accumulating oil tissues.   
Western analysis with the sunflower oleosin specific polyclonal antibody on extracts of leaves 
and siliques from plants transformed with the pBIN19-GM-based constructs demonstrated 
that the oleosin regulatory sequences derived from Glycine max tightly controlled the 
expression that was detectable only in siliques. Moreover, these sequences seem to be more 
efficient than the 35S promoter as expression levels of the sunflower oleosin in the siliques of 
plants transformed with pBIN19-GM were generally higher then those obtained from plants 
transformed with the constructs pBIN19-35S. Classical methods such as 1D PAGE followed 
by densitometry were found not to be appropriate to determine the precise expression levels 
of the chimeric sunflower oleosins in T2 plants transformed with pBIN19-GM-based vectors 
because of co-migration of the chimeric oleosins with endogenous oleosins and the lipidic 
nature of the organelles. Little difference in band intensities was observed on Coomassie-
stained SDS-PAGE gels between wild type and transgenic extracts. The G. max-derived 
regulatory sequences have been previously demonstrated to induce the expression of the 24 
kDa soybean oleosin isoforms A and B in rapeseed plants at Coomassie-staining sensitivity 
levels without affecting targeting to oil bodies of the endogenous counterparts (Sarmiento et 
al., 1997). The low expression levels observed could therefore be due to: i) low stability of the 
sunflower oleosin in A. thaliana; ii) different efficacy of the promoter in controlling a 
soybean or a sunflower sequence or iii) different efficacy of the promoter in different plant 
species.   
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Beside the differences in expression profiles in pBIN19-35S and pBIN19-GM lines, a 
common feature to the two groups of transgenic plants was the identification of three main 
bands, when crude protein extracts from leaves and/or siliques were separated by SDS-PAGE 
and analysed by Western blot. In the plants transformed with the sunflower oleosin fused to 
the Nef125 polypetide, these bands migrated with an apparent molecular weight of 23, 19 and 
15 kDa, whereas three polypeptides in the molecular range of approximately 20, 16 and 12 
kDa were visualized in the plants transformed with the sunflower oleosin fused to 2F5e and 
NP peptides. Analysis of the nucleotide sequence of the sunflower oleosin indicated that the 
three bands may be derived from three different ATG codons in frame. The use of these 
alternatives ATG would indeed generate polypeptides with expected molecular weights 
perfectly matching those experimentally visualized.  
The molecular masses of the observed bands in Nef 125 plants extracts were the first 
indication that the sunflower oleosin was indeed fused to the HIV-1-derived sequence. The 
same conclusion was reached after Western analysis of crude extracts from siliques of plants 
transformed with the 2F5e oleosin fusion (too small to induce a detectable migration shift on 
SDS-PAGE) with the monoclonal antibody (MAb) 2F5 (Buchacher et al., 1994). In the case 
of the NP peptide, due to the lack of specific antibodies, the presence was confirmed by 
MS/MS analysis of peptide fragments obtained by digesting with trypsin the oleosin bands 
identified by Coomassie-staining when proteins associated with oil bodies were separated on 
SDS-PAGE. Tandem mass spectrometry derived fragmentation data perfectly matched those 
predicted by in silico digestion. On the contrary, the tandem mass spectrometry approach did 
not reveal the 2F5e sequence in association with oil bodies extracted from the plants encoding 
this chimeric sunflower oleosin. Probably, as confirmed by the in silico prediction, this was 
due to the fact that trypsin digestion generates fragments bearing the epitope that, when 
doubly charged have m/z below the mass analyzer ion selection threshold (400<m/z<1600). 
Nonetheless, the MS/MS analysis of this sample identified the presence of five peptides of the 
sunflower oleosin sequence. Nef125 polypeptide presence was also further confirmed by 
MS/MS of oil bodies, although the C-terminal fragment of this polypeptide could not be 
detected. Similarly to the 2F5 peptide when this fragment is doubly charged its m/z is below 
the mass analyzer ion selection threshold. 
The MS approach was an excellent method not only to verify the presence of the polypeptides 
fused to the sunflower oleosin but also to get a detailed catalogue of the proteins associated to 
wild type oil bodies. Beside the interest in widening the knowledge, the possible use of oil 
bodies to the vaccine field imperatively requires the definition of the complete list of the 
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proteins associated to this organelle both to improve antigen delivery and/or to prevent side 
effects. The efficiency in removing seed contaminants from oil-bodies preparations of two 
different protocols of purification was verified by comparing the protein complement of each 
oil body preparation after each purification procedure (Tzen et al., 1997; Deckers et al., 2004). 
This experiment demonstrated that contaminants removal was more effective when performed 
by the final 8 M urea wash following the protocol devised by Tzen rather than a protocol 
devised by Deckers in which a final wash of 0.1 M Na2CO3 was employed. Although urea is a 
strong chaotropic agent, it has been demonstrated, by light microscopy observations, that oil 
bodies keep their integrity and dimensions after washing using solutions which contain urea 
(Tzen et al., 1997). After the purification, lipids were removed from oil bodies preparations to 
improve protein separation by SDS-PAGE and the subsequent MS analysis. 
The list of the proteins found through MS in the oil bodies preparations was compared to a 
published reference list obtained purifying oil bodies from A. thaliana cv. Wassilewskija 
seeds with the Tzen protocol (Jolivet et al., 2004). Both lists have been obtained by GeLC-
MS/MS. Indeed the separation of proteins through SDS-PAGE before MS reduces sample 
complexity (allowing the identification of low abundant proteins) and allows the use of high 
SDS concentration, therefore a better solubilization of hydrophobic proteins, such as oleosins, 
often under-represented in proteomics studies (Santoni et al., 2000). However, while, in our 
case, MS analysis was performed on slices cut across the whole lane of a gel loaded with oil 
bodies-associated proteins, the reference list was obtained by analysing only slices sampled in 
correspondence of bands visible after Coomassie-staining. As a consequence of this different 
approach, the reference list identifies as associated to oil bodies only a limited number of 
proteins (mainly structural) (i.e. four oleosin isoforms; a protein homologous to calcium 
binding protein (ATS 1); a 11-β-hydroxysteroid dehydrogenase-like protein; a probable 
aquaporin; a glycosylphosphatidylinositol-anchored protein with unknown function) while 
our list (in which natural components were discriminated from contaminants referring to the 
Gene Ontology database) indicates that oil bodies protein-composition is far more complex. 
In our complete list, the proteins with the highest emPAI value, therefore the most abundant, 
are a 11-β-hydroxysteroid dehydrogenase-like protein (identified as a genuine resident of oil 
bodies and also in the reference list) and five oleosin isoforms (out of a total of six oleosins 
found in our analysis). Comparing the relative abundance of the different oleosin isoforms we 
found that the most abundant isoform was the 20.3 kDa, despite the fact that the prevalent 
isoform was considered the 18.5 kDa,  in the previously published list. The analysis of oleosin 
gene expression in different A. thaliana tissues (florets, siliques, leaves, root, stem) indicates 
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that they are exclusively expressed in the floral tapetum and in siliques (Kim et al., 2002). 
Moreover, five genes have been identified that are exclusively expressed in siliques and at 
different times during embryo development (Kim et al., 2002). The oleosin isoforms reported 
in the reference list were the three intermediate- (18.5 kDa (At4g25140), 19.5 kDa 
(At3g01570), 21.3 kDa  At5g40420) and the late- (20.3 kDa (At3g27660)) expressed 
isoforms (Jolivet et al, 2004). Beside these isoforms, we have identified also the early-
expressed 14.3 kDa oleosin isoform (At5g51210), previously identified as an mRNA 
transcript (Kirik et al., 1996), and the 18.4 kDa isoform (At1g48990) never identified before 
in plant tissues, neither as transcript nor protein. Among all oleosins identified, the 19.5 kDa 
and the 20.3 kDa isoforms exhibit a neutral to sligthly acidic isoelectric point (pI) disproving 
the theory that the alkaline pI  is a common feature of oleosins (Kim et al., 2002). 
The comprehensive comparison of the MS data obtained by analysing “crude” oil bodies 
preparations (total seed extract; S1) and the final purified sample obtained with the Tzen 
protocol (S4T) indicated that the total number of proteins steeply decreases during the 
purification procedure. The preliminary analysis of the data on the basis of the emPAI value 
of the proteins shared between sample S1 and S4T, then classified and regrouped referring to 
the Gene Ontology database, allowed the identification of a group of proteins that were 
enriched and a group of proteins that were depleted during purification. Altogether these 
results confirmed what was observed on the Coomassie-stained gel where protein bands with 
an apparent molecular weight between 21 and 50 kDa (identified by the MS analysis as the 
α and β sub-units of 12S cruciferins) tended to disappear while the bands corresponding to 
the oleosin isoforms were enriched. Unexpectedly, from this analysis oleosins represent 30% 
of total oil body-associated proteins in purified oil bodies rather than 80% as previously 
reported by band intensity (Jolivet et al., 2004). However, it must be considered that emPAI 
values-based analyses implies that proteins are equally susceptible to digestion and the 
generated peptides equally detectable by LC-MS/MS. In the case of easily soluble proteins 
this assumption is probably valid but, if proteins include sections with no arginine or lysines, 
large tryptic peptides are generated which either are: i) poorly extracted from the gel; ii) not 
eluted from the column effectively during reverse phase chromatography; iii) ionised poorly 
or the m/z of the resulting peptide ions are so large that they are out of the mass range. In the 
case of hydrophobic proteins all that above described is more likely to occur as hydrophobic 
proteins usually have stretches with no charged residues and/or the resulting peptides are very 
hydrophobic and bind very strongly to the RP columns. Looking at the peptide coverage of 
the oleosins and comparing this with 11-β-dehydrogenase it was indeed verified that the 
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protein coverage was about 35% and 80%, respectively. In this way demonstrating that 
oleosin are detected less efficiently, giving some indications as to whether sections of 
sequence from the oleosin are missing. 
Among the proteins that are enriched throughout the purification steps, beside oleosins and β-
TIP, present also in the reference list (Jolivet et al., 2004), unexpected proteins with 
enzymatic activity were also enriched, while, seed storage proteins and the structural 
constituents of ribosomes were identified among depleted proteins.  
A further group of proteins, identified exclusively in the final purified fraction, was detected 
by mass spectrometric analysis only when the high abundant contaminants were removed. 
The analysis of these proteins on the basis of Gene Ontology, identified nucleus- and plastid-
associated proteins, that can be considered as residual contaminants, and membrane-
associated proteins. These latter together with the ribosome structural components may 
associate with oil bodies during their biogenesis, and immature oil bodies with synthetic 
machinery attached may also have partitioned with mature oil bodies during the purification 
protocol. Several studies have shown that the protein composition of plant oil bodies and of 
the analogous lipid bodies found in fungi and animal cells is very different from plant oil 
bodies which have the simplest protein composition (Kamisaka et al., 1997; Athenstaedt et 
al., 1999; Ohashi et al., 2003; Liu et al., 2004). By our approach two new oleosins (14 kDa 
oleosin isoform (At5g51210) and the 18.4 kDa oleosin isoform (At1g48990)) and 3 
membrane associated-proteins (benzodiazepine receptor-related (At2g47770), embryo-
specific protein 3 (ATS3) (At5g07190), alpha subunit precursor TRAP complex/Signal 
sequence receptor alpha subunit (SSR-alpha) (At2g21160)) have been identified as oil body-
associated proteins. If the data presented here will be further confirmed using alternative 
approaches, such as subtractive proteomics (Borner et al., 2006), the concept that plant oil-
bodies are “simple” organelles will be put into question. 
Oil bodies purified from transgenic T2 seeds which has been analysed by Western and MS to 
assess the presence on their surface of the immunogenic peptides as sunflower oleosin fusions 
were used to induce peptide-specific immune responses in mice. In the preliminary 
experiments mice were immunized only with oil bodies carrying the antibody epitope 2F5e or 
with those carrying the MHC class I-restricted NP peptide. To avoid urea contamination, 
known to be toxic for mice, oil bodies for immunisation were prepared from transgenic seeds 
using a protocol similar to that developed by Deckers, using sterile 0.9% NaCl for washing 
instead of sodium carbonate buffer. The attempts to quantify the dose of chimeric sunflower 
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into the purified oil bodies preparations by ELISA using peptide- (MAb 2F5) or sunflower 
oleosin-specific antibodies were unsuccessful. In fact, the titration curves obtained for the 
synthetic peptide and for the 2F5e chimeric oil bodies were inconsistent suggesting that the 
standard curve was not the appropriate reference to extrapolate peptide concentration in the 
oil body preparation. Probably, this is due to the interference of the lipid components. Indeed, 
an ELISA performed titrating 2F5e and non chimeric sunflower oleosin oil bodies using for 
detection the polyclonal antibody specific to the sunflower oleosin gave two parallel curves. 
This result indicate that non chimeric sunflower oleosin oil bodies could be the proper 
standard knowing the amount of heterologous oleosin associated to their surface. This last 
information will be acquired through the SRM and MRM quantitative MS-based approaches 
using AQUA peptides spiked in the sample mix at known concentration as standard. 
The immunological properties of the purified chimeric oil bodies carrying the NP peptide as 
sunflower oleosin fusion, were tested by subcutaneously injecting at day 0 and 14 C57BL/6J 
mice. Control mice were immunized with sterile saline alone, with the synthetic peptide 
ASNENMETM, or with oil bodies purified from A. thaliana plants expressing the wild type 
sunflower oleosin sequence. Immonogens were emulsified in Incomplete Freund’s Adjuvant 
(IFA). An additional group of mice was immunized with chimeric oil bodies in sterile saline 
to examine the intrinsic adjuvant capacities. Nineteen days after the second immunisation 
mice were sacrificed to set up IFN-γ ELISPOT assays aimed to assess the number of 
cytotoxic T cells specific to the NP-derived synthetic peptides ASNENMETM and 
TYQRTRALV (negative control) in the spleen of each group of mice. The results of these 
experiments clearly demonstrated that chimeric oil bodies activate ASNENMTEM-specific 
CD8+ T cells. No response was obtained without adjuvant co-delivery.  
The immunological properties of the purified chimeric oil bodies carrying the sunflower 
oleosin fusion the 2F5e peptide were also assessed following the same immunization schedule 
used for NP chimeric oil bodies. However, in this case the response was evaluated by titrating 
2F5e-specific antibodies in the sera collected at day 0 (pre-immune mice), 14, 21 and 42 in 
2F5e coated wells. The antibody response obtained using the prime-boost protocol was 
somewhat uninformative, suggesting that a further immunisation may be required. 
 It is common knowledge that the efficacy of vaccination depends both on the antigen dose 
and on the delivery system (Rosenthal and Zimmerman, 2006). In subunit- and peptide-based 
vaccines, the nature of the carrier affects the type of activated immune responses. Exogenous 
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antigens such as pathogen subunits mainly activate humoral responses and vaccinations 
performed with these antigens usually fail in eliciting CTL responses. This is due to the fact 
that they cannot enter the processing pathway ending in MHC class I molecules-associated 
presentation. This is true also when these antigens are co-administered with safe commercial 
adjuvants. Indeed, at present, adjuvants approved for human use (aluminum hydroxide and 
MF59) are effective only in inducing humoral immunity. Also IFA, used herein, is known as 
an adjuvant mainly effective in eliciting humoral responses, but studies performed using the 
combination of IFA with other adjuvant compounds widened the spectrum also to cell-
mediated immune responses (Chang et al., 1998).  
Some delivery strategies are able to overcome the barriers due to the mechanism of exogenous 
antigen processing as they exploit the so-called “cross-presentation” pathway of processing, 
culminating in the activation of naïve CTL by APC that are able to address exogenous antigens 
to the phagosome-cytosol pathway (Albert et al., 1988). An example of this is represented by 
liposome-based vaccines. Both liposome encapsulated and surface-conjugated peptides are 
indeed able to elicit CTL responses when administered in combination with innate immune 
activators (Nagata et al., 2007), although a stronger CTL response is obtained when antigens 
are conjugated to the surface.  The results obtained by immunising mice with the NP chimeric 
oil bodies demonstrate that this delivery strategy is effective in activating CTL responses. The 
response of the mice immunised with the synthetic NP peptide was higher than that observed 
in mice receiving the chimeric oil bodies, but the difference in the response is much less 
pronounced than the difference in the dose of antigen delivered. Although the amount of the 
NP peptide administered through oil bodies was certainly significantly lower than 50 µg, the 
system was still effective in addressing/delivering the antigen to proper APC for processing 
and presentation to MHC class I- restricted cytotoxic T lymphocytes, no matter if the epitope 
is not inserted in the natural context. Moreover, it is known that synthetic peptides do not 
require processing to activate CTL, rather they directly bind to MHC class I molecules 
displayed on cell surfaces. The use of plant oil bodies prepared by a “milder” purification 
protocol to render oil bodies compatible with mice immunization, results in oil body 
preparations with a greater degree of contamination with non-oil body protein. These 
contaminating proteins may mask the epitope, as suggested by results obtained with 2F5e 
chimeric oil bodies and may also lead to sensitization and detrimental allergic responses. It 
has been shown however, that allergic reactions to sesame and peanut proteins often targets 
oleosins isoforms (Pons et al. 2002; Leduc et al., 2006). Alternative approaches aimed to 
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reduce the risk of eliciting allergic responses should therefore be devised, in order to engineer 
chimeric oil bodies free of allergenic properties. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
93 
 
6. ACKNOWLEDGEMENTS 
 
My PhD studies have been an exciting time of my life with so much learning and personal 
development. Developing this project as a collaboration among three laboratories has been a 
great experience and I’ve got the chance to meet some special people I would like to thank. 
 
I would firstly like to thank Dr. Eugenio Benvenuto, for giving me the opportunity to work on 
this project and my supervisor Dr. Selene Baschieri for her support and advices through the 
years. I would especially like to thank Dr. Selene Baschieri for the enlightening discussions 
about the many directions questions may be addressed and for showing me that improvements 
are always possible.  
 
Special thanks must go to Dr. Kathryn Lilley and Prof. Johnathan Napier that keenly 
supervised my work for the time I spent working in their laboratories. 
 
I am also very grateful to Dr. Frederic Beaudoin not only for the technical supervision of my 
work but also for the expert advices that were crucial for the development of this project. I 
would especially like to thank Dr. Frederic Beaudoin for his promptness at providing 
materials, for the many interesting discussions and his friendly support and encouragement 
through the years.  
 
I also acknowledge the people I have collaborated with on some aspect of the project. Nick 
Bond worked with me on the study of the oil body proteome and the protein sequencing 
through  the Mass Spectrometry approach. Camillo Mancini carried out the injections in mice. 
 
I also thank everyone in the three labs for interesting discussion, practical help and friendly 
chats. In particular, I acknowledge the following people: Dr. Monica Venegas Caleron for her 
advices and help with plant transformation, Dr. Johanna Rees and Svenja Hester for help with 
Mass Spectrometry, Dr. Giampaolo Buriani and Dr. Chiara Lico for technical advices and 
help with immunizations. 
 
On a personal note, I thank the many special friends I have met in the course of this journey 
that shared with me their culture, knowledge and feelings and eventually their home. 
94 
 
 
Finally, I especially thank my parents, Angela and Luigi, for their support and 
encouragement. Through these years they have always been there for me, I could not have 
done all this without them.  
 
The PhD work was supported by the EC Integrated Project “Pharma-Planta” (LSHBCT-2003-
503565). Three laboratories were involved: Rothamsted Research Institute (tutors: Prof. J.A. 
Napier, Dr. F. Beaudoin ); Centre for Proteomics, University of Cambridge (tutor: Prof. K.S. 
Lilley); ENEA, Department of Biotechnology (tutor: Dr. S. Baschieri). The whole project was 
supervised by Dr. S. Baschieri & Dr. E. Benvenuto, ENEA. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
95 
 
7. REFERENCES 
 
Abell BM, Holbrook LA, Abenes M, Murphy DJ, Hills MJ, Moloney MM. 
Role of the proline knot motif in oleosin endoplasmic reticulum topology and oil body 
targeting.  
Plant Cell 9:1481-1493, 1997. 
 
Aguilar JC, Rodríguez EG.  
Vaccine adjuvants revisited.  
Vaccine 25: 3752-3762, 2007. 
 
Albert ML, Sauter B, Bhardwaj N.  
Dendritic cells acquire antigen from apoptotic cells and induce class I-restricted CTLs.  
Nature 392: 86–89, 1988. 
 
Alexander J, Oseroff C, Dahlberg C, Qin M, Ishioka G, Beebe M, Fikes J, Newman M, 
Chesnut RW, Morton PA, Fok K, Appella E, Sette A. 
A decaepitope polypeptide primes for multiple CD8 IFN-γ and Th lymphocyte responses: 
evaluation of multiepitope polypeptides as a mode for vaccine delivery. 
J. Immunol. 168: 6189–6198, 2002. 
 
Andersen JS, Wilkinson CJ, Mayor T, Mortensen P, Nigg EA, Mann M.  
Proteomic characterization of the human centrosome by protein correlation profiling. Nature 
426: 570-574, 2003. 
 
Andersen JS, Lam YW, Leung AKL, Ong S-E, Lyon CE, Lamond AI, MannM. 
Nucleolar proteome dynamics. 
Nature 433: 77-83, 2005. 
 
Arakawa T, Chong DK, Merritt JL, Langridge WH. 
Expression of cholera toxin B subunit oligomers in transgenic potato plants. Transgenic Res. 
6:403-413, 1997. 
 
96 
 
Arakawa T, Yu J, Chong DKX, Hough J, Engen PC,  Langridge WHR.  
A plant-based cholera toxin B subunit insulin fusion protein protects against the development 
of autoimmune diabetes.  
Nat. Biotechnol. 16: 934–938, 1998. 
 
Arlen PA, Singleton M, Adamovicz JJ, Ding Y, Davoodi-Semiromi A, Daniell H. 
Effective plague vaccination via oral delivery of plant cells expressing F1-V antigens in 
chloroplasts. 
Infection and Immunity 76: 3640–3650, 2008. 
 
Arnau J, Lauritzen C, Petersen GE, Pedersen J. 
Current strategies for the use of affnity tags and tag removal for the purification of 
recombinant proteins.  
Protein Expression and Purification 48: 1–13, 2006. 
 
Arora VK, Fredericksen BL, Garcia JV. 
Nef: agent of cell subversion. 
Microbes Infect..4:189-199, 2002. 
 
Athenstaedt K, Zweytick D, Jandrositz A, Kohlwein SD, Daum G. 
Identification and characterization of major lipid particle proteins of the yeast Saccharomyces 
cerevisiae.  
J. Bacteriol. 181: 6441–6448, 1999. 
 
Bakker H, Rouwendal GJA, Karnoup AS, Florack DE, Stoopen GM, Helsper JPFG, van Ree 
R, van Die I, Bosch D. 
An antibody produced in tobacco expressing a hybrid β-1,4-galactosylatransferase is 
essentially devoid of plant carbohydrate epitopes.  
Proc. Natl. Acad. Sci. USA 103: 7577-7582, 2006. 
 
Baneyx F, Mujacic M. 
Recombinant protein folding and misfolding in Escherichia coli. 
Nat. Biotechnol. 22: 1399-1408, 2004. 
 
97 
 
Barbante A, Irons S, Hawes C, Frigerio L, Vitale A, Pedrazzini E. 
Anchorage to the cytosolic face of the endoplasmic reticulum membrane: a new strategy to 
stabilize a cytosolic recombinant antigen in plants. 
Plant Biotechnol. J. 6:560-575, 2008.  
 
Beaudoin F, Napier JA. 
The targeting and accumulation of ectopically expressed oleosin in non-seed tissues of 
Arabidopsis thaliana.  
Planta 210: 439-445, 2000.  
 
Belanger FC, Kriz AL. 
Molecular basis for allelic polymorphism of the maize globulin-1 gene.  
Genetics 129: 863–872, 1991. 
 
Bendahmane M, Koo M, Karrer E, Beachy RN  
Display of epitopes on the surface of Tobacco Mosaic Virus: impact of charge and isoelectric 
point of the epitope on virus-host interaction.  
J. Mol. Biol. 290: 9-20, 1999. 
 
Bentley GA, Mariuzza RA. 
The structure of the T cell antigen receptor. 
Annu. Rev. Immunol. 14: 563-590, 1996. 
 
Billaut-Mulot O, Idziorek T, Loyens M, Capron A, Bahr GM. 
Modulation of cellular and humoral immune responses to a multiepitopic HIV-1 DNA 
vaccine by interleukin-18 DNA immunization/viral protein boost. 
Vaccine 19:2803–2811, 2001. 
 
Birch RG. 
Plant transformation: problems and strategies for practical application. 
Annu. Rev. Plant Physiol. Plant Mol. Biol. 48: 297-326, 1997. 
 
Borisjuk NV, Borisjuk LG, Logendra S, Petersen F, Gleba Y, Raskin I. 
Production of recombinant proteins in plant root exudates.  
98 
 
Nat. Biotechnol. 17: 466 – 469, 1999. 
 
Borner GHH, Harbour M, Hester S, Lilley KS, Robinson MS. 
Comparative proteomics of clathrin-coated vesicles. 
 J. Cell Biol. 175: 571-578, 2006. 
 
Bradford MM. 
A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing 
the principle of protein-dye binding.  
Ann. Biochem. 72: 248-254, 1976. 
 
Borrow P, Lewicki H, Hahn BH, Shaw GM, Oldstone MB. 
Virus-specific CD8+ cytotoxic T-lymphocyte activity associated with control of viremia in 
primary human immunodeficiency virus type 1 infection.  
J. Virol. 68:6103–6110, 1994. 
 
Broglie K, Chet I, Holliday M, Cressman R, Briddle P, Knowlton S, Mauvais CJ, Broglie R. 
Transgenic plants with enhanced resistance to the fungal pathogen Rhizoctonia solani. 
Science 254: 1194-1197, 1991. 
 
Buchacher A, Predl R, Strutzenberger K, Steinfellner W, Trkola A, Purtscher M, Gruber G, 
Tauer C, Steindl F, Jungbauer A, et al. 
Generation of human monoclonal antibodies against HIV-1 proteins; electrofusion and 
Epstein-Barr virus transformation for peripheral blood lymphocyte immortalization. 
AIDS Res. Hum. Retroviruses 10: 359-69, 1994. 
 
Bui HH, Peters B, Assarsson E, Mbawuike I, Sette A. 
Ab and T cell epitopes of influenza A virus, knowledge and opportunities. 
Proc. Natl. Acad. Sci. USA 104: 246-251, 2007. 
 
Canizares MC, Nicholson L, Lomonossoff GP.  
Use of viral vectors for vaccine production in plants.  
Immunol. Cell Biol. 83: 263–270, 2005. 
 
99 
 
Carrillo C, Wigdorovitz A, Oliveros JC, Zamorano PI, Sadir AM, Gomez N, Salinas J, 
Escribano JM, Borca MV. 
Protective immune response to foot-and-mouth disease virus with VP1 expressed in 
transgenic plants.  
J. Virol. 72: 1688-1690, 1998. 
 
Chang JCC, Diveley JP, Savary JR, Jensen FC. 
Adjuvant activity of incomplete Freund’s adjuvant. 
Advanced Drug Delivery Reviews 32: 173–186, 1998. 
 
Chargelegue D, Vine ND, van Dolleweerd CJ, Drake P, Ma JKC.  
A murine monoclonal antibody produced in transgenic plants with plant-specific glycans is 
not immunogenic in mice.  
Transgenic Res. 9: 187-194, 2000. 
 
Chen ECF, Tai SSK, Peng CC, Tzen JTC. 
Identification of three novel unique proteins in seed oil bodies of sesame.  
Plant Cell Physiol. 39: 935–941, 1998. 
 
Chen JCF, Tsai CCY, Tzen JTC. 
Cloning and secondary structure analysis of caleosin, a unique calcium-binding protein in oil 
bodies of plant seeds.  
Plant Cell Physiol. 40: 1079–1086, 1999. 
 
Chrispeels MJ, Faye L. 
The production of recombinant glycoproteins with defined nonimmunogenic glycans. In 
Owen MRL, Pen J (eds): Transgenic Plants: A Production System for Industrial and 
Pharmaceutical Proteins. Chichester, UK: John Wiley & Sons, pp 99–113, 1996. 
 
Clough SJ, Bent AF. 
Floral dip: a simplified method for Agrobacterium-mediated transformation of Arabidopsis 
thaliana. 
Plant J. 16: 735-743, 1998. 
 
100 
 
Conrad U, Fiedler U. 
Compartment-specific accumulation of recombinant immunoglobulins in plant cells: an 
essential tool for antibody production and immunomodulation of physiological functions and 
pathogen activity.  
Plant Mol. Biol. 38: 101–109, 1998. 
 
Cooper E, O'Reilly M.  
A novel staff vaccination strategy.  
Infect. Control. Hosp. Epidemiol. 23: 232-3, 2002. 
 
Cox KM, Sterling JD, Regan JT, Gasdaska JR, Frantz KK, Peele CG, Black A, Passmore D, 
Moldovan-Loomis C, Srinivasan M, Cuison S, Cardarelli PM, Dickey LF.  
Glycan optimization of a human monoclonal antibody in the acquatic planta Lemna minor.  
Nat. Biotech. 24: 1591-97, 2004 
 
Crowe SR, Miller SC, Woodland DL. 
Identification of protective and non-protective T cell epitopes in influenza. 
Vaccine 24 : 452–456, 2006. 
 
Daniell H. 
Production of biopharmaceuticals and vaccines in plants via the chloroplast genome. 
Biotechnol. J. 1: 1071–1079, 2006. 
 
Day CD, Lee E, Kobayashi J, Holappa LD, Albert H, Ow DW.  
Transgene integration into the same chromosome location can produce alleles that express at a 
predictable level, or alleles that are differentially silenced.  
Genes Dev. 14: 2869–2880, 2000. 
 
De Buck S, Van Montagu M, Depicker A. 
Transgene silencing of invertedly repeated transgenes is released upon deletion of one of the 
transgenes involved. 
Plant Mol. Biol. 46: 433-445, 2001. 
 
De Buck S, Windels P, De Loose M, Depicker A. 
101 
 
Single copy T-DNAs integrated at different positions in the Arabidopsis genome display 
uniform and comparable β-glucuronidase accumulation levels.  
Cell Mol. Life Sci. 61: 2632-2645, 2004. 
 
De Duve C. 
Tissue fractionation. Past and present.  
J. Cell Biol. 50: 20d-55d, 1971. 
 
De Jaeger G, Scheffer S, Jacobs A, Zambre M, Zobell O, Goossens A, Depicker A, Angenon 
G. 
Boosting heterologous protein production in transgenic dicotyledonous seeds using Phaseolus 
vulgaris regulatory sequences.  
Nat. Biotechnol. 20: 1265–1268, 2002. 
 
De Neve M, De Buck S, Jacobs A, Van Montagu M, Depicker A. 
T-DNA integration patterns in co-transformed plant cells suggest that T-DNA repeats 
originate from co-integration of separate T-DNAs. 
Plant J. 11: 15-29, 1997. 
 
de Virgilio M, De Marchis F, Bellocci M, Mainieri D, Rossi M, Benvenuto E, Arcioni S, 
Vitale A. 
The human immunodeficiency virus antigen Nef forms protein bodies in leaves of transgenic 
tobacco when fused to zeolin. 
J. Exp. Bot.  59: 2815–2829, 2008. 
 
Deckers HM, van Rooijen G, Boothe J, Moloney MM, Schryvers AB, Hutchins WA. 
Immunogenic formulations comprising oil bodies.  
Patent US6761914 B2, 2004.  
 
Doherty PC, Turner SJ, Webby RG, Thomas PG. 
Influenza and the challenge for immunology. 
Nat. Immunol. 7: 449-455, 2006. 
 
Drake PMW, Chargelegue DM, Vine ND, van Dolleweerd CJ, Obregon P, Ma JKC. 
102 
 
Rhizosecretion of a monoclonal antibody protein complex from transgenic tobacco roots.  
Plant Mol. Biol. 52: 233–241, 2003. 
 
Dunkley TPJ, Watson R, Griffin JL, Dupree P, Lilley KS. 
Localization of Organelle Proteins by Isotope Tagging (LOPIT). 
Molecular & Cellular Proteomics 3:1128-1134, 2004. 
 
Dunkley TPJ, Hester S, Shadforth IP, Runions J, Weimar T, Hanton SL,  Griffin JL, Bessant 
C, Brandizzi F, Hawes C, Watsonn RB, Cupree P,  Lilley KS. 
Mapping the Arabidopsis organelle proteome. 
Proc. Natl. Acad. Sci. USA 103: 6518–6523, 2006.  
 
Ehsani P, Khabiri A, Domansky NN. 
Polypeptides of hepatitis B surface antigen produced in transgenic potato.  
Gene 190:107-111, 1997. 
 
Elmayan T, Vaucheret H.  
Expression of single copies of a strongly expressed 35S transgene can be silenced post-
transcriptionally.  
Plant J. 9: 787–797, 1996. 
 
Feldmann K, Marks M.  
Agrobacterium-mediated transformation of germinating seeds of Arabidopsis thaliana: a non-
tissue culture approach.  
Mol. Gen. Genet. 208: 1-9, 1987. 
 
Flynn KJ, Belz GT, Altman JD, Ahmed R, Woodland DL, Doherty PC. 
Virus-specific CD8+ T cells in primary and secondary influenza pneumonia. 
Immunity 8: 683-691, 1998. 
  
Floss DM, Sack M, Stadlmann J, Rademacher T, Scheller J, Stöger E, Fischer R, Conrad U. 
Biochemical and functional characterization of anti-HIV antibody-ELP fusion protins from 
transgenic plants.  
Plant Biotechnol. J. 6: 379-391, 2008. 
103 
 
 
Foster LJ, de Hoog CL, Mann M.  
Unbiased quantitative proteomics of lipid rafts reveals high specificity for signalling factors.  
Proc. Natl. Acad. Sci. USA 100: 5813-5818, 2003. 
 
Frandsen GI, Mundy J, Tzen JTC. 
Oil bodies and their associated proteins, oleosin and caleosin.  
Physiol. Plant. 112: 301–307, 2001. 
 
Frankel AD, Young JAT. 
HIV-1: fifteen proteins and an RNA. 
Annu. Rev. Biochem. 67: 1-25, 1998. 
 
Frey-Wyssling A., Grieshaber E, Muhlethaler K. 
Origin of spherosomes in plant cells.  
J. Ultrastruct. Res. 8: 506–516, 1963. 
 
Garcia KC, Teyton L, Wilson IA. 
Structural basis of T cell recognition. 
Annu. Rev. Immunol. 17: 369-397, 1999. 
 
Gerngross TU. 
Advances in the production of human therapeutic proteins in yeasts and filamentous fungi. 
Nat. Biotechnol. 22: 1409-1414, 2004. 
 
Gil F, Reytor E, Pérez-Filgueira DM, Escribano JM. 
Multimerization of peptide antigens for production of stable immunogens in transgenic plants. 
J. Biotechnol. 128: 512-518, 2007. 
 
Gleba Y, Klimyuk V, Marillonnet S.  
Magnifection – a new platform for expressing recombinant vaccines in plants.  
Vaccine 23: 2042-2048, 2005. 
 
Gomez N, Carrillo C, Salinas J, Parra F, Borca MV, Escribano JM. 
104 
 
Expression of immunogenic glycoprotein S polypeptides from transmissible gastroenteritis 
coronavirus in transgenic plants.  
Virology 249: 352-358, 1998. 
 
Graves A, Goldman S.  
Agrobacterium tumefaciens-mediated transformation of the monocot genus Gladiolus: 
detection of expression of T-DNA-encoded genes.  
J. Bacteriol. 169: 1745-1746, 1987. 
 
Guilley H, Dudley RK, Jonard G, Balazs E, Richards KE. 
Transcription of Cauliflower Mosaic Virus DNA: detection of promoter sequences, and 
characterization of transcripts.  
Cell 30: 763-773, 1982. 
 
Gygi SP, Rist B, Gerber SA, Turecek F, Gelb MH, Aebersold R.  
Quantitative analysis of complex protein mixtures using isotope-coded affinity tags. Nat. 
Biotech.17: 994-999, 1999. 
 
Haq TA, Mason HS, Clements JD, Arntzen CJ. 
Oral immunization with a recombinant bacterial antigen produced in transgenic plants.  
Science 268:714-716, 1995. 
 
Hanin M, Paszkowski J. 
Plant genome modification by homologous recombination.  
Curr. Opin. Plant Biol. 6: 157-162, 2003. 
 
Hassan S, van Dolleweerd CJ, Ioakeimidis F, Keshavarz-Moore E, Ma JKC. 
Considerations for extraction of monoclonal antibodies targeted to different subcellular 
compartments in transgenic tobacco plants.  
Plant Biotechnol. J. 6: 733-748, 2008. 
 
Hobbs SL, Warkentin TD, DeLong CM. 
Transgene copy number can be positively or negatively associated with transgene expression. 
Plant Mol. Biol. 21: 17-26, 1993. 
105 
 
 
Holmgren J, Czerkinsky C. 
Mucosal immunity and vaccines. 
Nat. Med. 11: S45-S53, 2005. 
 
Hood EE, Witcher DR, Maddock S, Meyer T, Baszczynski C, Bailey M, Flynn P, Register J, 
Marshall L, Bond D et al. 
Commercial production of avidin from transgenic maize: characterization of transformant, 
production, processing, extraction and purification.  
Mol. Breed. 3:291-306, 1997. 
 
Hood EE, Bailey MR, Beifuss K, Magallanes-Lundback M, Horn ME, Callaway E, Drees C, 
Delaney DE, Clough R, Howard JA. 
Criteria for high-level expression of a fungal laccase gene in transgenic maize.  
Plant Biotechnol. J. 1:129-140, 2003. 
 
Horvath H, Huang J, Wong O, Kohl E, Okita T, Kannangara CG, von Wettstein D. 
The production of recombinant proteins in transgenic barley grains.  
Proc. Natl. Acad. Sci. USA 97:1914–1919, 2000. 
 
Houde M, Bertholet S, Gagnon E, Brunet S, Goyette G, Laplante A, Princiotta MF, Thibault 
P, Sacks D, Desjardins M.  
Phagosomes are competent organelles for antigen cross-presentation. 
Nature 425: 402-406, 2003. 
 
Huang AHC. 
Oleosins and oil bodies in seeds and other organs.  
Plant Physiol. 110:1055-1061, 1996. 
 
Hwang YS, Nichol S, Nandi S, Jernstedt JA, Huang N. 
Aleurone and embryo-specific expression of the β-glucuronidase gene controlled by the 
barley Chi26 and Ltp1 promoters in transgenic rice.  
Plant Cell Rep. 20: 647-654, 2001. 
 
106 
 
Ishihama Y, Oda Y, Tabata T, Sato T, Nagasu T, Rappsilber J, Mann M. 
Exponentially modified Protein Abundance Index (emPAI) for estimation of absolute protein 
amount in proteomics by the number of sequenced peptides per protein. 
Molecular & Cellular Proteomics 4:1265–1272, 2005. 
 
Jain R, Katavic V, Agrawal GC, Guzov VM, Thelen JJ. 
Purification and proteomic characterization of plastids from Brassica napus developing 
embryos. 
Proteomics 8: 3397–3405, 2008. 
 
Jaquinod M, Villiers F, Kieffer-Jaquinod S, Hugouvieux V, Bruley C, Garin J, Bourguignon 
J. 
A proteomics dissection of Arabidopsis thaliana vacuoles isolated from cell culture. 
Molecular & Cellular Proteomics 6: 394-412, 2007. 
 
Joensuu JJ, Kotiaho M, Riipi T, Snoeck V, Palva ET, Teeri TH, Lång H, Cox E, Goddeeris 
BM, Niklander-Teeri V. 
Fimbrial subunit protein FaeG expressed in transgenic tobacco inhibits the binding of F4ac 
enterotoxigenic Escherichia coli to porcine enterocytes. 
Transgenic Res. 13: 295-298, 2004. 
 
Johnson J, Lin T, Lomonossoff G. 
Presentation of heterologous peptides on plant viruses: genetics, structure, and function. 
Annu. Rev. Phytopathol. 35: 67-86, 1997. 
  
Jolivet P, Roux E, d’Andrea S, Davanture M, Negroni L, Zivy M, Chardot T.  
Protein composition of oilbodies in Arabidopsis thaliana ecotype WS.  
Plant Physiol. Biochem. 42: 501–509, 2004. 
 
Jorgensen RA, Cluster PD, English J, Que Q, Napoli CA. 
Chalcone synthase cosuppression phenotypes in petunia flowers: comparison of sense vs. 
antisense constructs and single-copy vs. complex T-DNA sequences.  
Plant Mol. Biol. 31: 957–973, 1996. 
 
107 
 
Kamisaka Y, Mishra S, Nakahara T.  
Purification and characterization of diacylglycerol acyltransferase from the lipid body fraction 
of an oleaginous fungus.  
J. Biochem. 121: 1107–1114, 1997. 
 
Kanamoto H, Yamashita A, Asao H, Okumura S, Takase H, Hattori M, Yokota A, Tomizawa 
K. 
Efficient and stable transformation of Lactuca sativa L. cv. Cisco (lettuce) plastids. 
Transgenic Res. 15: 205-217, 2006. 
 
Kapila J, De Rycke R, Van Montagu M, Angenon G. 
An Agrobacterium -mediated transient gene expression system for intact leaves.  
Plant Sci. 122: 101-108, 1997. 
 
Kapusta J, Modelska A, Figlerowicz M, Pniewski T, Letellier M, Lisowa O, Yusibov V, 
Koprowski H, Plucienniczak A, Legocki AB. 
A plant-derived edible vaccine against hepatitis B virus.  
FASEB J. 13:1796-1799, 1999. 
 
Karlsson Hedestam GB, Fouchier RAM, Phogat S, Burton DR, Sodroski J, Wyatt RT. 
The challenges of eliciting neutralizing antibodies to HIV-1 and to influenza virus. 
Nat. Rev. Microbiology 6: 143-155, 2008. 
 
Kessler F, Vidi P-A. 
Plastoglobule-lipid bodies: their function in chloroplast and their potential for application. 
Adv. Biochem. Engin./Biotechnol. 107: 153-172, 2007. 
 
Kim HU, Hsieh K, Ratnayake C, Huang AH. 
A novel group of oleosins is present inside the pollen of Arabidopsis.  
J. Biol. Chem. 277: 22677–22684, 2002. 
 
Kirik V, Kölle K, Balzer HJ, Bäumlein H. 
Two new oleosin isoforms with altered expression patterns in seeds of the Arabidopsis mutant 
fus3. 
108 
 
Plant Mol. Biol. 31: 413-417, 1996. 
 
Kirkpatrick DS, Gerber SA, Gygi SP. 
The absolute quantification strategy: a general procedure for the quantification of proteins and 
post-translational modifications. 
Methods 35:265–273, 2005. 
 
Klein MR, van Baalen CA, Holwerda AM, Kerkhof-Garde SR, Bende RJ, Keet IPM, 
Eeftinck-Schattenkerk JKM, Osterhaus ADME, Schuitemaker H, Miedema F.  
Kinetics of gag-specific cytotoxic T-lymphocyte responses during the clinical course of HIV-
1 infection: a longitudinal analysis of rapid progressors and long-term asymptomatics.  
J. Exp.Med. 181:1365–1372, 1995. 
 
Komarnytsky S, Borisjuk N, Yakoby N, Garvey A, Raskin I. 
Cosecretion of Protease Inhibitor Stabilizes Antibodies Produced by Plant Roots. Plant 
Physiol. 141: 1185–1193, 2006. 
 
Kost TA, Condreay JP, Jarvis DL. 
Baculovirus as versatile vectors for protein expression in insect and mammalian cells. 
Nat. Biotechnol. 23: 567-575, 2005. 
 
Koup RA, Safrit JT, Cao Y, Andrews CA, Wu Y, McLeod G, Borkowsky W, Farthing C, Ho 
DD.  
Temporal association of cellular immune response with the initial control of viremia in 
primary human immunodeficiency virus type 1 syndrome.  
J. Virol. 68:4650–4655, 1994. 
 
Koziel MG, Carozzi NB, Desai N. 
Optimizing expression of transgenes with an emphasis on plant-transcriptional events. Plant 
Mol. Biol. 32: 393-405, 1996. 
 
Krijgsveld J, Ketting RF, Mahmoudi T, Johansen J, Artal-Sanz M, Verrijzer CP, Plasterk RH, 
Heck AJ.  
Metabolic labeling of C. elegans and D. melanogaster for quantitative proteomics.  
109 
 
Nat. Biotechnol. 21: 927-931, 2003. 
 
Krishnan J, Selvarajoo K, Tsuchiya M, Lee G, Choi S.  
Toll-like receptor signal transduction. 
Exp. Mol. Med. 39: 421-38, 2007. 
 
Kusnadi AR, Hood EE, Witcher DR, Howard JA, Nikolov ZN. 
Production and purification of two recombinant proteins from transgenic corn. Biotechnol. 
Prog. 14:149-155, 1998. 
 
Kwong PD, Doyle ML, Casper DJ, Cicala C, Leavitt SA, Majeed S, Steenbeke TD, Venturi 
M, Chaiken I, Fung M, Katinger H, Parren PW, Robinson J, Van Ryk D, Wang L, Burton DR, 
Freire E, Wyatt R, Sodroski J, Hendrickson WA, Arthos J.  
HIV-1 evades antibody-mediated neutralization through conformational masking of receptor-
binding sites.  
Nature 420: 678–682, 2002. 
 
Lacasse P, Denis J, Lapointe R, Leclerc D, Lamarre A. 
Novel plant virus-based vaccine induces protective cytotoxic T-lymphocyte-mediated 
antiviral immunity through dendritic cell maturation. 
J. Virol. 82: 785-794, 2008. 
 
Lee RW, Cornelisse M, Ziauddin A, Slack PJ, Hodgins DC, Strommer JN, Shewen PE, Lo 
RY. 
Expression of a modified Mannheimia haemolytica GS60 outer membrane lipoprotein in 
transgenic alfalfa for the development of an edible vaccine against bovine pneumonic 
pasteurellosis. 
J. Biotechnol. 135:224-231, 2008. 
 
Leduc V, Moneret-Vautrin DA, Tzen JTC, Morisset M, Guerin L, Kanny G. 
Identification of oleosins as major allergens in sesame seed allergic patients. 
Allergy 61: 349–356, 2006. 
 
Li HY, Ramalingam S, Chye ML. 
110 
 
Accumulation of recombinant SARS-CoV spike protein in plant cytosol and chloroplasts 
indicate potential for development of plant-derived oral vaccines. 
Exp. Biol. Med.  231: 1346-1352, 2006.  
 
Lico C, Capuano F, Renzone G, Donini M, Marusic C, Scaloni A, Benvenuto E, Baschieri S. 
Peptide display on Potato virus X: molecular features of the coat protein-fused peptide 
affecting cell-to-cell and phloem movement of chimeric virus particles. 
J. Gen. Virol. 87: 3103-3112, 2006. 
 
Lilley KS, Razzaq A, Dupree P. 
Two-dimensional gel electrophoresis: recent advances in sample preparation, detection and 
quantitation.  
Curr. Opin. Chem. Biol. 6: 46-50, 2002. 
 
Lin L-J, Tai SSK, Peng C-C, Tzen JTC. 
Steroleosin, a sterolbinding dehydrogenase in seed oil bodies.  
Plant Physiol. 128: 1200–1211, 2002. 
 
Liu H, Sadygov RG, Yates JR. 
A model for random sampling and estimation of relative protein abundance in shotgun 
proteomics.  
Anal. Chem. 76: 4193-4201, 2004. 
 
Ma JK-C, Drake PMW, Christou P. 
The production of recombinant pharmaceutical proteins in plants. 
Nat. Rev. Gen. 4: 794-805, 2003. 
 
Malik K, Wu K, Li X-Q, Martin-Heller T, Hu M, Foster E, Tian L, Wang C, Ward K, Jordan 
M, Brown D, Gleddie S, Simmonds D, Zheng S, Simmonds J, Miki B. 
A constitutive gene expression system derived from the tCUP cryptic promoter elements.  
Theor. Appl. Genet. 105: 505-514, 2002. 
 
Mallory AC, Parks G, Endres MW, Baulcombe D, Bowman LH, Pruss GJ, Vance VB.  
The amplicon-plus system for high-level expression of transgenic plants.  
111 
 
Nat. Biotechnol. 20: 622-625, 2002. 
 
Marillonnet S, Thoeringer C, Kandzia M, Klimyuk V, Gleba Y. 
Systemic Agrobacterium tumefaciens-mediated transfection of viral replicons for efficient 
transient expression in plants.  
Nat. Biotechnol. 23:718-723, 2005. 
 
Martín-Alonso JM, Castañón S, Alonso P, Parra F, Ordás R. 
Oral immunization using tuber extracts from transgenic potato plants expressing rabbit 
hemorrhagic disease virus capsid protein. 
Transgenic Res. 12: 127-130, 2003.  
 
Marusic C, Rizza P, Lattanzi L, Mancini C, Spada M, Belardelli F, Benvenuto E, Capone I. 
Chimeric plant virus particles as immunogens for inducing murine and human immune 
responses against human immunodeficiency virus type 1. 
J. Virol. 75:8434-8439, 2001. 
 
Marusic C, Nuttall J, Buriani G, Lico C, Lombardi R, Baschieri S, Benvenuto E, Frigerio L. 
Expression, intracellular targeting and purification of HIV Nef variants in tobacco cells.  
BMC Biotechnology 7: 12-24, 2007. 
 
Mason HS, Lam DM, Arntzen CJ . 
Expression of hepatitis B surface antigen in transgenic plants.  
Proc. Natl. Acad. Sci. USA 89:11745-11749, 1992. 
 
Mason HS, Ball JM, Shi JJ, Jiang X, Estes MK, Arntzen CJ. 
Expression of Norwalk capsid protein in transgenic tobacco and potato and its oral 
immunogenicity in mice.  
Proc. Natl. Acad. Sci. USA 93:5335-5340, 1996. 
 
Mason HS, Haq TA, Clements JD, Arntzen CJ. 
Edible vaccine protects mice against Escherichia coli heat-labile enterotoxin (LT): potatoes 
expressing a synthetic LT-B gene.  
Vaccine 16:1336-1343, 1998. 
112 
 
 
McBurney SP, Young KR, Ross TM. 
Membrane embedded HIV-1 envelope on the surface of a virus-like particle elicits broader 
immune responses than soluble envelope.  
Virology 358: 334-346, 2006. 
 
McCormick AA, Corbo TA, Wykoff-Clary S, Palmer KE, Pogue GP. 
Chemical conjugate TMV-peptide bivalent fusion vaccines improve cellular immunity and 
tumor protection. 
Bioconjug. Chem. 17: 1330-8, 2006.  
 
McGarvey PB, Hammond J, Dienelt MM, Hooper DC, Fu ZF, Dietzschold B, Koprowski H, 
Michaels FH.  
Expression of the rabies virus glycoprotein in transgenic tomatoes.  
Bio/Technology 13:1484-1487, 1995. 
 
Medzhitov R, Janeway CA Jr. 
Innate immunity: the virtues of a non clonal system of recognition. 
Cell 91: 295-298, 1997. 
 
Menkhaus TJ, Bai Y, Zhang C, Nikolov ZL, Glatz CE. 
Considerations for the Recovery of Recombinant Proteins from Plants.  
Biotechnol. Prog. 20: 1001-1014, 2004. 
 
Meyer DE, Chilkoti A. 
Purification of recombinant proteins by fusion with thermally-responsive polypeptides. 
Nat. Biotechnol. 17:1112-1115, 1997. 
 
Moore JP, Parren PW, Burton DR. 
Genetic subtypes, humoral immunity and human immunodeficiency virus type I vaccine 
development.  
J. Virol. 75: 5721-5729, 2001. 
 
Mowat AM.  
113 
 
Anatomical basis of tolerance and immunity to intestinal antigens.  
Nat. Rev. Immunol. 3: 331-341, 2003. 
 
Murphy DJ. 
Storage lipid bodies in plants and other organisms.  
Prog. Lipid. Res. 29:299-324, 1990. 
 
Muskens MW, Vissers AP, Mol JN, Kooter JM. 
Role of inverted DNA repeats in transcriptional and post-transcriptional gene silencing. 
Plant Mol. Biol. 43: 243-260, 2000. 
 
Muster T, Steindl F, Purtscher M, Trkola A, Klima A, Himmler G,  Ruker F, Katinger H.  
A conserved neutralizing epitope on gp41 of human immunodeficiency virus type 1. J. Virol. 
67:6642–6647, 1993. 
 
Nagata T, Toyota T, Ishigaki H, Ichihashi T, Kajino K, Kashima Y, Itoh Y, Mori M, Odac H, 
Yamamurac H, Taneichi M, Uchida T, Ogasawara K. 
Peptides coupled to the surface of a kind of liposome protect infection of influenza viruses. 
Vaccine 25: 4914–4921, 2007. 
 
Napier JA, Stobart AK, Shewry PR. 
The structure and biogenesis of plant oil bodies: the role of the ER membrane and the oleosin 
class of protein.  
Plant Mol. Biol. 31: 945-956, 1996. 
 
Ni M, Cui D, Gelvin SB.  
Sequence-specific interactions of wound-inducible nuclear factors with mannopine synthase 
2’ promoter wound responsive elements. 
Plant Mol. Biol. 30: 77–96, 1996. 
 
Nicholson L, Gonzalez-Melendi P, van Dolleweerd C, Tuck H, Perrin Y, Ma JK-C, Fischer R, 
Christou P, Stoger E.  
A recombinant multimeric immunoglobulin expressed in rice shows assembly-dependent 
subcellular localization in endosperm cells.  
114 
 
Plant Biotech. J. 3: 115-127, 2005. 
 
Nykiforuk LC, Boothe JG, Murray EW, Keon RG, Goren HJ, Markley NA, Moloney MM. 
Transgenic expression and recovery of biologically active recombinant human insulin from 
Arabidopsis thaliana seeds.  
Plant Biotechnol. J. 4: 77–85, 2006. 
 
Oda Y, Huang K, Cross FR, Cowburn D, Chait BT.  
Accurate quantitation of protein expression and site-specific phosphorylation. 
Proc. Natl. Acad. Sci. USA 96: 6591-6596, 1999. 
 
Ohashi M, Mizushima N, Kabeya Y, Yoshimori T.  
Localization of mammalian NAD(P)H steroid dehydrogenase-like protein on lipid droplets.  
J. Biol. Chem. 278: 36819–36829, 2003. 
 
Ong S-E, Blagoev B, Kratchmarova I, Kristensen DB, Steen H, Pandey A, Mann M.  
Stable isotope labeling by amino acids in cell culture, SILAC, as a simple and accurate 
approach to expression proteomics.  
Mol. Cell. Proteomics 1: 376-386, 2002. 
 
Oszvald M, Kang TJ, Tomoskozi S, Jenes B, Kim TG, Cha YS, Tamas L, Yang MS. 
Expression of cholera toxin B subunit in transgenic rice endosperm. 
Mol. Biotechnol. 40: 261-268, 2008. 
 
Outchkourov NS, Peters J, de Jong J, Rademarkers W, Jongsma MA.  
The promoter-terminator of chrysanthemum rbcS1 directs very high expression levels in 
plants.  
Planta 216:1003-1012, 2003. 
 
Palmer KE, Thomson JA, Rybicki EP. 
Generation of maize cell lines containing autonomously replicating maize streak virus-based 
gene vectors. 
Arch. Virol. 144:1345-1360, 1999. 
 
115 
 
Pantophlet R, Wilson IA, Burton DR. 
Hyperglycosylated mutants of human immunodeficiency virus (HIV) type 1 monomeric 
gp120 as novel antigens for HIV vaccine design. 
J. Virol. 77: 5889-5901, 2003. 
 
Parmenter DL Boothe JG, van Rooijen GJH, Yeung EC, Moloney MM. 
Production of biologically active hirudin in plant seeds using oleosin partitioning. Plant Mol. 
Biol. 29: 1167-1180,1995. 
 
Pashine A, Valiante NM, Ulmer JB.  
Targeting the innate immune response with improved vaccine adjuvants.  
Nat. Med. 11: S63-S68, 2005. 
 
Patel J, Zhu H, Menassa R, Gyenis L, Richman A, Brandle J. 
Elastin-like polypeptide fusions enhance the accumulation of recombinant proteins in tobacco 
leaves.  
Transgenic Res. 16:239-249, 2007. 
 
Peng C-C, Tzen JTC. 
Analysis of the three essential constituents of oil bodies in developing sesame seeds. Plant 
Cell Physiol. 39: 35–42, 1998. 
 
Perkins DN, Pappin DJ, Creasy DM, Cottrell JS. 
Probability-based protein identification by searching sequence databases using mass 
spectrometry data.  
Electrophoresis, 20, 3551-3567, 1999. 
 
Phogat S, Svehla K, Tang M, Spadaccini A, Muller J, Mascola J, Berkower I, Wyatt R. 
Analysis of the human immunodeficiency virus type 1 gp41 membrane proximal external 
region arrayed on hepatitis B surface antigen particles.  
Virology 373:72-84, 2007. 
 
Phogat S, Wyatt R.  
Rational modification of HIV-1 envelope glycoproteins for immunogen design.  
116 
 
Curr. Pharm. Des. 13: 213–227, 2007. 
 
Pogrebnyak N, Golovkin M, Andrianov V, Spitsin S, Smirnov Y, Egolf R, Koprowski H. 
Severe acute respiratory syndrome (SARS) S protein production in plants: development of 
recombinant vaccine. 
Proc. Natl. Acad. Sci. USA 102: 9062-9067, 2005. 
 
Pogue GP, Lindbo JA, Garger SJ, Fitzmaurice WP. 
Making an ally from an enemy: plant virology and the new agriculture.  
Annu. Rev. Phytopathol. 40:45-74, 2002. 
 
Pons L, Chery C, Romano A, Namour F, Artesani MC, Guéant J-L. 
The 18 kDa peanut oleosin is a candidate allergen for IgE-mediated reactions to peanuts. 
Allergy 57 (Suppl. 72): 88–93, 2002. 
 
Porta C, Spall VE, Findlay KC, Gergerich RC, Farrance CE, Lomonossoff GP 
Cowpea mosaic virus-based chimaeras. Effects of inserted peptides on the phenotype, host 
range, and transmissibility of the modified viruses. 
Virology 310: 50-63, 2003. 
 
Rammensee HG, Bachmann J, Emmerich NN, Bachor OA, Stevanovic S. SYFPEITHI: 
database for MHC ligands and peptide motifs.  
Immunogenetics 50: 213-219, 1999. 
 
Rappuoli R. 
From Pasteur to genomics: progress and challenges to infectious diseases. 
Nat. Med. 10: 1117-1185, 2004. 
 
Richter LJ, Thanavala Y, Arntzen CJ, Mason HS. 
Production of hepatitis B surface antigen in transgenic plants for oral immunization. Nat. 
Biotechnol. 18:1167-1171, 2000. 
 
Rosenthal KS, Zimmerman DH. 
Vaccines: all things considered. 
117 
 
Clin. Vaccine Immunol. 13: 821-829, 2006. 
 
Ross JHE, Sanchez J, Millan F, Murphy DJ. 
Differential presence of oleosins in oleogenic seed and mesocarp tissues in olive (Olea 
europea) and avocado (Persea americana).  
Plant Sci. 93: 247–280, 1993. 
 
Ross PL, Huang YN, Marchese JN, Williamson B, Parker K, Hattan S, Khainovski N, Pillai 
S, Dey S, Daniels S, Purkayastha S, Juhasz P, Martin S, Bartlet-Jones M, He F, Jacobson A, 
Pappin DJ.  
Multiplexed protein quantitation in Saccharomyces cerevisiae using amine-reactive isobaric 
tagging reagents.  
Mol. Cell. Proteomics 3: 1154-1169, 2004. 
 
Roy CR.  
Immunology: professional secrets.  
Nature 425: 351-352, 2003. 
 
Russell DA, Fromm ME.  
Tissue-specific expression in transgenic maize of four endosperm promoters from maize and 
rice.  
Transgenic Res. 6: 157–168, 1997.  
 
Ryan EJ, Daly LM, Mills KH.  
Immunomodulators and delivery systems for vaccination by mucosal routes.  
Trends Biotechnol. 19: 293-304, 2001. 
 
Samac DA, Tesfaye M, Dornbusch M, Saruul P, Temple SJ. 
A comparison of constitutive promoters for expression of transgenes in alfalafa (Medicago 
sativa).  
Transgenic Res. 13: 349-361, 2004. 
 
Santi L, Giritch A, Roy CJ, Marillonnet S, Klimyuk V, Gleba Y, Webb R, Arntzen CJ, Mason 
HS. 
118 
 
Protection conferred by recombinant Yersinia pestis antigens produced by a rapid and highly 
scalable plant expression system. 
Proc. Natl. Acad. Sci. USA 24:861-866, 2006. 
 
Santoni V, Molloy M, Rabilloud T. 
Membrane proteins and proteomics: un amour impossible?  
Electrophoresis 21: 1054–1070, 2000. 
 
Sarmiento C, Ross JH, Herman E, Murphy DJ. 
Expression and subcellular targeting of a soybean oleosin in transgenic rapeseed. Implications 
for the mechanism of oil-body formation in seeds. 
Plant J. 11:783-796, 1997. 
 
Schmidt A, Kellermann J, Lottspeich F.  
A novel strategy for quantitative proteomics using isotope-coded protein labels.  
Proteomics 5: 4-15, 2005. 
 
Sette A, Sidney J. 
Nine major HLA class I supertypes account for the vast preponderance of HLA-A and –B 
polymorphism. 
Immunogenetics 50: 201-212, 1999. 
 
Siloto RMP, Findlay K, Lopez-Villalobos A, Yeung EC, Nykiforuk CL, Moloney MM. 
The accumulation of oleosins determines the size of seed oilbodies in Arabidopsis. The Plant 
Cell 18: 1961–1974, 2006. 
 
Southern EM. 
Detection of specific sequences among DNA fragments separated by gel electrophoresis. 
J. Mol. Biol. 98: 503-517, 1975. 
 
Srivastava V, Ow DW. 
Marker-free site-specific gene integration in plants.  
Trends Biotechnol. 22: 627-629, 2004. 
 
119 
 
Stiegler G, Kunert R, Purtscher M, Wolbank S, Voglauer R, Steindl F, Katinger H.  
A potent cross-clade neutralizing human monoclonal antibody against a novel epitope on 
gp41 of human immunodeficiency virus type 1.  
AIDS Res. Hum. Retroviruses 17:1757–1765, 2001. 
 
Stoger E, Sack M, Perrin Y, Vaquero C, Torres E, Twyman RM, Christou P, Fischer R.  
Practical considerations for pharmaceutical antibody production in different crop systems.  
Mol. Breed. 9:149-158, 2000.  
 
Stoger E, Ma JKC, Fischer R, Christou P. 
Sowing the seeds of success: pharmaceutical proteins from plants. Current Opinion in 
Biotechnology 16:167–173, 2005. 
 
Streatfield SJ, Jilka JM, Hood EE, Turner DD, Bailey MR, Mayor JM, Woodard SL, Beifuss 
KK, Horn ME, Delaney DE, Tizard IR, Howard JA. 
Plant based vaccines: unique advantages.  
Vaccine 19: 2742-2748, 2001. 
 
Sullivan ML, Green PJ. 
Post-transcriptional regulation of nuclear-encoded genes in higher plants: the roles of mRNA 
stability and translation.  
Plant Mol. Biol. 23: 1091-1104, 1993. 
 
Tackaberry ES, Dudani AK, Prior F, Tocchi M, Sardana R, Altosaar I, Ganz PR. 
Development of biopharmaceuticals in plant expression systems: cloning, expression and 
immunological rectivity of human cytomegalovirus glycoprotein B (UL55) in seeds of 
transgenic tobacco.  
Vaccine 17:3020-3029, 1999. 
 
Tacket CO, Mason HS, Losonsky G, Clements JD, Levine MM, Arntzen JC. 
Immunogenicity in humans of a recombinant bacterial antigen delivered in transgenic potato.  
Nat. Med. 4:607-609, 1998. 
 
Tacket CO, Mason HS, Losonsky G, Estes MK, Levine MM, Arntzen JC. 
120 
 
Human immune responses to a novel Norwalk virus vaccine delivered in transgenic potatoes.  
J.Infect.Dis. 182: 302-305, 2000. 
 
Tacket CO, Pasetti M, Edelman R, Howard JA, Streatfield S.  
Immunogenicity of recombinant LT-B delivered orally to humans in transgenic corn. Vaccine 
22:4385-4389, 2004. 
 
Tavladoraki P, Benvenuto E, Trinca S, De Martinis D, Cattaneo A, Galeffi P. 
Transgenic plants expressing a functional single-chain Fv antibody are specifically protected 
from virus attack. 
Nature 366: 469-472, 1993. 
 
Terpe K. 
Overview of tag protein fusions: from molecular and biochemical fundamentals to 
commercial systems.  
Appl. Microbiol. Biotechnol. 60:523–533, 2003. 
 
Thanavala Y, Yang Y, Lyons P, Mason HS, Arntzen C. 
Immunogenicity of transgenic plant-derived hepatitis B surface antigen.  
Proc. Natl. Acad. Sci. USA 92:3358-3361, 1995. 
 
Thanavala Y, Mahoney M, Pal S, Scott A, Richter L, Natarajan N, Goodwin P, Arntzen CJ, 
Mason HS. 
Immunogenicity in humans of an edible vaccine for hepatitis B.  
Proc. Natl. Acad. Sci. USA 102:3378-3382, 2005. 
 
Thoyts PJE., Millichip MI, Stobart AK, Griffiths WT, Shewry PR, Napier JA. 
Expression and in vitro targeting of a sunflower oleosin.  
Plant  Mol. Biol. 29: 403-410, 1995. 
 
Tregoning JS, Nixon P, Kuroda H, Svab Z, Clare S, Bowe F, Fairweather N, Ytterberg J, 
Wijk KJ, Dougan G, Maliga P. 
Expression of tetanus toxin Fragment C in tobacco chloroplasts.  
Nucleic Acid Res. 31: 1174-1179, 2003. 
121 
 
 
Trkola A, Purtscher M, Muster T, Ballaun C, Buchacher A, Sullivan N, Srinivasan K, 
Sodroski J, Moore JP, Katinger H. 
Human monoclonal antibody 2G12 defines a distinctive neutralization epitope on the gp120 
glycoprotein of human immunodeficiency virus type 1.  
J. Virol. 70: 1100–1118, 1996. 
 
Tzen JTC, Huang AHC. 
Surface structure and properties of plant seed oil bodies.  
J. Cell. Biol. 117: 327-335, 1992. 
 
Tzen JTC, Cao Y, Laurent P, Ratnayake C, Huang AHC. 
Lipids, proteins, and structure of seed oil bodies from diverse species.  
Plant Physiol. 101: 267–276, 1993. 
 
Tzen JTC, Peng C, Cheng D, Chen ECF, Chiu JMH. 
A New Method for Seed Oil Body Purification and Examination of Oil Body Integrity 
Following Germination. 
J. Biochem. 121: 762-768, 1997. 
 
Tzfira T, Li J, Lacroix B, Citovsky V. 
Agrobacterium T-DNA integration: molecules and models. 
Trends Genet. 20: 375-83, 2004. 
 
Tuboly T, Yu W, Bailey A, Degrandis S, Du S, Erickson L, Nagy E. 
Immunogenicity of porcine transmissible gastroenteritis virus spike protein expressed in 
plants.  
Vaccine 18:2023-2028, 2000. 
 
Ulmer JB, Valley U, Rappuoli R. 
Vaccine manufacturing: challenges and solutions.  
Nature Biotechnology 24: 1377-1383, 2006. 
 
122 
 
Vaeck M, Reynaerts A, Höfte H, Jansens S, De Beuckeleer M, Dean C, Zabeau M, 
Van Montagu M, Leemans J. 
Transgenic plants protected from insect attack.  
Nature 328: 33–37, 1987. 
 
van Rooijen GJ, Moloney MM. 
Plant seed oil-bodies as carriers for foreign proteins.  
Biotechnology 13:72-77, 1995a. 
 
van Rooijen GJ, Moloney MM. 
Structural requirements of oleosin domains for subcellular targeting to the oilbody. Plant 
Physiol. 109: 1353–1361, 1995b.  
 
Vidi PA, Kessler F, Bréhélin C. 
Plastoglobules: a new address for targeting recombinant proteins in the chloroplast. BMC 
Biotechnology  7:4-16, 2007. 
 
Wahlroos T, Soukka J, Denesyuk A, Wahlroos R, Korpela T, Kilby NJ.  
Oleosin expression and trafficking during oil body biogenesis in tobacco leaf cells.  
Genesis 35: 125–132, 2003. 
 
Walsh SR, Bhardwaj N, Gandhil RT. 
Dendritic cells and the promise of therapeutic vaccines for human immunodeficiency virus 
(HIV)-1. 
Curr. HIV Res. 1:205-16, 2003. 
 
Wang W, Vignani R, Scali M, Sensi E, Tiberi P, Cresti M. 
Removal of lipid contaminants by organic solvents from oilseed protein extract prior to 
electrophoresis. 
Analytical Biochemistry 329: 139–141, 2004. 
 
Wei X, Decker JM, Wang S, Hui H, Kappes JC, Wu X, Salazar-Gonzalez JF, Salazar MG, 
Kilby JM, Saag MS, Komarova NL, Nowak MA, Hahn BH, Kwong PD, Shaw GM. 
Antibody neutralization and escape by HIV-1.  
123 
 
Nature 422: 307–312, 2003. 
 
Williamson JD, Hirsch-Wyncott ME, Larkins BA, Gelvin SB. 
Differential accumulation of a transcript driven by the CAMV 35S promoter in transgenic 
tobacco.  
Plant Physiol. 90: 1570-1576, 1989. 
 
Witcher DR, Hood EE, Peterson D, Bailey M, Bond D, Kusnadi A, Evangelista R, Nikolov Z, 
Wooge C, Mehigh R et al.:  
Commercial production of β-glucuronidase (GUS): a model system for the production of 
proteins in plants.  
Mol. Breed. 4:301-312, 1998. 
 
Wu CC, MacCoss MJ, Howell KE, Matthews DE, Yates JR.  
Metabolic labeling of mammalian organisms with stable isotopes for quantitative proteomic 
analysis.  
Anal. Chem. 76: 4951-4959, 2004. 
 
Wurm FM. 
Production of recombinant proteins therapeutics in cultivated mammalian cells. 
Nat. Biotech. 22: 1393-1398, 2004. 
 
Yang DC, Guo FL, Liu B, Huang N, Watkins SC. 
Expression and localization of human lysozyme in the endosperm of transgenic rice. Planta 
216: 597-603, 2003. 
 
Yates JR, Eng JK, McCormack AL.  
Mining genomes: correlating tandem mass spectra of modified and unmodified peptides to 
sequences in nucleotide databases. 
Anal. Chem. 67: 3202-3210, 1995. 
 
Yewdell J, Antón LC, Bacik I, Schubert U, Snyder HL, Bennink JR. 
Generating MHC class I ligands from viral gene products.  
Immunol. Rev. 172: 97-108, 1999. 
124 
 
 
Zhang X, Mason H . 
Bean Yellow Dwarf Virus replicons for high-level transgene expression in transgenic plants 
and cell cultures.  
Biotechnol. Bioengineering 93: 271-279, 2005. 
 
Zhong W, Reche PA, Lai CC, Reinhold B, Reinherz EL.  
Genome wide characterization of a viral cytotoxic T lymphocyte epitope repertoire.  
J. Biol. Chem. 278: 45135–44, 2003. 
 
Zhou F, Badillo-Corona JA, Karcher D, Gonzalez-Rabade N, Piepenburg K, Borchers AM, 
Maloney AP, Kavanagh TA, Gray JC, Bock R. 
High-level expression of human immunodeficiency virus antigens from the tobacco and 
tomato plastid genomes. 
Plant Biotechnol J. 2008 Epub ahead of print 
 
Zhou T, Xu L, Dey B, Hessell AJ, Van Ryk D, Xiang SH, Yang X, Zhang MY, Zwick MB, 
Arthos J, Burton DR, Dimitrov DS, Sodroski J, Wyatt R, Nabel GJ, Kwong PD. 
Structural definition of a conserved neutralization epitope on HIV-1 gp120. 
Nature 445: 732–37, 2007. 
 
Zolla-Pazner S, Cohen SS, Krachmarov C, Wang S, Pinter A, Lu S. 
Focusing the immune response on the V3 loop, a neutralizing epitope of HIV-1 gp120 
envelope.  
Virology 372: 233-246, 2008. 
 
Zwick MB, Jensen R, Church S, Wang M, Stiegler G, Kunert R, Katinger H, Burton DR. 
Anti-human immunodeficiency virus type 1 (HIV-1) antibodies 2F5 and 4E10 require 
surprisingly few crucial residues in the membrane-proximal external region of glycoprotein 
gp41 to neutralize HIV-1.  
J. Virology 79: 1252–1261, 2005. 
 
